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ABSTRACT 
____________________________________________________________________________________________ 
 
  
 
Dengue virus (DENV) is among the most important mosquito-borne human 
pathogens worldwide. Concerns regarding the effectiveness of Dengue vaccines together 
with emergence of Zika virus (ZIKV) have reignited the interest for new vaccines using 
alternative approaches. Given that the envelope glycoprotein (E) is the main target of 
neutralizing antibodies, it has been used as the antigen of choice for vaccine development 
efforts.  
Here we present a detailed analysis of factors involved in the expression, secretion 
and folding of the E ectodomain from all four DENV serotypes and ZIKV in mammalian 
cells. Our data demonstrate that E domains II and III (DII and DIII) are important for proper 
E folding and stabilization of soluble dimers, respectively. In addition, we show that 
successful covalent stabilisation of E dimers, and E folding in general is strongly 
dependent on temperature but not on PrM co-expression, and that DENV and ZIKV E 
proteins can form heterodimers and assemble into mosaic viral particles. 
Our findings also show that antigen secretion determines the efficiency of DNA 
vaccines. Based on this, we developed a novel DNA gene-gun immunisation strategy 
using an engineered version of DIII fused to the CH3 domain of the IgG H chain, which is 
efficiently secreted from transfected cells and induced strong antibody responses that 
neutralise all DENV serotypes. The antibody responses were stable over long periods of 
time and different tetravalent formulations of the vaccine showed induction of neutralising 
antibodies against all four dengue serotypes as well. 
Finally, our results also indicate that the polyclonal antibody responses against DI/DII 
are highly cross-reactive, poorly neutralising and promote ADE towards all DENV 
serotypes, ZIKV, WNV and YFV. Conversely, anti-DIII antibodies are type-specific, with no 
ADE towards related flaviviruses, and with strong neutralisation activity restricted only to 
DENV. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ii 
 
  
iii 
 
ACKNOWLEDGMENTS 
______________________________________________________________________________________________ 
 
First, I would like to thank Dr Burrone, who believed in me when I had nothing to 
show besides my enthusiasm and willingness to work, thank you for giving me a chance 
to prove myself. I’m afraid that I will never be able to give back all that you have given me, 
your kindness, patience, passion, dedication and ethics will stay with me always. 
To Monica, who worked side-by-side with me for the past four years and from whom I 
learned every technique and procedure presented in this thesis, thanks for your friendship 
and patience, you have been the best teacher I could have asked for and I will miss our 
crazy mega-experiments the most. To Marco, thank you for your constant advice and help 
throughout the project. To Sara and Monica (M), thanks for the patience and dedication, I 
sincerely hope that you learned from me, at least half of all that I learned from you. And to 
all the members of the Molecular Immunology group, past and present, thank you all. 
To Dr John McLauchlan, who was much more than a supervisor throughout these 
years. Thank you for advice, dedication, time and friendship.  
To Tea, Poto, Nadja, Riccardo, Francy and Nico, thank you putting up with me and 
my grumpiness, and making me feel like I had a family away from home. Trieste would 
have been a much lonelier place without you.  
A mi familia, a mi papá, mis hermanos, pero muy especialmente a mi mamá; gracias 
por el apoyo constante durante este período. Sin ustedes todo el esfuerzo y sacrificio 
invertido en estas páginas no tendría sentido; sepan que mi meta es, y será siempre, que 
sientan por mí, el orgullo y amor que siento por ustedes.   
A mis amigos (hermanos), Manuel y Walla, que se mantuvieron junto a mí cuando 
menos los merecía y me sostuvieron en pie durante los períodos más oscuros de este 
viaje a pesar de la distancia. Estar lejos no ha sido fácil y me han salvado más veces de 
las que se puedan imaginar, gracias.  
E a Eli... grazie per la luce, le risate, i balli, i colori e tante altre cose; ma soprattutto, 
grazie per la magia.  
  
iv 
 
  
v 
 
TABLE OF CONTENTS 
_________________________________________________________________________________________ 
 
Abstract ................................................................................................................... i 
Acknowledgements ................................................................................................. iii 
Introduction ...................................................................................................................... 1 
Overview on the history of Dengue ................................................................................. 2 
History of dengue disease ............................................................................................ 2 
Etymology of “Dengue” ................................................................................................. 3 
The Dengue virus ........................................................................................................... 3 
Classification: General perspectives of flaviviruses ........................................................ 3 
Origin and evolution of Dengue virus ............................................................................. 5 
Dengue virus serotype 1 ...................................................................................................... 7 
Dengue virus serotype 2 ...................................................................................................... 7 
Dengue virus serotype 3 ...................................................................................................... 7 
Dengue virus serotype 4 ...................................................................................................... 8 
Viral structure .............................................................................................................. 9 
Dengue virus genome structure .................................................................................. 10 
Proteins encoded by the virus ..................................................................................... 11 
Structural proteins .............................................................................................................. 12 
Capsid protein ............................................................................................................ 12 
Precursor peptide and membrane protein ................................................................. 13 
Envelope protein ........................................................................................................ 14 
Non-structural proteins ...................................................................................................... 17 
Non-structural protein 1  ............................................................................................ 17 
Non-structural protein 2A  .......................................................................................... 17 
Non-structural protein 2B  .......................................................................................... 18 
Non-structural protein 3  ............................................................................................ 18 
Non-structural protein 4A  .......................................................................................... 19 
Non-structural protein 4B  .......................................................................................... 19 
Non-structural protein 5  ............................................................................................ 19 
Viral replication cycle ................................................................................................. 20 
Attachment-entry-fusion..................................................................................................... 21 
Translation and polyprotein processing ............................................................................. 22 
RNA replication .................................................................................................................. 23 
Assembly, maturation and release of viral particles .......................................................... 24 
Dengue disease ........................................................................................................... 25 
Virus-vector interactions ............................................................................................. 25 
Virus-host interactions ................................................................................................ 26 
Clinical manifestations of the disease .......................................................................... 27 
Phases of the dengue disease .......................................................................................... 28 
The febrile phase  ...................................................................................................... 28 
vi 
 
The critical phase  ...................................................................................................... 28 
The recovery phase ................................................................................................... 29 
Epidemiology............................................................................................................. 29 
Distribution of the disease ................................................................................................. 30 
Factors influencing incidence and geographic spread of dengue ..................................... 31 
Lack of efficient mosquito control  ............................................................................. 31 
Increase in travel and trade due to globalization  ...................................................... 32 
Urbanisation-related factors   .................................................................................... 32 
Climate factors  .......................................................................................................... 32 
The immune response against Dengue virus ............................................................... 32 
Innate immunity ......................................................................................................... 33 
Toll-like receptors and other intracellular sensors............................................................. 33 
Interferons and cytokine response .................................................................................... 33 
The complement system ................................................................................................... 34 
Natural killer cells .............................................................................................................. 34 
Adaptive immunity: Lymphocytes ............................................................................... 35 
Targets of the T cell response against dengue virus ........................................................ 35 
CD4+ T lymphocytes ......................................................................................................... 36 
CD8+ T lymphocytes ......................................................................................................... 37 
Adaptive immunity: Antibody response ....................................................................... 37 
Antigenic structure of Dengue virus and antibody specificity ............................................ 37 
The envelope protein  ................................................................................................ 38 
PrM protein  ............................................................................................................... 39 
NS1 protein  ............................................................................................................... 39 
The antibody response against Dengue virus ................................................................... 40 
Mechanisms of protection ................................................................................................. 41 
Opsonisation of pathogens  ....................................................................................... 41 
Targeting of infected cells for elimination  ................................................................. 41 
Neutralisation  ............................................................................................................ 42 
Antibody-dependent enhancement of infection ................................................................. 43 
Fc Receptors  ........................................................................................................... 45 
Vaccines against Dengue virus .................................................................................... 46 
Live attenuated virus vaccines .................................................................................... 47 
Molecularly attenuated live virus vaccines  .................................................................. 48 
Live chimeric virus vaccines  ...................................................................................... 48 
Inactivated virus vaccines  ......................................................................................... 50 
Recombinant subunit vaccines  .................................................................................. 50 
Genetic vaccines  ...................................................................................................... 51 
DNA vaccines .................................................................................................................... 51 
Virus-vectored vaccines .................................................................................................... 53 
Materials and Methods .................................................................................................. 55 
Cell lines ...................................................................................................................... 56 
Viruses ......................................................................................................................... 56 
Plasmid DNA constructs .............................................................................................. 56 
vii 
 
Production of recombinant Adeno-Associated virus vectors ......................................... 58 
Animal immunisations .................................................................................................. 58 
Monoclonal antibodies .................................................................................................. 59 
Expression of recombinant proteins ............................................................................. 59 
Western blot and Slot blot analyses ............................................................................. 60 
Immunoprecipitations ................................................................................................... 61 
Radioactive labelling .................................................................................................... 61 
ELISA ........................................................................................................................... 61 
Evaluation of anti-DIII specific antibody concentrations  .................................................... 63 
Dengue virus-capture ELISA  ............................................................................................. 63 
Avidity assay  ...................................................................................................................... 63 
Cytofluorimetry ............................................................................................................. 64 
Immunofluorescence .................................................................................................... 64 
Production and analysis of pseudoviruses .................................................................... 65 
Detection of pseudoviral particles in western blot  ............................................................. 65 
Quantification of pseudoviruses by real-time PCR  ............................................................ 65 
Immunofluorescence ........................................................................................................... 66 
Infection of mammalian cells  ............................................................................................. 66 
Antibody-dependent pseudoviral infection of K562 cells .................................................... 66 
Neutralisation assays ................................................................................................... 66 
Plaque reduction neutralisation test ................................................................................... 66 
Foci reduction neutralisation test ........................................................................................ 67 
Antibody-dependent enhancement of infection assays ................................................. 67 
ADE in THP-1 cells  ............................................................................................................ 67 
ADE in K562 cells ............................................................................................................... 67 
Statistical analysis ........................................................................................................ 68 
Results and Discussion ................................................................................................ 69 
Part I: Analysis of E protein production, folding, dimerisation and secretion from 
mammalian cells ............................................................................................................ 71 
Synopsis ...................................................................................................................... 71 
Results ......................................................................................................................... 72 
DII determines sE secretion from mammalian cells ........................................................... 72 
sE dimerisation ................................................................................................................... 78 
DIII stabilises sE dimeric interactions ................................................................................ 78 
Secretion of covalently stabilised dimeric sE is temperature-dependent .......................... 81 
Covalent stabilisation of E dimers on the viral surface ...................................................... 87 
Dimerisation of heterotypic sE proteins ............................................................................. 89 
E mosaic viruses ................................................................................................................ 91 
Antigen secretion and immune response upon DNA vaccination ...................................... 94 
Discussion .................................................................................................................... 97 
Part II: Development and preliminary evaluation of a DIII-based DNA vaccine against 
Dengue virus ................................................................................................................ 109 
viii 
 
Synopsis ..................................................................................................................... 109 
Results ........................................................................................................................ 110 
Design and evaluation of a tetravalent DIII-based DNA vaccines ................................... 110 
Production and secretion of engineered DIII antigens .................................................... 110 
DIII- constructs induce strong and highly specific antibody responses in mice ............ 112 
Antibodies induced by DIII- vaccines show neutralising activity  ................................... 117 
Cross-neutralisation and ADE activities of DIII- antigens .............................................. 119 
Immune responses against DIII depend on DIII- secretion ........................................... 120 
A tetravalent formulation of the DIII- vaccine ................................................................. 124 
Optimisation of the DIII- vaccine ..................................................................................... 125 
Expression of DIII- in pVAX vectors enhances antigen availability ............................... 125 
Evaluation of alternative vaccination protocols and DNA delivery systems .................... 126 
Longitudinal analyses of anti-DIII DNA-induced antibody responses .............................. 129 
Monovalent DIII- formulations ........................................................................................ 129 
Tetravalent formulations .................................................................................................. 131 
Functional dissection of the antibody response against DENV sE .................................. 134 
DI/DII epitopes dominate the immune response against sE ........................................... 134 
Antibodies induced against DI/DII, but not against DIII are highly cross-reactive to other 
flaviviruses ....................................................................................................................... 136 
Neutralising and enhancing activities of polyclonal antibodies against DENV DIII and 
DI/DII ............................................................................................................................... 138 
Discussion .................................................................................................................. 143 
References .................................................................................................................... 157 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
 
 
 
INTRODUCTION 
______________________________________________________________________________________________ 
 
  
2 
 
1. OVERVIEW ON THE HISTORY OF DENGUE 
1.1. History of Dengue Disease 
The historic footprint of mosquito-borne dengue disease became a subject of study 
after the isolation of viral agent in suckling mice by Sabin and Schlesinger in 19441,2. 
Leading to this discovery, the data accumulated since the beginning of the 1900´s 
was pivotal to understand the behaviour of the disease starting with the description of its 
transmission by Aedes aegypti in 19061,3, the demonstration that the etiologic agent had 
virus-between mosquito and humans1,3,4. 
Dengue viruses have been impacting humans for centuries. The first epidemic report 
of a disease with the clinical and epidemiological presentation of dengue was made by 
Benjamin Rush in Philadelphia, United States, in 1780 with similar epidemic reports of 
dengue-like illnesses in Africa, Asia and Europe also happening during that period5,6. 
Although the aforementioned records describe the characteristics of dengue with 
precision, the oldest recorded illnesses with dengue-like symptoms date back to the 3rd , 
7th and 10th century in China for a disease called “water poison” due to its association with 
near-water environments5,7. Thus, dengue disease reached global distribution and 
pandemic proportions before the wake of 1800, which coincides with the increase in 
sailing and ship-mediated global commerce7. 
A second wave of pandemics with the same clinical features was registered across 
the world during most of the 19th century and the beginning of the 20th, where a 
commerce-driven explanation for the spreading of the disease was first made by 
recognizing dengue as a condition typical of seaports and coastal areas that travelled 
inland along the rivers1,3,5,7. Parallel observations regarding not only the introduction and 
spreading, but also the domestication of mosquitos in America and other regions of the 
world8, laid the ground for the discovery of A. aegypti as vector of the disease. The sum of 
all these factors altered the behaviour of dengue allowing the establishment of endemic 
regions across the Southeast Asia region before 19507. 
It was World War II that created the conditions for a new relationship between dengue 
and humans: the movement of troops and war materials from the coasts to the inlands in 
Asia and the Pacific, along with the huge environmental changes provoked by the war 
effort, completely transformed the ecological and epidemiological scenery of dengue, 
allowing the spread of the vector and, consequently, increasing the transmission and 
distribution of the disease, setting the stage for the beginning of the global dengue 
pandemic5,9. By the end of the war, many regions in Asia reach hyperendemic status with 
active co-circulation of all four viral serotypes. Additionally, the demographic changes 
induced by the war and the economic growth that followed in many Southeast Asian 
countries, led to uncontrolled urbanization where inadequate housing and management of 
both water supply and sewage allowed further expansion and domestication of the vector, 
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increasing the rates of transmission and facilitating the dispersal of the virus across the 
region5,7. It was during this period that the first documented epidemics of dengue 
haemorrhagic fever occurred in the Philippines and Thailand. Within 20 years, dengue 
spread throughout the region becoming a leading cause of children’s hospitalization and 
death by the 1980’s5,10,11. 
Epidemiological changes were most dramatic in America where, following World War 
II, dengue epidemics appeared to be under control due to the efforts of the Pan-American 
Health Organization to control yellow fever disease, which led to the eradication of A. 
aegypti from most of Central and South America5,7,11. After the discontinuation of the 
programme in the 1970´s the vector was reintroduced in the region where it regained its 
previous geographic distribution6,12. By the end of the 1980’s, the region was experiencing 
major epidemics that worsen after the introduction of new serotypes and strains; ten years 
later, many countries evolved from non-endemicity to hyper-endemicity with active 
circulation of all serotypes in the continent5,13-15. 
By the end of the 20th century, dengue viruses reached worldwide distribution within 
the tropics and caused more illness and death than any other arthropod-borne virus in 
humans5,6,12. 
 
1.2. Etymology of “Dengue” 
The origins of the word dengue are not clear. A dengue-like disease that originated in 
West Africa during 1870 and spread to India the following year, led to the discovery that 
the Swahili word for the illness was ki-dinga-pepo that means “cramp-like seizure caused 
by an evil spirit”3. Historic records show that the term dyenga had been used to describe a 
similar disease breakout during the 1820´s, however, the earliest record of the word 
dengue comes from 1800’s records of the Spanish court, so it’s possible that the Swahili 
word dinga may have actually originated from Spanish16.  
There is substantial evidence indicating that the disease, was spread along the 
Caribbean and the West Indies as a result of the African slave trade16. In Cuba, the 
disease was identified again with the Spanish word dengue during an 1828 outbreak of a 
similar condition, while word dandy was used in the West Indies. In both cases, the 
meaning of the word indicates “fastidiousness” and seem to reference the stiffness and 
joint pain associated with the disease16. After being used within the Cuban medical 
records, the word dengue was established in medical literature3. 
 
2. THE DENGUE VIRUS 
2.1.  Classification: General perspectives of Flaviviruses 
Dengue viruses are members of the Flavivirus genus that together with the genera 
Hepacivirus, Pestivirus and Pegivirus, form the taxonomical family known as Flaviviridae, 
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one of the largest families of viral pathogens responsible for causing severe diseases and 
mortality in humans and animals1,17. 
Initially, flaviviruses (along with the pestiviruses) were considered members of the 
family Togaviridae; however, deeper analysis into the biology, genetics and structure of 
these viruses justified their reclassification into the new Flaviviridae family1. The Flavivirus 
genus is composed of more than 70 viruses, most of them associated with human 
diseases including some of the most important human pathogenic viruses in the world 
besides dengue: Zika virus (ZIKV), Yellow fever virus (YFV), Japanese encephalitis virus 
(JEV), West Nile virus (WNV) and tick-borne encephalitis virus (TBEV) (Fig. 1). Species 
demarcation criteria within the genus include: nucleotide and aminoacid sequences, 
antigenic characteristics, geographic association, vector association, host association and 
ecological characteristics18.  
 
  
 
Figure 1. Phylogeny using the conserved sequences in the RNA-dependent RNA-polymerase of 
flaviviruses (Reprint from reference 18).
18
 
 
Structurally, flaviviruses virions are around 50nm in diameter, spherical in shape and 
consist of a spherical ribonucleoprotein core surrounded by a lipoprotein envelope with 
small projections. Each virion’s dry weight consists roughly of 6% RNA, 66% proteins, 
17% of lipids derived from the host cell membrane and about 9% of carbohydrate with a 
composition and structure that varies depending on the host cell1,17,18. Regarding their 
physicochemical properties, flaviviruses are stable at an alkaline pH between 8.0 and 8.4 
showing high sensitivity to acid environment1. Additionally, these agents are rapidly 
inactivated at temperatures above 50°C, ultraviolet light, gamma irradiation, organic 
solvents, detergents, alcohol and hydrogen peroxide1,18. 
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Genome-wise, the Flaviviridae family are characterized by carrying single-stranded, 
positive-sense RNA genomes between 9.5 kb and 12.5 long. Members of the Flavivirus 
genus in particular, possess the distinguishing feature of having a type I cap (me7-GpppA-
me2) at the 5’ end of their genome1,18.  
 On the basis of their ecology, flaviviruses belong to the group termed “arbovirus”. 
Arboviruses (Arthropod-borne viruses) are a taxonomically diverse group biologically 
transmitted among their vertebrate hosts by haematophagous arthropod vectors like 
mosquitos, ticks, midges and biting flies7,19,20. By definition, biological transmission 
implicates that arboviruses must replicate in the vector before being transmitted to the 
vertebrate host, this means that the transmission cycle requires viral replication within the 
arthropod as opposed to mechanical transmission which can occur without20. Biological 
transmission can be vertical or horizontal. This last mode of transmission, mainly involves 
transmission from vector to vertebrate host during blood feeding and is the most common 
route of infection for the majority of arboviruses20.  
Besides Flaviviridae, the arboviruses include a very diverse group are RNA viruses 
taxa like Bunyaviridae, Orthomyxoviridae, Reoviridae and Rhabdoviridae; the fact that 
these groups show a wide variety of RNA genomes and replication strategies indicates 
that the arthropod-borne transmission trait has arisen many different times during the 
evolution of RNA viruses19.  
Dengue viruses are highly restricted in their natural vertebrate host range, utilizing 
primates, almost exclusively humans, as reservoir and amplification host 7; therefore, it’s 
no surprise that among all arboviruses, Dengue viruses are the most important human 
pathogens19. 
 
2.2. Origin and Evolution of Dengue Virus 
All Dengue viruses are classified within the same antigenic complex in the genus 
Flavivirus; the inclusion in this group was based on antigenic cross-reactivity with other 
flaviviruses and confirmed with genomic organisation and sequence homology studies7,21. 
Evolution, dispersal patterns and epidemiological traits of flaviviruses originated in a 
combination of barriers imposed by the nature of their vectors and the ecology in which 
they have developed22. However, it was only after the development of detailed molecular 
techniques that the evolutionary history of dengue virus started to be unveiled23,24. 
Dengue virus serogroup comprises four different but closely related serotypes 
(DENV1, DENV2, DENV3 and DENV4) defined originally on the basis of antigenic cross-
reactivity of the virus envelope glycoprotein (E) with neutralising antibodies from sera of 
infected volunteers in diverse serological tests4,25. The four dengue serotypes were later 
confirmed by nucleic acid sequencing and also by ecologic, phylogenetic and evolution 
studies1,7,23. Genetically, the four serotypes are diverse and share between 60-75% 
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aminoacid identity26,27, while isolates within the same serotypes have only an average of 
3% aminoacid divergence (roughly 6% at the nucleotide level)28 which has been 
associated with fitness and virulence determinants26. However, given the lack of resolution 
within the flaviviral phylogenetic tree, the closest relatives of dengue virus cannot be 
identified with any certainty, which renders the reconstruction of dengue virus origin a 
difficult task.  
The strongest data on dengue virus origin concerns the identification of dengue’s last 
animal reservoir before evolving into a human disease. Researchers hypothesized that 
the actual version of the human endemic virus initially evolved from sylvatic strains that 
utilized non-human primates (NHP) as hosts with environmentally-associated Aedes spp. 
mosquitoes serving as vectors7,15,23.  
This assumption of Dengue virus being originally zoonotic is supported by some key 
observations on the existence of sylvatic strains of DENV2 and DENV 4 in Africa that fell 
basal to the human-isolated strains within their serotype in phylogenetic studies7,29,30. The 
hypothesis of a sylvatic Dengue virus origin was further supported by performing 
phylogenetic analysis after sequencing the E gene of DENV 1, 2 and 4 sylvatic strains 
from Malaysia and Africa30,31. As before, the sylvatic strains of the virus were distinct from 
those isolated from humans and vectors in an endemic scene. Although a sylvatic strain of 
DENV3 has not been isolated, the presence of antibodies against this serotype in 
Malaysian primates points to the existence of a sylvatic DENV3 cycle as well30. Thus, 
there is strong data supporting the sylvatic nonhuman-primate origin of dengue virus and 
that transmission to humans occurred later on for all four serotypes7,23. 
Less clear is where Dengue virus originated. Gaunt and others22 proposed an African 
origin based on the available data for other mosquito-borne flaviviruses, implying that the 
whole clade may have originated there; moreover, A. aegypti is also believed to have 
originated in Africa8,23. Conversely, the fact that there is abundant evidence for the sylvatic 
presence of all 4 serotypes in Asia suggest an Asian origin rather than African23. 
By estimating rates of nucleotide substitution, various investigators have been able to 
draw some light into the time-scale evolution of dengue virus32. Using the E gene from 
dengue, several groups reached the common conclusion that the endemic variants of 
DENV2 diverged first from their sylvatic ancestor close to 300 years ago, with the origin of 
the whole dengue virus group tracing back to a remarkable recent date of about 1000 
years which is in accordance with the first reports of the disease32-35. Therefore, the 
history of dengue seems to be a recent one in which up to a few hundred years ago the 
virus was mainly a zoonotic disease causing only rare outbreaks in humans. Transmission 
among humans was sustainable only after the demographic changes of the last 
centuries23. 
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Regarding the origin of the serotypes, most evidence gathered so far favours an 
independent evolution hypothesis in which the virus originally separated into different 
groups because of geographic or ecological reasons, in such a way that the 4 serotypes 
evolved independently from each other in four separate dengue epidemics with repeated 
adaptations to new vectors and vertebrate hosts5,7,23.  
 
2.2.1. Dengue virus serotype 1 (DENV1) 
This serotype was first reported in 1943 in French Polynesia and Japan, with reports 
increasing constantly over time in Asia from the late 1950’s. It was not reported in America 
until 1977 in Barbados, Cuba and Puerto Rico; since then, occurrences increased 
persistently across the region peaking in 2006. In Africa, the serotype was first reported in 
1984 and has been sporadically reported ever since36. 
Phylogenies based on the complete sequence of DENV1 E gene have confirmed the 
existence of 5 different genotypes: i) genotype I from strains of Southeast Asia, China and 
East Africa; ii) genotype II representing the 1950´s-1960’s strain from Thailand; iii) 
genotype III for the Malaysian sylvatic strain; iv) genotype IV representing the strains of 
the West Pacific and Australia and v) genotype V grouping all the American, African and 
remaining Asian strains7,37,38. 
 
2.2.2. Dengue virus serotype 2 (DENV2)  
This serotype was first reported in Papua New Guinea in 1944 followed by recurrent 
and increasing reports in Southeast Asia and the Pacific islands since then. In Africa and 
America, this serotype was first recorded in the 1960’s with frequent reporting of the 
serotype ever since36.  
5 genotypes of DENV2 are now recognized based on complete E gene sequences: i) 
Asian genotype I representing strains from Asia and the Pacific islands; ii) the 
cosmopolitan genotype that groups strains from all over the world; iii) the America 
genotype representing strains from Latin America and older strains from the Caribbean 
and India; iv) the Southeast Asia/American genotype representing strains collected from 
Thailand, Vietnam and America over the last 20 years; and v) the sylvatic genotype of the 
strains collected mainly from forest mosquitos and monkeys in Africa and Asia7,29. 
 
2.2.3. Dengue virus serotype 3 (DENV3)  
First reported in 1953 in the Philippines and Thailand, DENV3 has been continuously 
reported in Asia since then. In America, it was first reported in Puerto Rico in 1963 with 
the majority of American countries not reporting the serotype until the late 1980’s. In 
Africa, only a small number of cases have been reported since the first reports in 198436. 
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Current DENV3 phylogenies confirm the existence of 4 real genotypes and one 
theoretical: i) genotype I, representing isolates from the Pacific Islands; ii) genotype II that 
groups strains from Thailand, Vietnam and Bangladesh; iii) genotype III represents the 
strains from Africa and some Indian isolates; and iv) genotype IV representing all 
American strains. The theoretical genotype V is reserved for sylvatic strains that have not 
been isolated in the case of Dengue 3 but are believed to exist in Malaysia7. 
 
2.2.4. Dengue virus serotype 4 (DENV4)  
As for serotype 3, this variant was first reported in 1953 in the Philippines with yearly 
reports of cases since then. It was not encountered in America until 1981 with continuous 
reports occurring since36. 
Phylogenies for this serotype delineate 4 genotypes: i) genotype I representing 
strains from Thailand, Philippines, Sri Lanka and Japan; ii) genotype II grouping strains 
from the Pacific and America; iii) genotype III representing recent Thai strains; and iv) 
genotype IV that includes the sylvatic strains from Malaysia7,38. 
  
Although in need of further studies and official recognition, there seems to be 
evidence pointing towards the discovery of a fifth DENV serotype. This new isolate taken 
from the 2007 dengue outbreak in Malaysia’s Sarawak state, was initially thought to be a 
strain of DENV4, however, the virus did not respond to diagnostic tests as expected. After 
sequencing its entire genome, it became clear that this virus occupied a new branch in the 
dengue phylogenetic tree as a new fifth serotype. It was later determined that the 
antibodies elicited by this strain differed substantially from those obtained after an 
infection with the other serotypes. Nevertheless, the implications of this event in public 
health are still unclear because there is no evidence of a sustained transmission cycle of 
this new serotype in humans, with researchers suspecting that the virus is still contained 
in sylvatic circulation among macaques39. This report serves as a perfect example for the 
intense diversification pattern of Dengue viruses. 
In general, Flavivirus evolution and epidemiology is largely determined by the 
ecological needs of their arthropod vector and vertebrate host. This type of horizontal 
biological transmission implicates that these viruses, have to replicate alternately in very 
different environments7. The selective pressures that come from adapting to two very 
disparate hosts in order to ensure transmission might explain the paradox that, despite the 
significant potential for sequence changes in RNA viruses mainly because of their error 
prone RdRp, the consensus sequences of most arboviruses show a very high genetic 
stability7,19. This implies that, arboviruses requirement for replication in divergent hosts 
may impose evolutionary constraints in which only mutations that are either beneficial or 
neutral in both hosts become fixed. 
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2.3.  Viral Structure 
Dengue virions have a diameter of ≈500Å and consist of a proteic capsule containing 
a single molecule of the viral RNA genome inside a host-derived lipid membrane17. 
Flaviviral genomes code for 3 structural proteins (the capsid protein (C), the membrane 
protein (M) and the envelope protein (E)) that ensemble together into viral particles: the 
envelope protein and the membrane protein form a glycoprotein-based outer shell that’s 
embedded in the lipid membrane while the capsid protein surrounds the viral genome 
forming the nucleocapsid at the viral core40. 
As pictured in Fig. 2, cryoelectron microscopy (CryoEM) studies have shown that 
mature particles have a relatively round, smooth surface with an icosahedral structure 
formed by asymmetric units of three E-M heterodimers41,42. The highly ordered 
icosahedral scaffold of the viral surface consists of 180 E molecules that are distributed in 
30 rafts of 3 parallel dimers organized in a herringbone pattern (Fig. 2a and 2b)3,40,43. 
Density analyses show that the viral particle is actually composed of a series of spherical 
shells (Fig. 2c) starting with the shell formed by the E protein on the viral surface; right 
underneath lies a M protein shell that is in close contact with the layer formed by the lipid 
membrane and the transmembrane domains of E and M; together, these three layers 
compose the viral envelope43. The nucleocapsid shell is inside the lipid membrane and 
appears to have a disordered structure with only random contacts with the inner layer on 
the envelope44.  
 
 
Figure 2. Structure of a mature dengue virus. a) Raft organization of three parallel E homo-dimers. b) 
Proposed structure for the mature dengue virion highlighting the packaging of the E protein rafts in a 
herringbone pattern. c) A central cross-section of dengue virus showing the different layers that compose the 
viral particle (Reprint from references 42, 40 and 44). 
40,42,44
 
   
The CryoEM structures of the different DENV serotypes have been calculated at 
different resolutions with superposition analysis showing no significant structural 
differences among them or among other flaviviruses. There are, however, important 
variations regarding the electric charge distribution on the surface of the E protein that 
provoke slight changes on the exposed surface of the virus41,43,45-47. 
Early antibody binding studies on the E protein were contradictory with the first 
structural reports of the virus in the sense that several neutralising antibodies tested on 
c b a 
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the viral surface, bound epitopes that were not exposed on the mature virions48. These 
observations are explained by a model called viral “breathing”, in which the E proteins that 
cover the viral surface are in a continuously dynamic state that involves slight changes in 
their configuration and arrangement48,49. In addition, recent data published independently 
by Zhang et al and Fibriansah et al, indicate that dengue virions suffer further structural 
variation at temperatures above 33°C, in which the envelope expands (Fig. 3) and 
increased exposure of E, theoretically favouring viral binding and entry, which has 
significant implications regarding treatment and vaccine development50-52.  
 
 
 
Figure 3. Effect of temperature on viral structure. a) The mature and smooth dengue viral particle at 28°C 
showing all the typical characteristics of classic dengue virion descriptions. b) and c) The structural models 
proposed by Zhang et al
51
 and Fibriansah et al
50
, respectively, depicting the structural changes adopted by the 
E protein at temperatures above 33°C (Reprint from reference 52).
52
.  
 
2.4.  Dengue virus genome structure 
Like all other flaviviruses, the dengue virus genome, is a single-stranded, positive 
sense RNA molecule of approximately 11 Kb18,53. Characteristically, viruses belonging to 
this genus carry a type I cap (m7GpppAmpN2) at the 5’ end followed by a conserved AG 
sequence while the 3’end lacks the typical poly-A tail of cellular messenger RNAs3,17,54. 
The flaviviral RNA genome acts as the messenger RNA for translation of the single 
open reading frame (ORF) encoding a large, ≈3440 aminoacids-long, precursor 
polyprotein that is cleaved and processed post- and co-translationally by viral and cellular 
proteases into the 10 mature viral proteins3,53. However, unlike cellular mRNAs, which 
contain only translational regulatory motifs, DENV genomes have evolved to contain a 
variety of signals and regulatory regions that act at different stages of the viral life cycle55. 
These regulations are mediated by RNA sequences and secondary structures present in 
the translated and untranslated regions (UTRs) of the molecule that function as 
promoters, enhancers and repressors of translation, transcription, replication and 
encapsidation17,54,56. The sequence, localization and predicted secondary structures of 
these RNA elements are shown in Fig. 4. 
 
a c b 
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Figure 4. Schematic representation of Dengue virus genome with the sequences and predicted 
secondary structures of the 5’ and 3’ untranslated regions (Reprint from reference 56).
56  
 
Dengue virus 5’UTR sequence is between 95 and 101 bases long depending on the 
serotype and contains two distinct RNA domains56. The first domain is close to 70 
nucleotides long and folds into a large stem-loop (SLA) composed of 3 helical regions 
(S1,S2,and S3), a side stem-loop (SSL) and a top loop (TL). The SLA domain has been 
proposed to function as a promoter to activate viral RdRp54,57. The second 5´UTR domain 
is a short stem-loop (SLB) which contains specific signals allowing the long-range RNA-
RNA interactions required for replication58-60. Additionally, these two domains are 
separated by an oligo(U) spacer sequence which allows proper function of both stem-
loops during replication56,61. Within the coding sequence of dengue virus genome, there´s 
a stable RNA hairpin (cHP) inside the capsid gene after the translation initiation codon, 
that is required for viral RNA replication62. 
The ≈450 nucleotide 3’UTR includes several conserved sequences and structures 
that play important roles in viral replication and translation7. Domain I is the most variable 
region of the 3’UTR (VR) and is a located immediately after the stop codon54,63. Domain II 
is more or less conserved and includes a characteristic duplicated dumbbell structure 
(DB1-DB2) containing conserved sequences (CS2 and RCS2) present in all mosquito-
borne flaviviruses55,56. Studies have confirmed that both domains participate in the 
regulation of RNA synthesis and translation as enhancers64,65. Domain III is the most 
conserved region of the 3’ UTR and participates in the regulation of RNA replication66. 
Another conserved element in the flaviviral genome is the presence of inverted 
complementary sequences that mediate RNA-RNA long range interactions leading to a 
cyclization of the viral ARN, an essential event during viral replication58.  
 
2.5.  Proteins encoded by the virus 
As shown in Fig. 5, the flaviviral genome codes for 3 structural proteins (C-PrM-E) 
that are contained in the N-terminal portion of the polyprotein, and 7 non-structural 
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proteins (NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5) that are coded in the remaining C-
terminal region67. As their names indicate, the structural proteins are components of the 
mature viral particle whereas the non-structural proteins are presented only in the infected 
cells to fulfil roles in the viral life cycle3,17,68.  
 
 
 
Figure 5. Membrane topology of dengue virus polyprotein. The viral RNA is translated at the ER 
membrane into a large polyprotein with different membrane, cytosolic and luminal domains that is processed 
by different proteases indicated by the differently coloured arrows to render la mature viral proteins (Reprint 
from reference 67). 
67
 
 
The genomes of flaviviruses are among the smallest within human pathogens with a 
maximum capacity of close to a dozen proteins69. In spite of these, flaviviruses must 
coordinate all the steps involved in the production of new viral particles while dealing with 
the immune system attempts to stop viral replication and destroy infected cells. As a 
consequence, most viral proteins, including the structural ones, have several 
functions17,69.  
 
2.5.1.  Structural Proteins 
2.5.1.1. Capsid Protein (C) 
 Known also as core protein, the capsid protein is a highly basic protein of 12kDa that 
is essential for encapsidation of the genome forming the viral nucleocapsid structure 
together with the genomic RNA molecule7.  
Flavivirus capsid proteins share a similar distribution of basic aminoacids which leads 
to an overall conserved structure and charge distribution70. Each protein contains 4 alpha-
helices, the first three forming the protein’s core and the last one extends away on the 
surface forming a highly basic domain that is proposed to interact with the viral RNA71,72. 
As shown on Fig. 6, on the opposite side of the molecule there’s a largely hydrophobic 
domain formed by helices 1 and 2, that behaves as a hydrophobic signal sequence 
allowing interactions between the protein and the cell membranes which has been 
proposed as fundamental for viral assembly17,70,73.  
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Figure 6. Ribbon diagram for the dimeric structure of dengue virus capsid protein (Reprint from 
reference 73). 
73
 
 
The capsid protein is also involved in a variety of non-structural roles during the viral 
life cycle that may include RNA replication, regulation of translation, modulation of 
infectivity, cellular environment and cell survival73-75. 
 
2.5.1.2. Precursor peptide and membrane protein (PrM) 
Upon translation, the membrane protein is the first viral protein to be translocated into 
the endoplasmic reticulum (ER). Initially, the protein is synthesised as a glycosylated, 
26kDa precursor named pre-membrane protein (PrM) which consist of an N-terminal 
precursor (Pr) domain followed by the M protein at C-terminus, with a sequence coding for 
a furin cleavage site between them17,76. Structurally, the Pr domain carries the only 
glycosylation site and is formed by seven antiparallel -strands that are stabilized by 3 
highly conserved disulphide bridges, while the M protein is basically a linear structure 
formed by an N-terminal loop followed by an amphipathic alpha-helical stem (MH) that 
interacts very closely with the lipid layer and two transmembrane helices76. 
After translation, PrM interacts with the nascent envelope protein and remains bound 
to its fusion loop during the transport through the Trans-Golgi network. The increasingly 
acid environment triggers a severe conformational change of the PrM-E interaction 
provoking the release of Pr from the M protein by furin-mediated cleavage, although Pr 
remains attached to the E protein preventing premature fusion during viral release17,77,78. 
Other studies in WNV, have shown that proper folding of E can occur only when is co-
synthesised with PrM79. As a consequence, it has been generally accepted that PrM 
assists E’s proper folding in a chaperone-like manner, with a significant effect on the 
generation of infective viral particles17,77,79. Once released from the host cell, the Pr 
peptide separates from the mature infective particle77,80.  
Additionally, Zhang et al and Hsieh et al, presented data supporting an important role 
for M’s MH domain during viral maturation and assembly, and in the entry process to the 
host cell76,81.  
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2.5.1.3. Envelope protein (E) 
In addition to being the main target for neutralising antibodies, the proteins embedded 
in the viral membrane of enveloped viruses have essential functions during the virus life 
cycle as determinants of host range, cellular and tissue tropism, virus-cell attachment, 
virulence, cellular entry (membrane fusion) and viral assembly17,45,82. In flaviviruses, the E 
glycoprotein is the major constituent of the viral membrane and is synthesized as a ≈500 
aminoacids-long, type I membrane protein17. 
Viral membrane fusion proteins can be classified into three different structural groups. 
Flaviviral E proteins fall into class II proteins that share a 3-domain structure composed 
mainly of -strands with a fusion loop in the central domain that serves as the initiator of 
the membrane fusion process83,84. In the case of dengue, the E protein folds into an 
elongated rod-like structure that forms antiparallel dimers, with approximate dimensions of 
150Å x 55Å x 30Å, that lay with the long axis of the dimer parallel to the membrane in a 
herringbone-like configuration that induces a curvature to the structure with the convex 
face of the dimer facing outward45,70 
As pictured in Fig. 7, the E ectodomain, which involves E’s first ≈400 aminoacids, 
folds into three different structural domains named I, II and III that are discontinuous when 
compared against the primary structure of the protein45,85. 
 
 
 
Figure 7. Structure of dengue virus soluble E dimer in mature viruses Showing domain I in red, 
domain II in yellow, domain III in blue. a) Representation of Dengue virus E primary structure including the 
100 residue C-terminal section missing from the soluble form that includes the stem segments (solid cyan) 
and the transmembrane anchors (stripped cyan). b) Upper view of the soluble E dimer from Dengue virus 3 
(Reprint from reference 85). 
85
 
 
Domain I (DI) occupies a central position in the E monomer86. As pictured in Fig. 7a, 
this linearly discontinuous structure it is formed by approximately 120 aminoacids 
distributed in three different segments of the protein that, when folded together, form an 8-
stranded -barrel with an axis parallel to the viral membrane that serves as organizing 
point for the whole protein45,85,87. 
Domain II (DII) is formed by two large peptidic sequences intercalated between the 
segments that form DI. These two loops fold together forming an elongated finger-like 
a 
b 
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structure with an antiparallel -sheet of 5 strands and 2 -helices that form a highly stable 
core from which an elongated 3-stranded -sheet expands distally forming two loops45,87; 
the most distal loop (cd loop) carries a highly hydrophobic glycine-rich sequence, 
conserved in closely-related flaviviruses, that serves as the internal fusion loop (FL)17,45,88. 
The flaviviral FL is strongly constrained by several intra-molecular forces that maintain its 
structure even when exposed to highly polar environments, which makes viral infection 
possible87,89. Additionally, DII provides the surface where the main interactions necessary 
for stabilizing the dimer conformation occur45.  
Domain III (DIII) is the C-terminal domain, and the only linearly continuous domain90. 
Structurally, it’s formed by an immunoglobulin constant region-like -barrel in which the 
sides form an internal hydrophobic pocket (together with DI) and the outer-lateral, most 
outward-prominent surface of the E dimer45,86. Regarding its functions, DIII is thought to 
contain the putative receptor-binding sites responsible for interacting with the host cell 
initiating the infection process40. This is supported by reports in which highly neutralizing 
antibodies have been mapped mainly to DIII epitopes17,91,92 and soluble recombinant 
version of DIII are able to block infection93. Besides this function, DIII has also been 
implicated in determination of host range, tropism and virulence17,45.  
In addition to these well-defined domains, the E ectodomain has two extra functional 
regions that fulfil very important roles: the hinge region formed by the 4 peptide strands 
that connect DI and DII fragments, and the linker that connects DI and DIII. 
The four peptide strands that form the hinge region are loosely packed in the interface 
between DI and DII, and provide the required flexibility for pH-induced conformational 
changes in the orientation of DII that are necessary at several stages of the viral 
lifecycle82. The presence of conserved glycines and the distribution of polar and non-polar 
aminoacids facilitate this pivot-type motion45,94. In fact, the rotation of DII about the hinge 
region is essential for viral infectivity, tropism and maturation94,95. 
The DI-DIII linker is a short (11 residues), moderately-conserved, poorly-organized 
peptide. Recently, de Wispelaere and Yang conducted a study in which they tried to pin 
down the functions of this linker by mutating aminoacids conserved in all four dengue 
virus serotypes96. Their findings, along with other crystallographic studies, suggest an 
important role of this linker in the assembly of the viral particles and in the process of host-
cell infection by aiding in the trimerisation of the E protein87,89,96. 
The last ≈100 aminoacids of E contain the stem and anchor regions that connect the 
E ectodomain to the viral envelope. The stem region is directly linked to the C-terminal 
end of DIII and consists of ≈50 aminoacids distributed in two consecutive amphipathic -
helices (EH1-EH2), partially embedded in the outer layer of the viral lipid membrane, 
separated by a highly-conserved linker-like aminoacid sequence (CS)44,97,98. The 
remaining ≈50 residues constitute the anchor region, formed by two transmembrane -
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helix domains (ET1-ET2) that cross the viral lipid bilayer in an antiparallel coiled-coils 
configuration with an stretch of 6 non-hydrophobic aminoacids between them (Fig. 8)44,98. 
It has been shown that the stem region plays a big role in viral assembly by neutralizing 
the electric repulsion between the negatively-charged inner surface of the E ectodomain 
and the non-polar viral membrane99,100, and in the stabilization of the PrM-E 
heterodimer98,101,102. The stem region also participates in the viral entry process by aiding 
in the trimerisation of the E protein that is required to expose the FL98,101. The anchor 
region, on the other hand, has been related to important functions regarding the assembly 
and release of mature viral particles98,100,103.  
 
 
Figure 8. Top view (left) and side view (right) diagrams of the dengue virus E protein ectodomain and 
transmembrane domains. The stem-anchor region of E and the transmembrane helices of M (M-H, M-T1 
and M-T2) proteins are shown in blue and orange, respectively (Reprint from reference 40).
40
.
40
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Dengue virus E protein has two conserved N-linked glycosylation sites at asparagine 
(Asn)67 in DII and Asn153 in DI. The Asn153 site is conserved in flaviviruses while the 
Asn67 is present exclusively in dengue viruses45,85. Structural studies proved that both 
glycosylation sites are used in mammalian cells and that each one carries a 
pentasaccharide mannose 3 core that is common to all N-linked oligosaccharides85. 
Usually, the functions attached to glycosylations on viral proteins include guidance in 
proper folding of the protein, adequate traffic in the secretory pathway, interaction with 
cellular receptors and immunogenicity104. Although there are contradictions about the role 
of these sites in dengue viruses, available data indicate that they might play an important 
role in tropism, pathogenesis, assembly of infective particles and cellular attachment105,106. 
Stronger evidence supports the notion that both sites are associated with increased 
infectivity and proper release of mature viral particles107. The dengue-specific 
glycosylation site at Asn67 has been implicated in mediating the attachment of the virus to 
the C-type lectin DC-SIGN expressed on dendritic cells and a subset of macrophages in 
the skin, which are thought to be the first target cells during dengue virus infection105,108. 
The E protein is a highly dynamic structure that undergoes severe conformational 
changes during the viral cycle. Each one of these intermediates (immature, pre-fusion and 
post-fusion trimeric conformations) is related to a particular purpose during a stage of the 
viral lifecycle and will be discussed later. The typical antiparallel dimeric conformation of 
the mature E protein is stabilized by a mixture of hydrophilic and hydrophobic interactions 
that take place along DII but that are concentrated in two regions: the inner face of the 
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opposing DIIs concentrate most polar interactions between the hydrophilic side chain of 
the -helices of each monomer, while the hydrophobic interactions occurred 
predominantly at the distal end of DII where the fusion loop is buried within a hydrophobic 
pocket formed at the interface of DI and DIII of the opposed monomer45,84,85,87-89,94,99. This 
last interaction is further promoted by the presence of the glycosylation at DI that further 
stabilizes the dimer by keeping DII in place45,89.  
 
2.5.2. Non-structural (NS) proteins 
2.5.2.1. Non-Structural Protein 1  
The NS1 protein is a variably glycosylated, ≈46kDa, protein that is translocated into 
the ER during translation of the viral mRNA17,21. NS1 folds into its mature structure and 
forms highly stable dimers with affinity for membrane interaction109,110. 
NS1 is mainly intracellular, but can also follow the secretory pathway and can localize 
to the cell membrane or be secreted17,110. 
Although its exact involvement remains unclear, studies have shown that intracellular 
NS1 plays an essential role as a cofactor for viral RNA replication111,112. The finding of 
NS1 co-localising at sites of RNA replication and with dsRNA intermediates, have 
suggested a structural role within the replication complex in close interaction with 
NS4A111,113,114. 
Extracellular NS1 can be found as a secreted hexamer or as a membrane-bound 
dimer115,116. The secreted soluble forms have been implicated in viral pathogenesis117-119, 
evasion of immune response120,121 and induction of autoimmunity122,123, while the 
membrane-anchored NS1 has been linked with a signal transduction capacity that might 
affect viral replication inside infected cells124. 
More recently, a series of studies have successfully connected NS1 from dengue 
virus to disruption of the endothelial cell integrity by inducing degradation of proteoglycans 
present on the cell surface125 and by inducing a strong pro-inflammatory response via 
TLR4 signalling, leading to endothelium hyper-permeability126,127. 
 
2.5.2.2. Non-Structural Protein 2A  
NS2A is a ≈22kDa, hydrophobic protein (Fig. 5) that is not well conserved among 
flaviviruses but seems to share similar structural features, the most important being the 
presence of an internal hydrophobic domain that suggests a transmembrane 
topology17,128. Regarding its functions, several studies have demonstrated a role for NS2A 
in viral assembly129,130, particularly in the process of generating viral-induced membrane 
structures which seem to be pivotal for the assembling process130. Additionally, NS2A not 
only co-localises with the double-stranded RNA (a replication intermediate) foci within 
infected cells, but also binds strongly to the 3’UTR region of the flaviviral genome, NS3 
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and NS5131. Taken together these results suggest that NS2A might also have a role in 
RNA replication with a function in coordinating the transition between RNA replication and 
viral assembly that leads to the generation of new viral particles86,131. 
Recently, NS2A has also been linked to a role in modulation of the host immune 
response by inhibiting interferon signals in infected cells132,133. 
 
2.5.2.3. Non-Structural Protein2B  
NS2B is a (≈14kDa) membrane-associated protein that associates with NS3 to 
activate the serine protease activity of NS3. In this sense NS2B serves as a cofactor for 
the viral protease134,135. Structurally, NS2B is formed by a hydrophilic central domain 
between two hydrophobic regions at the N- and C-terminus17. Residues 67-80 within the 
hydrophilic domain are critical for the cofactor activity of NS2B and had been shown to 
change the structure of NS3 activating its proteolytic activity136,137. The hydrophobic 
domains of NS2B also mediate the association of the NS2B-NS3 complex to the ER 
membrane138,139. 
 
2.5.2.4. Non-Structural Protein 3 
NS3 (≈70kDa) is a multifunctional protein that contains several enzymatic activities 
involved in the processing of viral proteins and replication of viral genome86,140.  
The N-terminal third of NS3 bears the chymotrypsin-like, serine protease catalytic 
domain involved in post-translational processing of the viral polyprotein17,134,141. The 
enzyme is formed by two -barrels (each one consisting of 6 -strands) with the catalytic 
triad (His51, Asp75, Ser135) located between them86,142; binding of NS2B stabilises NS3 
structure activating the substrate binding site and the protease activity136,143. The NS3 
cleavage site requires two basic aminoacids (dibasic (Arg/Lys)-Arg motif) followed by a 
small, un-branched aminoacid at P1’ position144. 
Following a poorly conserved inter-domain linker, the C-terminal portion of NS3 
carries domains with several functions associated with RNA replication including: sites for 
RNA binding, RNA helicase, RNA-stimulated nucleoside triphosphatase (NTPase) and 
RNA triphosphatase (RTPase)17,140. The helicase structure comprises 3 subdomains: the 
helicase activity is contained within a complex of -sheets and -helices and has been 
proven to be essential for viral replication142,145; the subdomain III is unique to the 
flaviviruses and contains a small region of highly basic aminoacids that may serve as site 
for protein and RNA binding, specifically to the 3’SL and the NS5 protein, during viral 
replication146,147. In addition to these proposed functions, subdomain III also encodes for 
the RTPase activity involved in dephosphorylating the 5’ end of the genomic RNA for the 
subsequent addition of the cap148,149. 
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NS3 has also been involved in other functions regarding virus assembly150 and 
modulation of intracellular environment151-153. In particular, the NS2B/NS3 protease 
complex is directly involved in cleaving the human mediator of interferon regulatory factor 
3 activator (STING) which down-regulates the intracellular defence against viral 
infections154 
 
2.5.2.5. Non-Structural Protein 4A  
NS4A is a small, hydrophobic protein (≈16kDa) that consists of an initial cytoplasmic 
N-terminal sequence, a central hydrophobic region formed by three different domains that 
are tightly associated with the ER membrane, and a final C-terminal sequence that acts as 
a signal for the translocation of NS4B into the ER155,156. Among its many proposed 
functions, NS4A is reported to be a cofactor for the NS3 helicase157-159; additionally, the 
membrane-interacting domains of the protein have been reported to participate in inducing 
membrane rearrangements for the viral replication site as well as in anchoring the 
replication complex157,160-162.  
Additional functions seem to involve modulation of the cellular environment163 and 
inhibition of immune response by blocking IFN signalling133,164. 
 
2.5.2.6. Non-Structural Protein 4B  
NS4B is a small (27kDa) hydrophobic protein closely associated with the ER 
membrane through at least 4 transmembrane domains, although its complete structure 
and topology is not fully understood156,165,166. Little is known about the actual role of NS4B 
during viral infection but it has been proved to be essential for viral RNA replication167,168. 
In particular, the protein co-localises to the RNA replication sites169, aids in the 
disassociation of the NS3 and the replication intermediates168,170, and induces the 
formation of specialized membrane compartments for replication168. 
In addition to these functions, NS4B has also been described as suppressor of 
cellular interference RNA and immune responses171-173. 
 
2.5.2.7. Non-Structural Protein 5 
Located at the C-terminus of the viral polyprotein, NS5 is the largest (≈105kDa) and 
most conserved of the flaviviral proteins with two main functions: it serves as the viral 
RdRp and as a methyltransferase (MTase) involved in cap-processing of the RNA17,174. 
The N-terminal region of NS5 carries the MTase function with close homology to S-
adenosyl-methionine (SAM) dependent methyltranferases motifs175,176. The enzymatic 
domain is conserved, both in structure and function, among all flaviviruses, with data 
showing its capacity to sequentially catalyse a guanine N-7 and a ribose2’-O-
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methylation174,177. Its involvement in capping of the viral genome was further supported by 
studies demonstrating the lethal effect of mutations disrupting the MTase activity178,179. 
The C-terminus of NS5 contains the viral RdRp enzyme, which has significant 
homology to other single-strand, positive-sense RNA viruses’ polymerases180,181. 
The central region between the MTase and the RdRp domains has nuclear 
localization signals that effectively guide a fraction of the viral protein to the nucleus of 
infected cells suggesting additional roles for NS5 probably involving suppression of 
cellular immune responses although this has not yet been confirmed182,183. Finally, this 
interdomain region also mediates the interactions with the 3’SL element of the viral 
genome146 and with NS3, which regulates its NTPase-RTPase activities184. 
Moreover, in the case of dengue, NS5 mediates STAT2 degradation by interaction 
with the host UBR-4 (ubiquitin protein ligase E3 component N-recognin 4) protein, thus 
interfering with the IFN signalling pathway185. 
 
2.6.  Viral Replication Cycle 
Although the understanding of the dengue virus replication cycle is far from complete, 
there’s enough evidence to believe that it shares many characteristics with other members 
of the Flaviviridae family17,186. The general process is shown in Fig. 9 and the most 
relevant stages are described in this section. 
  
 
Figure 9. Schematic representation of the general steps involved in the dengue life cycle. 1) Depending 
on the level of PrM cleavage, dengue viral particles exist as a mixture of different structures, fully mature 
particles are infectious while fully immature particles aren’t; depending on the amount of PrM uncleaved, some 
partially mature particles can be infectious. The virus attaches to the host cell receptor (or the Fc-receptor in 
the case of ADE) (2) and enters the cell via clathrin-mediated endocytosis (3). Acidification of the early 
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endosome triggers viral fusion with the endosomal membranes and the liberation of the nucleocapsid (4). The 
viral ARN is then translated and processed to produce viral proteins (5) before commencing the replication 
process (6). The new viral genomes are packaged by the capsid protein (7). Viral assembly initiates when the 
nucleocapsid buds into the ER (8). The immature viruses follow the secretory pathway and arrive to the trans-
Golgi network where low pH triggers maturation thru PrM cleavage by furin protease (9). Pr remains attached 
until it’s released by the neutral pH of the extracellular environment (Reprint from reference 186). 
 
186
.  
2.6.1. Attachment-Entry-Fusion: 
 In this initial step, the virus attaches to the membrane of the target cell and interacts 
with the cellular receptor inducing its internalization via clathrin-mediated endocytosis187.  
Although there is compelling evidence indicating that the viral cell receptor-binding 
motif resides somewhere within DIII, the identity of the cell receptor(s) is still unknown188. 
Several groups have identified cell receptors that are able to bind dengue virus’ E protein, 
including: glycosaminoglycans (heparan sulphate in particular)189, stress response 
proteins190, heat shock proteins191, mannose receptor in macrophages192 and the already 
mentioned DC-SIGN and L-SIGN105,193. The general consensus is that dengue virus entry 
into the host cell probably involves a receptor complex composed of several molecules in 
which the glycan-binding receptors serve as an initial interaction to allow close range 
contacts between the virus and the cell188,194.  
Following intake, the exposure to acidic pH inside the endosome triggers E protein 
trimerisation (Fig. 10) which leads to the exposure of the fusion loop, a necessary step to 
initiate the fusion process17,42. 
 
 
Figure 10. Changes on the viral surface arrangements upon exposure to acidic pH inside the early 
endosome. Schematic representation of the surface of a mature flaviviral particle at a) neutral pH and b) 
acidic pH (Reprint from reference 42).
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Upon exposure to low pH condition in the early endosome, several key histidine 
residues along the E protein change their protonation state and become doubly-positively 
charged, which generates a motion that breaks all the intersubunit contacts on the viral 
surface thus giving the initial energy required for trimerisation84,99,195. As pictured in Fig. 
11, the trimeric structure of E involves a conformational change that reorients the 
molecule from a horizontal antiparallel dimer into a vertical parallel trimer, where the 
fusion loops are exposed at the tip of the trimer but retaining their original conformation, 
a b 
22 
 
forming an “aromatic ring” that serves as anchor for the fusion process with neighbouring 
hydrophilic residues and restricting the insertion of the complex to the inner leaflet of the 
endosome membrane87,196. After anchoring to the endosomic membrane, the E pre-fusion 
intermediate folds back on itself in such a way that the anchor region is pushed towards 
the fusion loop into what is known as the post-fusion intermediate. This movement fuses 
the viral membrane and the endosomal membrane and allows the release of the viral 
nucleocapsid into the cytosol84,87. 
 
 
 
Figure 11. Membrane fusion by flaviviruses. Schematic representation of the conformational 
intermediates of the E protein during the fusion process. a) Dimeric conformation of the E protein at 
neutral pH, b) Prefusion intermediate conformation of E as the result of the acidification in the early endosome 
that leads to a rearrangement of the dimer and the exposure of the fusion loops forming an anchor that inserts 
into the endosome membrane, c) Following the insertion into the host membrane the trimeric E suffers further 
rearrangements that cause a folding back motion which brings the anchor regions and the fusion loop together 
into a postfusion intermediate that connects viral and host membranes completing the fusion process (Reprint 
from reference 84). 
84
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2.6.2. Translation and polyprotein processing:  
After viral entry and genome uncoating, the RNA genome serves as a messenger 
RNA (mRNA) and is translated by the cell machinery to produce a large polyprotein that is 
cleaved by host and viral proteases to yield the mature structural and non-structural 
proteins 70,86. The general topology of the viral polyprotein is shown in Fig. 5. 
The main mechanism for translation is the typical cap-dependent initiation in which 
the type 1 cap at the 5’ end of the viral genome is recognized by eIF4E that in turn recruits 
the whole translation machinery197. In cellular mRNAs, translation is enhanced by the 
presence of the poly(A) tail and the 3’ end of the RNA; in dengue, several secondary 
structures at the 3’ UTR region of the viral genome increase viral translation which seems 
to be even more important to compete for the recruitment of the translation complex as 
dengue virus is unable to shut down cellular translation during infection197,198. Additional 
ways to overcome this translational competition include the generation of viral-induced 
ER-derived membrane structures where the viral replication, translation and assembly 
machinery are concentrated199, as well as a non-canonical, cap-independent alternative 
a b c 
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mechanism of translation that ensures viral translation in adverse cellular conditions like 
high osmolality or reduced levels of eIF4G200. 
As represented in Fig. 5, the viral polyprotein is co-translationally cleaved by the host 
signal peptidase at sites between C-PrM, PrM-E, E-NS1 and at the C-terminus of NS4A 
while the viral protease (NS3/NS2B) is responsible for the cleavages at NS2A-NS2B, 
NS2B-NS3, NS3-NS4A, NS4A-NS4B and NS4B-NS586. The enzyme that cleaves at the 
NS1-NS2A site is unknown17. Cleavage of Pr from M is carried out by the trans-Golgi 
localised host enzyme furin. 
 
2.6.3. RNA Replication:  
Flavivirus replication occurs within viral-induced membrane structures, which facilitate 
RNA replication by increasing the local concentration of the necessary components and 
also by providing a scaffold for the assembly of the replication complex86,201. In addition, 
these membrane-sites may fulfil a role in hiding the viral intermediates from the cellular 
defences202. 
Available data show that the flavivirus replication complex probably consists of a 
double-stranded RNA template in association with all the non-structural viral proteins and 
some host factors within the aforementioned membrane structures (a proposed model is 
shown in Fig. 12)17,203,204. 
 
  
 
Figure 12. Schematic representation of the dengue virus replication complex. Derived from available 
literature in flavivirus replication, this hypothetical model shows the replication complex (RC) anchored within 
viral-derived membrane vesicles facing the cytoplasm and has been variably shown to comprise a double-
stranded RNA template, the viral non-structural proteins and host derived factors (Reprint from reference 204). 
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Viral replication begins with the synthesis of a complementary minus strand to the 
genome RNA that serves as a template to generate additional genomic RNA molecules, 
and forms the double-stranded intermediated (named replicative form (RF))17. Dengue 
virus RNA replication is a semiconservative, asymmetric process in which the positive-
sense RNA is synthesized between 10 to 100 times more than the negative strand205; 
additionally, the process is coupled with the RTPase activity of NS3 and the MTase 
activity of NS5 to produce the 5’ cap of the viral genome, thus the newly-made positive-
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sense RNA genomic molecules can be further used for replication or translation or 
packaged into new virion70,86. 
 
2.6.4. Assembly, Maturation and Release of Viral particles:  
Although it remains a highly unknown process, viral assembly occurs within the ER-
derived membrane structure induced by the virus in the infected cells206. Viral assembly 
begins when the capsid protein, attached to the cytosolic side of ER membrane, 
associates with one molecule of the RNA viral genome and forms the nucleocapsid70. 
Once formed, the nucleocapsid acquires the viral envelope by budding into the ER 
lumen where the PrM and E proteins remain attached by means of their transmembrane 
anchors70. The budding particles enter the ER lumen as immature non-infective particles 
with a characteristic “spiky” appearance due to the presence of the covalently-linked Pr-M 
peptides that form heterodimers with the E protein across the viral surface17,80. Maturation 
occurs as the viral particles are transported through the secretory pathway where the viral 
surface undergoes major changes due to the acidic environment of the trans-Golgi 
network (TGN)44,207. As shown in Fig. 13, exposure to a low pH induces significant 
rearrangements of the surface proteins that shift from an E trimeric spike-like 
conformation to an E dimeric antiparallel herringbone organization that exposes the furin 
cleavage site on PrM207. The cleavage of the Pr peptide renders mature infective viral 
particles. However, the Pr peptide remains attached to the E dimer acting as a cap-like 
structure to protect the fusion loop from premature exposure that could lead to viral-
membrane interaction with membranes of the secretory pathway before viral release78,80. 
After mature particles are secreted from the cell, the change to a neutral pH environment 
stabilises the E dimeric formation and disassociation of the Pr peptide67.  
 
 
 
Figure 13. Structure of the dengue virion and conformation of the E protein during maturation. a) Cryo-
EM reconstruction of the immature virion at neutral pH after budding into the ER lumen, where the E exist as a 
Pr-E heterodimer in a trimeric conformation, hence the “spiky” appearance of the virus. b) Structural 
rearrangements of the immature particle at the low-pH in the TGN where the Pr-E heterodimer change to a flat 
a b c d 
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dimeric conformation. c) The structural change exposes the furin cleavage site in PrM that remains attach to 
the E protein after cleavage. d) The mature viral particle is secreted from the cell into a neutral pH 
environment where the Pr peptide is released (Reprint from reference 67). 
67
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In practice, however, the process of maturation appears to be inefficient and many 
particles, usually referred as mosaic as they contain both mature and immature regions, 
are released with various degrees of Pr cleavage, the extent of which determines whether 
they are infective or not207,208. If Pr is not cleaved the E protein rearranges it’s dimeric 
organisation at neutral pH and reverts to the “spiky” intracellular configuration causing a 
shift on the viral surface with the formation of 60 prominent and irregular Pr-E trimeric 
spikes that increase the particle diameter by about 100Å (Fig. 14)207. Previous studies 
have demonstrated that fully and partly immature particles constitute approximately 40% 
of all particles released from infected cells207. In addition subviral particles (also known as 
virus-like particles (VLPs)) are routinely observed in flaviviral infections. These are small 
(≈300 Å), smooth, mature-like particles formed by the E and M proteins and the lipid 
bilayer without the nucleocapsid209. These particles undergo the same maturation process 
as the mature virions, and can be artificially produced from cells by expressing the genes 
coding for the PrM-E proteins40. As a consequence of all these viral and subviral forms 
released from infected cells, and together with viral “breathing” and the temperature-
dependent changes on the configuration of the viral surface, the level of structural 
variability in flaviviruses is very large, and has significant implications not only for the 
infection process but also for the immune response against it.  
 
 
 
Figure 14. Cryo-EM images of two WNV preparations. Red arrows indicate fully immature “spiky” particles 
while blue arrows indicate fully mature “smooth” virions. Partially mature mosaic particles are indicated by 
green arrows. Bar represents 500 Å (Reprint from reference 210). 210. 
 
3. DENGUE DISEASE 
3.1.  Virus-Vector Interactions 
Two different transmission cycles have been proven to exist for dengue virus: the 
sylvatic cycle and the endemic urban cycle (Fig. 15)7. The urban endemic cycle is the 
most important for dengue and humans serve both as reservoir and amplification host. 
This cycle is dependent on A. aegypti and A. albopictus as transmission vectors53,211. 
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Figure 15. Dengue transmission. Dengue virus has been shown to be maintained through two different 
transmission cycles: the sylvatic cycle which involve mainly non-human primates as host and forest canopy-
dwelling mosquitos as vectors and the epidemic urban cycle in which the virus is transmitted among humans 
by Aedes spp. mosquitos, principally A. aegypti and A. albopictus (Reprint from reference 212). 
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The efficiency of the endemic cycle is favoured by the ecology and behaviour of A. 
aegypti, the most important vector in this scenario: it is closely associated with human 
dwellings and has adapted to urban environments; vector competence is further increased 
by the fact that females feed almost exclusively on human blood during the gonotrophic 
cycle. In addition, unlike many other mosquitos, A. aegypti is active during daylight hours, 
and feed on several hosts during each blood meal, which further increases the risk of 
transmission53,213.  
A. albopictus serves as a secondary vector of dengue and is found mainly in forest 
areas. Both species show high water requirements for breeding and lay their eggs in 
water-holding vessels or tree holes, which implies a peak of mosquito densities, and 
disease incidence during rainy seasons211,214. 
In the sylvatic cycle dengue virus circulates among non-human primates that serve as 
hosts and reservoirs. Some of the mosquitos species involved in this transmission are A. 
africanus, A. leuteocephalus and A. furcifer among others7,214. 
Once ingested, the virus infects the epithelial cells of the midgut where it spreads into 
the haemocele, finally infecting the salivary glands from which the virus is transmitted to 
the vertebrate host during the blood meal215.  
 
3.2.  Virus-Host Interactions 
In the case of dengue, identification of the target cells and spread of the infection in 
vertebrate hosts has proven to be difficult. However, available data support the notion that 
cells from the reticuloendothelial system (consisting primarily of monocytes, macrophages 
and derived cells) are the main target of the viral infection with the Langerhans immature 
dendritic cells in the skin serving as the initial replication target for the virus108,216. These 
cells migrate into lymph nodes where the virus spreads to other cells from the 
macrophage-monocyte lineage53. The infection is amplified in lymph nodes and then 
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spreads through the blood via infected monocytes to the spleen, liver and bone marrow 
that serve as additional sites for amplification217. 
Data demonstrating viral dissemination in solid organs has been inconsistent, with 
studies reporting detection of viral antigens in lymphocytes, hepatocytes, cardiac fibres 
and pneumocytes218,219; however, any organ containing reticuloendothelial cells could 
eventually serve as a site for viral replication220. Although relevant during the 
pathogenesis of infection125, the role of endothelial cells within the infection is not yet 
confirmed because they are susceptible to viral infection in vitro but infection of the 
endothelium does not seem to be present in vivo even in severe manifestations of the 
disease53.  
 
3.3.  Clinical Manifestations of the disease 
Dengue infection causes a systemic disease in humans with a wide symptomatic 
spectrum that ranges from non-symptomatic to severe haemorrhagic disease211. 
The majority of dengue infections, especially those involving children and people in 
highly endemic regions, are asymptomatic221. In patients with clinical disease, the illness 
can be divided in three different phases: febrile, critical and recovery; the main aspects of 
each phase are resumed in Fig. 16. Additionally, depending on the clinical evolution of the 
patient, the infection can be classified in three different conditions: the non-severe form of 
the disease called Dengue Fever (DF), and the more compromising manifestations named 
Dengue Haemorrhagic Fever (DHF), and Dengue Shock Syndrome (DSS)211,222. 
Paradoxically, the clinical management of the patient is simple and effective211. The 
key resides in a deep knowledge and early recognition of the disease to initiate correct 
and timely treatment222. However, given the relatively common symptoms involved in the 
initial stages, early diagnosis of the disease is complicated by the vast differential 
diagnosis211. 
 
    
Figure 16. The course of dengue illness (Reprint from reference 211). 
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3.3.1. Phases of the Dengue disease  
3.3.1.1. The Febrile Phase   
 After an incubation period of 4-7 days patients develop high fever (39-41.5°C) that 
marks the beginning of the febrile phase. This phase usually last between 2 and 7 days 
and is accompanied by generalised body ache, arthralgia, myalgia, frontal headache, 
retroocular pain and skin maculopapular rash (starting in the trunk and expanding to the 
face and extremities but not affecting palms or soles); together, these findings explain why 
dengue disease is also known as “Breakbone fever” in many countries211. Although not as 
common, some haemorrhagic manifestations like mucosal bleeding (mainly on the nose 
and gums) can be seen5. Significant laboratory findings include neutropenia with 
associated lymphocytosis (including a high percentage of atypical lymphocytes) and 
thrombocytopenia5. 
At this stage of the disease, severe and non-severe forms of the disease are 
indistinguishable and monitoring the patient is crucial to avoid complications that could 
lead to a fatal outcome211. 
 
3.3.1.2. Critical Phase 
The febrile phase finishes when the patient’s temperature drops back to normal 
levels, or slightly higher (37.5-38°C). This event may be accompanied by an increased in 
capillary permeability which leads to a significant plasma leakage and marks the start of 
the critical phase211. Capillary permeability also marks the difference between the non-
severe and severe forms of the disease: patients without an increase in capillary 
permeability will recover without complications marking the end of the typical course for 
DF, while those suffering from capillary leakage (DHF) may show an increasingly 
worsening condition as a result of the reducing plasma volume that may end in a very 
complicated scenario of severe shock (DSS)5,211,222.  
Significant extravasation of plasma through the gaps between endothelial cells last 
between 24-48 hours. Patients suffering from DHF usually present haemorrhagic features 
like scattered petechiae, purpuric lesions, epistaxis and mucosal bleeding; in addition, 
patients may present ascites and pleural effusion211,221. Blood analysis during this phase 
shows haemoconcentration as evidence of the vascular leak of plasma, together with a 
more severe thrombocytopenia and absolute granulocytopenia5,17. 
If plasma leakage is not treated, patient develops severe hypovolemia that results in 
circulatory failure and shock (DSS)5. Some warning signs of DHF progressing into DSS 
are: intense abdominal pain, persistent vomiting and a sudden change from fever to 
hypothermia with profuse sweating221. At this point treatment is critical as prolonged shock 
and the consequent hypoxia could develop into multiorgan failure compromising the life of 
the patient211.  
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3.3.1.3. Recovery Phase 
If the patient survives the critical phase, the body reabsorbs the leaked fluid thus 
returning to a stable haemodynamic state211. However, prolonged asthenia, mental 
depression and cardiac abnormalities are also common in infected patients after the fever 
breaks222. 
In addition, rare manifestations like encephalopathy, liver failure or cardiomyopathy, 
have been described in several patients during the course of a dengue infection211.    
 
3.4.  Epidemiology 
In order to get a clear grasp of dengue virus’ impact on the different aspects of human 
life, it is fundamental to understand the viral geographic distribution and the overall burden 
of the disease in endemic countries223. This is also critical to determine the best way to 
properly use and distribute the limited resources available for disease control211. In 
addition, epidemiological data is crucial when performing clinical surveillance and for 
scoping preventive measures when facing epidemics or outbreaks in endemic 
countries6,224. 
Together with the current situation of Zika virus225, dengue is the most rapidly 
spreading mosquito-borne viral disease in the planet and a major health concern for 
nearly half of the world’s population, and is also one of the principal causes of paediatric 
hospitalization and deaths in endemic countries211,226. Recent data indicates that up to 3.6 
billion people are currently living in areas under primary risk of infection (Fig. 17)6,26. 
Although estimates vary, there are over 300 million infections each year with close to 100 
million symptomatic cases and over 500,000 episodes of DHF/DSS, with an annual 
mortality reaching over 20,000 deaths224,226,227. Moreover, due to poor and passive 
surveillance systems in endemic countries, difficulties in the diagnosis and low case 
fatality, the true incidence and impact of dengue is probably much higher6,223; in fact, 
Samir Bhatt and others developed an algorithm to create an evidence based map of 
dengue risk and estimates of worldwide infections on the basis of the global population in 
2010, obtaining total infection figures that were more than three times those predicted by 
the World Health Organization (WHO)223. 
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Figure 17. The global distribution of dengue, 2014 (Reprint from reference 26). 
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The remarkable spread of this infection means that nearly 120 countries are endemic 
for dengue with the incidence of the disease showing a 30-fold increase over the past 5 
decades (Fig. 18), which is probably among the main reasons why the WHO classified it 
as the “most important mosquito-borne viral disease in the world”224.   
  
 
 
Figure 18. Average number of cases reported to the WHO from 1955-2007 and number of cases 
reported in recent years (2008-2010) (Reprint from reference 224). 
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. 
 
Dengue epidemics are a significant health, economic, social and even political burden 
on the countries where they occur, generating consequences that are difficult to 
measure11. Indeed, determine the actual economic impact (cost) of dengue in endemic 
countries has proven to be a very difficult task11,228. A recent study made by Shepard and 
collaborators229 concluded that dengue epidemics in America cost the region around 2.1 
billion US dollars per year on average, without including the cost of vector control 
measures. Similar studies have been done generating figures that in general 
underestimate the real cost of the disease25,230,231.  
 
3.4.1. Distribution of the disease  
Despite the uncertainty in the actual number on infections, there’s enough evidence 
showing dengue transmission in every populated continent. 
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Asia: Although dengue is a global concern, 75% of the population exposed to the 
infection live in the Asia-Pacific region. Within these regions, Southeast Asia is by far the 
most affected with 1.3 billion people at risk and rates for severe dengue disease almost 20 
times higher than those reported in America211,230. In the last decade, the disease 
expanded to almost every country in the region231. 
Africa: Little is known about the current situation of dengue in Africa mainly because 
the disease is not officially reported to the WHO and there’s a higher probability of under-
recognizing the disease amidst the wide variety of similar infectious conditions that affect 
the region, especially malaria6,211. However, there´s evidence suggesting that the number 
of infections and the spread of the disease are increasing with endemic dengue 
transmission in 34 countries and confirmed isolation of all four serotypes in the 
continent211,232. 
America: Almost all American countries are hyperendemic with active dengue 
transmission224. The situation is more severe in Latin America where the four serotype are 
in circulation and the vast majority of the infection events are reported: 65% of them in the 
region comprising Brazil, Paraguay and Argentina followed by the Andean region of 
Colombia, Ecuador, Peru, Venezuela and Bolivia with 20% and Central America and the 
Caribbean reporting almost all remaining cases6,211. In North America, almost all the 
reported dengue infections are imported from endemic regions although outbreaks in 
Hawaii and Texas have been reported211,233. 
Europe: After the last documented epidemic of dengue in Greece between 1926-
1928, no transmission has been reported in the region and data available indicates that 
most of the reported cases are imported211.  
 
3.4.2. Factors influencing incidence and geographic spread of DENV 
As with any vector-borne infectious disease, dengue’s epidemiology is determined by 
an epidemiological triad that includes the human host, the pathogen and the mosquito 
vectors11,226. Although there are many factors that have positively influenced the incidence 
and spread of the disease, there are some that are considered among the principal drivers 
for dengue’s current epidemiological landscape: 
 
3.4.2.1. Lack of efficient mosquito control  
Prevention and control of dengue disease currently depends on effective control of 
the mosquito vector5; however, the scarce resources available have been mostly used for 
emergency spraying (Ultra low volume) of organophosphate insecticides in response to 
reported cases of dengue with the objective of interrupting transmission11. This control 
method has higher impact in society because of its visibility, but fails in controlling the 
spread of the disease because it is meant to interrupt transmission by killing the infected 
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adult females that usually dwell indoors where the treatments don’t reach and have no 
effect on larvae that remain behind to restart the transmission cycle1,11,15. The only 
effective way to control the vector is to pair the insecticide spraying with elimination of 
breeding sites1. 
 
3.4.2.2. Increase in travel and trade due to globalization 
The contributions of increased mobility in vector and host populations may be one of 
the top reasons behind the recent increase in transmission and spread of dengue. The 
globalized economy has created a global reality of international travel and exchange of 
goods in which the movement of infected people via air travel has been a relevant driver 
in the expansion of the disease6,11. International trade, especially that involving sea 
shipment, can also be involved in the introduction of vectors in new regions6. 
 
3.4.2.3. Urbanization-related factors  
Unplanned population growth paired with inadequate housing conditions especially 
regarding water supply, sewage or waste management have facilitated the creation of 
urban breeding sites for the mosquito vector, increasing vector densities in intimate 
association with crowded human populations resulting in a higher risk of dengue 
transmission5,6. Indeed, data from seroprevalence studies performed between 
neighbouring border cities in Northern Mexico and Southern Texas, indicate that 
socioeconomic factors have a significant impact over dengue’s dynamics, concluding that 
more favourable conditions correlated with reduced larvae breeding sites and lower 
dengue transmission233,234.  
 
3.4.2.4. Climate factors  
Climatologic conditions play a fundamental role in mosquito biology, especially in the 
transmission cycles of the virus they transmit, with higher temperatures increasing not 
only the distribution of the vector, but also the rate of larval development and the biting 
rate of a complete blood-meal while reducing the replication time of the virus in the vector, 
thus facilitating the overall transmission of the pathogen235. Several studies have shown 
the connection between the increase in temperature and dengue incidence226,236,237. 
These studies also arrived concluded that relative humidity is also an important factor in 
dengue’s dynamics as well226,238. 
 
4. THE IMMUNE RESPONSE AGAINST DENGUE VIRUS 
During their life span, animals encounter a wide variety of pathogenic viruses and 
microorganisms. The immune system constitutes the defence line that protects these 
hosts from otherwise lethal or compromising infections.  
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In the case of viruses, prevention of infection or viral clearance depends on both 
innate and adaptive immune response mechanisms, where the humoral immune 
responses (mainly antibodies) are able to prevent the infection of cells at the earliest 
stage, while the cellular component of immunity is more involved in the elimination of the 
viral infection once it has been established239. 
Dengue virus is a particular case among human pathogens in that the immune 
response of the host may direct the clinical outcome of the infection in two completely 
opposite directions: it can either increase the severity of the disease or it can efficiently 
neutralise the pathogen1. This appears to be the result of a combination of unique viral 
characteristics, more importantly, the existence of four serotypes that share many 
common antigens but are different enough to avoid cross-neutralisation, and their tropism 
toward the mononuclear phagocytic cell line which is one the main components of the 
immune system220. 
 
4.1.  Innate Immunity 
The innate immune system is the first line of defence against viral infections and 
involves the recognition of pathogen-associated molecular patterns (PAMPs) within 
infected cells that trigger a variety of immediate defensive measures220. The main 
characteristics of innate responses are that they do not require previous exposure to the 
pathogen for activation and don’t show enhancement upon subsequent responses. Some 
examples of innate immune mechanisms are the Toll-like receptors which can signal cells 
to produce different cytokines, the complement system and natural-killer cells239.  
 
4.1.1. Toll-like receptors (TLRs) and other intracellular sensors 
TLRs are important pattern recognition receptors that, together with other intracellular 
proteins, like the helicases melanoma differentiation-associated protein 5 (MDA5) and 
retinoic acid-inducible gene 1 (RIG-I), act as sensors to mediate some of the first innate 
responses against viral RNA240,241. TLR3, RIG-I and MDA5 have been shown to recognize 
the viral genome during the entry process and modulate viral replication by inducing a 
strong Interferon- and IL-8 response240,242. Other TLRs involved in a similar way are 
TLR7 and TLR8 which rare also able to recognize viral RNA molecules and induce a 
similar cytokine response to prevent viral amplification243,244. Upon stimulation of these 
receptors, the activation of an intracellular signalling pathway leads to an increase 
production of proinflammatory cytokines that compromise viral replication within the cell245. 
 
4.1.2. Interferons (IFNs) and cytokine response 
IFNs can be divided in three different types on the basis of their biochemical 
characteristics, pattern of expression and mechanism of action, in the case of DENV type 
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I and type II IFNs are particularly important239. Type I IFNs like IFN and IFN are 
produced by a wide range of cell types and have antiviral activity against DNA and RNA 
viruses220.  
After dengue virus infection, IFNs are rapidly induced and promote a general antiviral 
state within the infected cell by activation of RNA nucleases, stimulation of lymphocytes 
and activation of other effector cells220. Several studies have shown that production of 
IFN and IFN have an inhibitory effect on dengue virus infection, especially during the 
initial stages of the RNA replication, and that these types of innate responses are 
important to control the infection in vivo246,247. 
IFN is a type II IFN and is produced mainly by T lymphocytes and natural-killer cells 
in response to the interaction with proteins derived from dengue virus (not as a result of 
viral infection)239. The function of this cytokine can be either beneficial or detrimental for 
the host depending on the scenario: there are studies indicating that IFN can prevent the 
infection and spread of dengue virus246,248,249, while others state that it can actually 
promote infection by increasing the expression of the Fc receptor in monocytes through 
an antibody-dependent mechanism250. 
In response to these antiviral effects, dengue viruses have developed mechanisms to 
block IFN’s antiviral activities with NS2A, NS4A, NS4B and NS5 showing the ability to 
inhibit the IFN-induced gene expression133,173. 
 
4.1.3. The complement system (C’) 
The C’ is considered one of the main effectors of the innate immune systems 
although it also has the ability to interact with the adaptive branch of immunity251. This 
system consists of a network of proteins able to recognize target proteins and initiate an 
amplifying chain-reaction type activation that leads to the lysis of infected cells or even 
enveloped viruses like dengue252. In addition, C’ can also mediate the neutralization of 
viral particles reducing the levels of infection251,253. 
However, dengue virus interactions with the proteins of C’ are thought to play an 
important role in viral pathogenesis, particularly in the process of vascular permeability 
through the viral protein NS1 that has been shown to regulate C’ function by degrading 
some of its components110,117. 
 
4.1.4. Natural killer (NK) cells 
NK cells are a specialised type of cytotoxic lymphocytes that have an analogous 
function in the innate immune system to that of the CD8+ T lymphocytes in the adaptive 
immunity. These cells represent between 5-15% of circulating lymphocytes and are able 
to rapidly kill cancer-prone or virus-infected cells220. 
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The cytotoxic activity of NK cells does not depend on the specific recognition of viral 
peptides, but rather on the detection of an “altered cell” phenotype through the balanced 
response involving a variety of stimulatory and inhibitory receptors on the surface of the 
cells. NK cells are particularly sensitive to a reduced expression of major 
histocompatibility complex (MHC) protein and their lytic activity is greatly enhanced by the 
presence of IFNs in the cellular milieu254. Moreover, antibodies bound to cell surface 
proteins mediate antibody-dependent cellular cytotoxicity (ADCC) through the Fc 
receptors on the NK cell220. 
In the case of dengue infection, cytotoxicity of infected cells by NK cells in an ADCC 
manner has been demonstrated255. Although ADCC seems to be the main lytic 
mechanism involved in clearance of infected cells, NK cells are also able perform this 
function in the absence of antibodies which implies the existence of a more direct way of 
activation; in fact, NK cell surface protein NKp44 has been implicated in the direct 
recognition of dengue E-derived peptides, although its actual role in NK cell function 
during dengue virus infection needs further confirmation256,257. 
In an attempt to counteract NK cell function, dengue viruses can cause an increased 
expression of MCH-I antigens on the surface of infected cells making them less 
susceptible to NK cell mediated lysis258. In spite of this, the role of NK cells on the defence 
against dengue virus infection in vivo is still highly unknown.  
 
4.2.  Adaptive Immunity: Lymphocytes 
When the pathogen is able to surpass the defence established by innate immunity, it 
generates a threshold level of antigens and stimulatory signals that triggers the activation 
of the adaptive immunity252. Opposite to the innate mechanisms, adaptive immunity refers 
to responses that develop after a first exposure to the pathogen and act in an antigen-
specific way, showing enhancement of the response in terms of time, affinity and intensity 
after subsequent encounters239. The adaptive immune response is divided into two major 
components: the humoral immune response involves the activities of B lymphocytes and 
antibodies, while the cellular responses cover the functions of the CD4+ and CD8+ T 
lymphocytes. 
  
4.2.1. Targets of the T cell response against dengue virus 
Primary infection with dengue virus induces the response of very diverse virus-
specific T cells in which some are specific against the infecting serotype while others are 
heterologous and show cross-reactivity against other serotypes and related flaviviruses239.  
As show in Fig. 19, although the viral epitopes responsible for inducing CD4+ and 
CD8+ T cell-mediated immunity are found throughout the viral polyprotein, most of them 
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are concentrated on the non-structural proteins, especially on NS3 and NS5, which 
represent the main target of the adaptive cellular response259,260.  
 
 
  
Figure 19. Dengue virus protein targets to T cell response. Scheme showing the general structure of the 
dengue virus polyprotein indicating (with arrows) the position of epitopes recognize by CD4+ and CD8+ 
human T cells (Reprint from reference 260). 
260
 
 
Given that NS3 protein represents a small fraction of the viral genome and that 
there’s a ≈70% sequence identity between the four dengue serotypes, T cell epitopes are 
highly conserved and generally induce cross-reactive immune responses260. Extending 
this idea to the whole viral genome we can conclude that, in general, an adaptive immune 
response directed against a non-structural protein will show a great degree of cross-
reactivity while responses against structural proteins, which show a higher variation 
among DENV serotypes, tends to be more type-specific239. 
 
4.2.2. CD4+ T lymphocytes 
After recognising virus infected cells, dengue virus-specific CD4+ T cells are activated 
and respond with a diverse range of functions that include: proliferation, cytokines (CKs) 
production and target cell lysis53.  
Although these cells have demonstrated the capacity to lyse infected cells in vitro, 
CD4+ T cells principal response during a dengue infection involves the production of a 
wide range of CKs. Most studies agree that the pattern of CKs produced in these contexts 
follows a TH1- or TH0-like pro-inflammatory type I CKs profile, like tumour necrosis factor 
 (TNF), IFN and interleukin 2 (IL2)261. In addition, CD4+ T cells activated against 
dengue virus have been shown to express Fas-ligand and perforin which might be 
involved not only in direct killing of infected cells but also on tissue damage, thus 
contributing to the pathogenesis of the infection262. 
It’s important to mention that the aminoacid differences between dengue viruses can 
affect the interaction between the viral-derived peptide-MHC complexes on the infected 
cells and the T cell receptor (TCR) of the lymphocyte, which could have significant 
functional consequences, since the type of response elicited by T cells is highly 
dependent on the strength of the signal sensed though the TCR260. Especially during a 
secondary heterotypic dengue infection, memory T cells created during the first infection 
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may not interact properly with the peptides of a different serotype, inducing an abnormal 
response that could influence the clinical outcome of the infection53. 
 
4.2.3. CD8+ T lymphocytes 
 Like CD4+ T lymphocytes, upon primary infection with dengue virus, specific CD8+ 
(cytotoxic) T lymphocytes (CTLs) generate responses specific to the infective serotype 
and others that cross-react with heterologous serotypes239,263. 
Although their role during dengue infection is not very clear, some studies have 
shown evidence supporting the idea that activated CTLs have an important role in 
controlling the infection264. Activation of CTLs happens after recognition of the specific 
epitope in the context of MHC-I molecules which induce IFN production, clonal 
proliferation and cytolytic activity265. Interestingly, some epitope variants derived from 
heterologous viral serotypes have been shown to alter the proportional response of CTL 
by acting as superagonists causing an effect that may contribute to the pathologic 
manifestations of the infection; this is more relevant given the fact that CTLs responses 
against dengue virus are frequently cross-reactive239,266. 
 
In summary, since T lymphocytes recognise virus-derived peptides in the context of 
MHC molecules and are not able to recognize complete viral particles, their main role is 
not in preventing viral infection. Conversely, through their diverse responses after 
activation, specific T cells could restrict viral replication and the development of the 
disease by eliminating infected cells and producing proinflammatory CKs260.  
T cells have also been involved in the pathogenesis of the severe manifestations 
seen during dengue virus infection, mainly as a result of the proinflammatory effects of the 
T-cell derived CKs. However, it’s still unclear to what extent is T cell activation involved in 
either protective immunity or pathogenic processes267. 
  
4.3.  Adaptive Immunity: Antibody response 
Neutralising antibodies against viruses are widely considered to be vital for controlling 
infection and dissemination of the pathogen; moreover, they are the most common 
element used to indicate protection against most viral diseases53,220. These statements 
apply also to the infection with dengue, although in this case the correlation is not always 
clear220. 
 
4.3.1. Antigenic structure of dengue virus and antibody specificity 
 After an infection with dengue virus, both human patients and murine models have 
been shown to developed antibodies against structural and non-structural viral proteins. 
Proteins E, PrM and NS1 are the main targets of the antibody response while antibodies 
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against C, NS3, NS4b and NS5 have also been described although they are not as 
common or abundant268-270.  
 
4.3.1.1. The envelope protein 
E protein is the most important target of the antibody response during infection. 
Neutralising epitopes have been described on all three domains displaying varying 
degrees of cross-reactivity not only between dengue serotypes, but also among other 
flaviviruses64,260. Several reports indicate that antibodies against DIII, particularly those 
that recognise the upper lateral surface of the domain, show the highest neutralizing 
capacity; coincidently, this is also the most variable domain between serotypes, which 
means that these antibodies are usually highly specific and explain why DIII has been 
considered for vaccine development92,271,272.  
However, studies have shown that after natural dengue infection, the immune 
response is dominated by highly cross-reactive, weakly neutralising antibodies, directed 
mostly against epitopes on DI/DII273,274. While the FL appears to be a major target of the 
antibody response275, there are reasons to think that the contribution of DIII is very limited 
and does not account for the strong type-specific neutralising response seen in patients: 
levels of anti-DIII antibodies in human sera are very low276 and depletion of DIII-specific 
antibodies has little effect on the viral neutralizing capacity of human sera271. Moreover, 
viruses carrying mutations in DIII epitopes recognised by neutralising antibodies were still 
efficiently neutralised by human immune sera277.  
While enhancing cross-reactive epitopes seem to be simpler in structure, recent data 
indicates that the majority of neutralising antibodies present in sera from infected patients 
recognise complex quaternary epitopes that are only present on the surface of the intact 
virion278,279. In fact, the symmetric organisation of E proteins on the viral surface, together 
with the curvature imposed on E by restriction of the membrane attachment, creates 
unique quaternary and conformational epitopes involving two or more E molecules that 
are targeted by strong neutralising antibodies275. Of note, some of these antibodies bind 
quaternary epitopes that are formed on the herring-bone configuration of E and are thus 
restricted to the viral surface: monoclonal antibody (mAb) HM14c10 binds an epitope 
present between two adjacent E dimers of DENV1280, while mAb 5J7 footprint involves 
critical interaction with 3 adjacent E monomers281. On the other hand, mAb 1F4 epitope is 
restricted to a single E monomer of DENV1 but on a particular conformation that exist only 
within the context of the viral particle and not on the recombinant protein282. Binding of 
epitopes located at the DI/DII hinge region is a common feature of these mAbs, indicating 
that interference with this region has highly neutralising potential283. 
Recently, a new group of strongly neutralising antibodies that target complex 
quaternary epitopes was described. These mAbs target epitopes restricted to the interface 
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between two E proteins in a head-to-tail dimer conformation and therefore do not require 
higher-order arrangements of E like mAbs HM14c10 and 5J7284. MAb 2D22 for example, 
binds to the dimer interface but its epitope involves significant interactions with residues 
on DIII, which is why it only recognises DENV2285. In contrast, a recent group of mAbs 
isolated from previously infected patients target the valley formed between the E 
monomers; specifically, these antibodies target conserved residues on the DI/DIII-DII 
dimer interface284,286. This epitope, named EDE (E-dimer epitope), overlaps the highly 
conserved region of interaction with PrM which explains why these antibodies are able to 
induce strong neutralisation of all 4 serotypes286. The binding determinants of these EDE 
mAbs involve the FL and the loops in its close vicinity within the context of the E dimer 
and were further classified in two groups: EDE1 mAbs were shown to improve binding in 
absence of the Asn-153 glycosylation, while EDE2 mAbs showed better binding in 
presence of the glycan284. Moreover, a recent study demonstrated that EDE1 antibodies 
are also able to neutralise ZIKV, EDE2 antibodies showed less affinity towards ZIKV287-289.  
  
 
4.3.1.2. PrM protein 
Antibodies against this protein seem to be stimulated by the Pr peptide released from 
the viral surface once the maturation process is complete. In addition, the presence of 
immature viral particles as a result of incomplete cleavage of the Pr peptide can also 
stimulate the response against this protein78. 
PrM antibodies are highly cross-reactive among the different serotypes and show 
very little neutralizing capacity78,260,290. Instead, increasing amounts of evidence supports 
the notion that anti-Pr antibodies can actually favour the infection process by promoting 
the internalization and infection of immature viruses102,291,292. 
 
4.3.1.3. NS1 protein 
 As mentioned before the NS1 glycoprotein can be found attached to the surface of 
infected cells and is also secreted from them as a hexamer. This explains why, in spite of 
being a non-structural protein, it’s among the significant targets of the antibody 
response110. When compared with antibodies induced against the E protein or PrM, 
antibodies against NS1 show restricted cross-reactivity between the four serotypes291. 
  
Beside antibodies that cross-react with other dengue serotypes, the antibodies 
produced during viral infection have the capacity to recognise host proteins. Antibodies 
against E protein obtained from infected patients were shown to recognise human 
plasminogen and fibrinogen, while there is evidence suggesting the existence of 
molecular mimicry between NS1 and several host protein in a way that anti-NS1 
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antibodies are able to cross recognize human plasminogen, coagulation factors, platelets 
and endothelial cells and elicit responses that might be implicated in the pathogenesis of 
infection122,293,294. 
 
4.3.2. The antibody response upon Dengue Virus infection 
Since earlier studies on the course of infection and immunity of dengue, it was 
demonstrated that after the first infection with any of the four serotypes, patients showed 
long-lasting protection against reinfection with the same serotype, but only short term 
protection when challenged with heterologous serotypes295. Moreover, after this period of 
time, patients suffering subsequent heterotypic DENV infection showed higher incidence 
of dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS) compared to 
the cases present during primary infection295. An antibody-dependent enhancement of 
infection (ADE) was initially proposed to explain this phenomenon, which is explained in 
detail below53,270.  
Chang et al gave compelling evidence to explain the short-term broad neutralising 
phase of the immune response against dengue296 showing that soon after the infection 
with a particular serotype, patients sera contained high concentrations of weakly 
neutralising antibodies that were able to form large aggregates when facing a different 
viral serotype, thus preventing viral infection. This type of protection is temporal because it 
depends on a high threshold level of cross-reactive antibodies that diminishes in time. 
The differences seen on the immune response against a different dengue serotype 
during a secondary infection are the result of the pre-existing heterotypic immunity in 
which the second response occurs: when facing the new serotype, cross-reactive B and T 
lymphocytes are able to respond faster than naïve immune cells producing an anamnestic 
response to the antigens that are shared between the previous and the infecting 
serotype220. Since this early response to the secondary is based on cross-reactive 
antigens, it shows lower affinity and appears to be less efficient in neutralising the virus 
responsible for the initial infection, a feature known as “original antigenic sin”260. In time, 
the neutralising response against the second serotype increases leading to a protective 
long-lasting response that includes serotypes that have not been previously encountered 
by the individual which explains why tertiary infection with dengue is rare270. Indeed, T cell 
response has been shown to favour the selection of cells that recognise cross-reactive 
epitopes297, while in the case of B cells, type-specific cells show a steady reduction from 
the time of infection in such a way that, by the time of the secondary infection, mainly 
cross-reactive cells are present298-300. 
The kinetics of the antibody response has also been studied. During the primary 
infection anti-dengue IgM antibodies (predominately directed against the E protein) 
appear 4-5 days after the onset of fever and remain for up to three months following the 
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infection. IgG antibodies are detectable a couple of days after the IgM, their titre peaks 
several weeks after the infection process has ended and then declines to levels that 
remain stable for decades220. During the first infection, the IgG antibodies produced show 
specificity against PrM and E and belong mainly to the IgG1 and IgG3 subclasses, which 
indicates a bias towards a proinflammatory response270,301,302. During a secondary 
infection, the memory B-cells from the primary infection respond with an acute rise in IgG 
titres that are detectable on the first day of fever, while IgM response varies and in some 
cases is undetectable; additionally, antibodies against the non-structural proteins of the 
virus are more likely detected during secondary infections270.  
Regarding specificity, several studies have shown that antibodies elicited after 
infection are directed mainly against the E protein and to lesser degree against PrM and 
NS1. However, even though the results across studies are highly variable, contrary to the 
response during primary infections which is strongly dominated by E, antibodies induced 
in a second infection show a broader range of recognition with an increasing percentage 
of antibodies directed towards PrM and NS1, which points to a fundamental difference 
between primary and secondary dengue infections273,303.  
 
4.3.3. Mechanisms of protection 
There are several mechanisms through which antibodies can elicit their protective 
function against viral infection: opsonisation, targeting infected cells for elimination and 
neutralisation.  
 
4.3.3.1. Opsonisation of pathogens 
In this mechanism, antibody molecules bind to the surface of the viral particles and 
targets them for elimination by lysis through C’, or by phagocytosis in Fc receptor-bearing 
phagocytic cells. This is a very efficient method to eliminate pathogens that are not able to 
replicate in phagocytic cells; however, in the case of dengue, the small size of the virions 
limits the lytic function of the complement system and the opsonisation (that is, antibody 
binding below the threshold required for neutralisation) would actually favour the infection 
process since it facilities the uptake of the virus by its target cell via ADE as mentioned 
previously220. 
 
4.3.3.2. Targeting of infected cells for elimination 
As opposed to what happens during opsonisation, in this mechanism antibodies bind 
to infected cells that express viral antigens on their surface. Like in opsonisation, the 
binding of antibodies recruits lytic agents like C’ or NK cells, CTLs and macrophages that 
could kill the infected cell through ADCC220.  
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Several studies indicate that this mechanism can provide partial protection against 
the infection and is mediated by antibodies directed against non-structural viral proteins, 
mainly NS1 and NS3304,305 
  
4.3.3.3. Neutralisation 
This last mechanism is also considered the most important in determining protection 
against most viruses. In the case of dengue, the E protein is the main antigen involved in 
the generation of protective antibodies220. 
For flaviviruses in general, neutralisation of virions follows the “multi-hit” requirement 
model in which neutralisation happens when an individual viral particle is bound by a 
critical number of antibody molecules that surpass a determined threshold306,307. This 
threshold is different for each epitope and depends mainly on a combination of two 
biochemical factors: antibody affinity and the accessibility of the epitope on the virus272. 
Antibody affinity refers to the strength of binding between an antibody molecule and 
its antigen, and determines the fraction of the available epitopes on the viral surface that 
are occupied by the antibody at any given concentration of the latter308. Affinity usually 
correlates with neutralising activity since antibodies with higher affinity for their epitope are 
able to reach the neutralization threshold even at lower concentrations309 . However this is 
not always the case, as the number of available epitopes required for neutralisation might 
be very high or even impossible to reach regardless of the antibody binding affinity. 
While affinity determines the relative occupancy of epitope by an antibody, antigen 
accessibility determines the total number of epitopes that are available for binding on the 
viral surface under any particular condition307. Thus, epitopes that are highly exposed may 
exceed the neutralization threshold with a low affinity antibody, while poorly expressed 
sites could need highly or complete occupancy to achieve neutralization272. In the case of 
dengue, several factors regulate epitope accessibility on the viral surface: 
1. Steric constraints: As a consequence of the dimeric conformation of the E protein 
and its dense arrangement on the viral surface, not all of the antibody epitopes are 
equally accessible for binding and antibody recognition is also limited, which means 
that, for some epitopes, it is not possible to exceed the neutralization threshold at 
any antibody concentration260,307. 
2. Structural dynamics of E: As explained in previous sections, the E protein is a highly 
dynamic structure that is not only in constant movement due to the slight 
conformational changes involved in viral “breathing”48, but also suffers changes in its 
oligomeric state during the viral life cycle and in response to temperature and pH260. 
This directly influences the neutralization capacity of antibodies as the epitopes on 
the viral surface are highly dependent on these factors307. 
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3. Steric interference of the antibody molecule: The space occupied by an antibody 
molecule is considerably larger than the surface of the paratope it recognises, which 
limits the amount of molecules that are able to bind to the viral surface and may also 
interfere with the accessibility to other closely located epitopes308.  
 
Regarding their function, there are several mechanisms by which antibodies can 
neutralise flavivirus virions, all of them involving the steps in the entry process to the host 
cell. As depicted in Fig. 20, some antibodies, prevent infection by actively blocking 
attachment of the virus to the host cell, or promoting viral detachment from cells. A 
different type of neutralising antibodies act downstream of the binding step by interfering 
with the conformational changes of the virus surface required for membrane fusion310. In 
fact, structural analyses indicate that the strong neutralising capacity of antibodies against 
quaternary epitopes derives from their ability to interfere with viral surface dynamics: As 
mentioned before, DENV fusion with the endosome requires a reorganisation of the viral 
surface in which the E dimers disassociate and form trimeric structures; binding of 
antibodies to complex quaternary epitopes that span between 2 or more E monomers, 
may inhibits trimerisation by locking the E monomers into a fixed position, thus preventing 
viral escape from the endosome281,284,285. This mechanism of action has also been 
described for antibodies directed against the DI/DII hinge region272,282. 
                                
 
Figure 20. Mechanisms of antibody-mediated neutralisation. Antibody-mediated neutralisation of 
flaviviruses may be achieved by interfering with critical steps of the viral cycle preceding the release of the 
viral genome in the host cells, such as a) blocking viral attachment to the cell membrane by preventing 
interaction with cell receptors, b) promoting detachment of the viral particle before the clathrin-mediated 
endocytosis and c) by inhibiting the process on viral fusion with the endosome membrane. (Adapted from 
reference 310). 
310
 
 
4.3.4. Antibody-dependent enhancement of infection (ADE) 
As mentioned before, ADE describes a situation in which there is a significant 
increase in the efficiency of viral infection in presence of non-neutralising concentrations 
of antibodies (mainly cross-reactive antibodies) against the virus307. This event is the 
a) Blocking attachment 
c) Preventing membrane 
fusion 
  
 
b) Promoting detachment 
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leading theory to explain the data showing that, after a period of broad cross-protection 
following a primary infection with dengue, a secondary infection with a different serotype 
carries higher risk of developing severe haemorrhagic manifestations of the disease270. 
Moreover, this risk has been shown to increase as the time between the primary and 
secondary infection increases27,311. 
Although it has been hypothesised for many years312, early studies in Thailand 
pointed out that the DHF/DSS cases were found mainly in two groups: fist-time infected 
babies born to immune mothers, and children with a secondary infection312. Observations 
made from a series of studies from Cuba provided new data to further support the effect of 
this phenomenon in dengue pathogenesis: before 1990, the Cuban population had only 
experienced 2 outbreaks of dengue following the introduction of serotype 1 in 1971 and 
serotype 2 in 1981. After that, the strategies to control the vector prevented the 
transmission of the virus until 1997 when the serotype 2 was reintroduced in the capital; in 
this outbreak, the cases of severe dengue were restricted to patients old enough to live 
through the serotype 1 outbreak in the 70’s, a situation that was confirmed for all cases 
after serologic analyses313. The ADE concept was born to explain the association between 
secondary infection and severe disease, and has been described for several viruses apart 
from dengue314-316.  
In vitro, all the antibodies against the dengue virion have the capacity of eliciting ADE 
when used at a concentration below the threshold for neutralisation270,309. In these 
conditions, antibodies bind to the viral surface in a weak opsonic-like manner that allows 
the interaction of the virus with Fc receptor-bearing myeloid cells like monocytes and 
macrophages, where the infection occurs after the endocytosis of the complex317. 
Contrary to a regular infection, in ADE there is significant increase in viral production 
which results in a higher viremia and more severe symptoms318. This could be the result of 
an increased number of infected cells due to the alternative route of infection295. In 
addition, it has been demonstrated that infection through the Fc-receptor down regulates 
the antiviral response of phagocytic cell by enhancing IL-10 production and other anti-
inflammatory CKs319,320, and inhibiting the production of IFN and TNF319. In contrast, a 
recent study in macrophages failed to find a diminished intracellular antiviral response, but 
rather observed increased membrane fusion activity within infected cells, a feature 
associated with increased viral production321. 
Besides the cellular-related mechanisms for enhancing infection, cross-reactive 
antibodies have been shown to allow the infection of immature viral particles. Available 
data indicates that immature viruses are not able to interact properly with the host-cell 
receptors, but are able to bypass this requirement through the interaction with antibodies 
and Fc-receptors; once inside the cell, uncleaved PrM is efficiently processed allowing 
viral infection292. 
45 
 
In fact, accumulated evidence indicates that the cross-reactive antibodies targeting 
structural proteins on the viral surface, especially those against PrM and FL, are the main 
serum component responsible for ADE in vivo and in vitro279. Previous studies have 
confirmed the possibility of ADE, not only among DENV serotypes, but also among 
heterologous flaviviruses; which is expected given that the epitopes recognise by highly 
cross-reactive antibodies are also conserved in other viruses322-324. Models done 
considering the effect of ADE on viral dynamics suggest that this form of enhancement 
provides a fitness advantage that naturally selects strains that undergo enhancement over 
those that do not325. 
Although there a significant amount of evidence supporting the ADE theory in humans 
and in animal models295, its true impact in dengue infection has not been fully elucidated 
and its role in severe haemorrhagic disease remains circumstantial295. Instead, several 
observations indicate that there are other elements involved in the severe pathogenesis of 
dengue260: 
1. DHF and DSS can occur during the first infection with dengue, in absence of 
enhancing antibodies. 
2. Even though high viremia and plasma leakage are usually correlated, there is no 
causality link between increased viremia and the occurrence of haemorrhagic 
manifestations of the infection. 
3. Some studies show that there is no difference in the ADE activity of pre-infection 
sera from patients who did and did not develop severe dengue disease after 
secondary infection. 
4. As mentioned before, recently a group a laboratories was able to demonstrate the 
role of NS1 in vascular permeability125, an antibody-independent mechanism that 
might be important to initiate the haemorrhagic manifestations of the disease. 
 
Among the mechanisms that could contribute to the development of DHF/DSS are: C’ 
activation by immune complexes, induction of autoimmunity by molecular mimicry of the 
virus, existence of highly pathogenic viral strains and overstimulation of T lymphocytes 
leading to a pathogenic cytokine storm260.  
 
4.3.4.1. Fc Receptors (FcRs) 
FcRs are a family of glycoproteins found on the surface of haematopoietic cells and 
serve important functions during maturation, cell activation and phagocytosis194. Humans 
express three types of FcRs: FcRI (CD64), FcRII (CD32, subdivided in FcRIIa and 
FcRIIb) and FcRIII (CD16, also divided in FcRIIIa and FcRIIIb) that vary in terms of 
binding affinities to IgG and type of signal transmitted upon stimulation194. For example, 
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FcRI is the only one capable of binding monomeric IgGs, while FcRIIb is the only one 
that induce an inhibitory signal326. 
As previously mentioned, dengue virus primarily targets cells from the macrophage-
monocyte linage that express FcRs on their surface. Although both FcRI and FcRIIa 
are able to mediate the internalization of viral particles bound to IgG, FcRIIa has proven 
to be more relevant since it’s more widely expressed, binds all IgG subclasses and is 
more efficient in mediating the antibody-mediated uptake327,328. In contrast, FcRIIb 
stimulation inhibits FcR-mediated phagocytosis thus preventing ADE329. 
Integrating new data regarding the neutralization and enhancing capacity of 
antibodies against different viral proteins into the design of immunogens, could benefit 
greatly the development of vaccines and therapeutics against dengue. In the case of 
vaccines, a major goal is to engineer antigens with the capacity of steering the humoral 
immune response away from poorly neutralizing, cross-reactive and enhancing epitopes 
in order to target the ones able to elicit highly neutralizing antibodies against all four 
serotypes272. 
 
5. VACCINES AGAINST DENGUE VIRUS 
The efforts to develop vaccines against other members of the Flaviviridae family have 
rendered efficient compounds for YFV, JEV, TBEV and others330-333. However, despite the 
considerable amount of work made over the years220, the development of an efficient 
vaccine against dengue virus is still unresolved and faces many challenges that severely 
compromise any progress that has been made in the field: 
1. The existence of four different serotypes of dengue virus, together with the potential 
detrimental effect of the immune response via ADE, impose the requirement for any 
viable vaccine candidate to generate a balanced, long-lasting neutralizing response 
against all four serotypes at the same time334-336.  
2. The lack of an adequate animal model limits the strength of the data obtained for 
each vaccine candidate during preliminary testing, since there’s poor correlation 
between the course and the immunity of the infection when compared to humans. 
Initially, animal models for dengue infection were limited to the demonstration of 
immunogenicity in mice and non-human primates (NHP)337,338. However, the AG129 
mouse model (IFN-/ and – receptor deficient) has been shown to sustain DENV2 
replication and suffers from vascular features similar to those present in humans 
with haemorrhagic manifestations of the infection, thus allowing further data to be 
derived from in vivo experiments339,340. 
3. The fact that the pathogenesis of the disease is still not fully understood limits the 
process of testing the vaccine candidates to assess their immunogenicity and 
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possible side effects, thus increasing the risk of eventual clinical trials220. Moreover, 
although it is well known that antibodies play a major role in protection against the 
infection341, there’re still many unanswered questions regarding the quantity or 
quality of antibodies needed to achieve protection342. 
4. The epidemiology of the disease directly affects the formulation requirements of the 
vaccine since it should take into account the target population. In endemic areas, 
there is an urgent need for routine vaccination of children, so the vaccine should be 
safe and compatible with other childhood vaccines. In addition, due to the fact that 
nearly all endemic countries are underdeveloped, the vaccine should also be 
inexpensive and stable. In contrast, vaccines aimed for international travellers could 
cost more but require a short vaccination protocol53. 
  
The first efforts to develop a vaccine against dengue started 50 years ago with 
significant advances occurring in the last 10 years. Several vaccine candidates are 
currently at advanced stages of development and show promise in clinical studies; on top 
of that, the understanding of the human immune response against dengue virus and, 
more importantly, the notion of what constitutes a protective response against this 
pathogen is increasing334,336. Presently, the vaccine candidates under development cover 
a wide range of approaches including: live attenuated virus vaccines, molecularly 
attenuated live virus vaccines, live chimeric virus vaccines, inactivated virus vaccines, 
recombinant subunit vaccines and genetic (DNA/RNA) vaccines. 
 
5.1. Live attenuated virus vaccines  
Live attenuated virus (LAV) vaccines represent the most common type of 
commercially available viral vaccines (including yellow fever, measles, mumps, influenza, 
varicella and polio) and are composed of weakened viruses that are still able to induce a 
long-lasting adaptive immune response (both cellular and humoral) by mimicking the 
natural infection and exposing the same antigens that a wild type virus do during a normal 
infection, but with a diminished replication and infective potential in order to avoid 
pathological effects343.  
In the case of dengue, the first attempts to develop a LAV vaccine were in 1929 with 
major advances happening after the second world war when Sabin and Schlesinger were 
able to obtain the first attenuated strain of dengue virus (Dengue virus 1 and Dengue virus 
2, respectively) through serial passages in mouse brain220. After figuring out the process 
to achieve attenuation of the viral strains, a number of groups produced and tested 
different attenuated strains, however they all failed in proving seroconversion against all 
four serotypes and adequate safety, with reports of unacceptable reactogenicity related to 
some of them344-347. Moreover, achieving a balanced response against all serotypes has 
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proven to be complex obstacle for LAV vaccines, as immune interference between the 
different viruses of the formulation is common348.  
Further safety issues inherent to LAV vaccines are: the risk of reversion from the 
attenuated phenotype back to its original virulence, uncontrolled variation in the 
attenuated strain during culture passages , the risk of developing ADE due to weak or 
unbalanced immune responses, the risk of severe side effects in immunocompromised 
patients as in those with pre-existing immunity, and the risk of spreading the vaccination 
strains220.  
 
5.2. Molecularly attenuated live virus (MALV) vaccines 
Contrary to classic attenuation methods, MALV vaccines are based on obtaining 
attenuated variants of wild-type strains by means of conscious genetic alteration, which 
allows for the generation of vaccine candidates in a direct and controlled manner, 
circumventing many of the safety issues related to LAV vaccines, particularly those 
involving the risk of reversion to wild type virulence220.  
The work of C.J. Lai and colleagues to develop an attenuated variant of Dengue virus 
4 represents one of the efforts of vaccine development using MALV technology349. In this 
particular case, the attenuation consisted in a large 30nt deletion in the 3’ UTR (named 
DENV4-30), and initial results of Phase 1 trials revealed that the virus was not only 
immunogenic but also stable and well tolerated by the subjects although it only involved 
one serotype350. 
In collaboration with the Novartis Institute for Tropical Research, The Agency for 
Science, Technology and Research in Singapore developed a DENV2 MALV vaccine 
candidate that lacks NS5’s MTase activity, which eliminates the ability of the virus to block 
the IFN response within infected cells and is highly attenuated in animal models351. Initial 
results showed that a single dose of the vaccine was able induce a 100% of 
seroconversion and protect NHPs from viremia. In addition, the virus is not able to 
replicate in mosquitos, which eliminates the risk of spreading the attenuated strain351. 
Using another approach, researchers from Arbovax developed attenuated strains for 
all 4 DENV serotypes by altering the transmembrane domain of E and selecting for 
mutants that replicate well in insect cells but not in mammalian cells. The tetravalent 
vaccine obtained using these host range mutations (HR-tet), was able to induce a 
balanced response with 100% seroconversion in African green monkeys after a single 
dose352. 
  
5.3. Live chimeric virus (LCV) vaccines  
As an extension from the MALV vaccines, LCV vaccines also involve genetic 
manipulation of the viral genome but in this case, the vaccine is compose of live (generally 
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attenuated) viruses that are commonly used as a backbone to express antigens of 
another virus353. One of the first efforts in this field came from the same group of C.J. Lai 
by using the DENV4-30 strain as a background for generating new chimeric viruses 
through the substitution of the genes coding for all (C-PrM-E) or some (PrM-E) of the 
structural proteins with the those of the other dengue serotypes, thus generating DENV-
1/DENV-4 and DENV-2/DENV-4 chimeras with the DENV-1 or DENV-2 antigenicity but 
the attenuated properties of the DENV4-30 strain354. This exemplifies the advantage of 
the LCV vaccines: retaining the desired markers or properties of a particular strain while 
changing the immunogenic properties of the viral particle220. 
Currently the US National Institutes of Health are developing two tetravalent LCV 
vaccines based on the DENV4-30 attenuated strain called TV003 and TV005355. These 
formulations were made by incorporating the 3’UTR 30 attenuations on wild-type strains 
using a combination of MALV and chimeric approaches to achieve an efficient type-
specific strains to include in the tetravalent formulation356. So far, the vaccine has 
demonstrated to be safe in humans357 and elicits a robust and balanced tetravalent 
response after a single dose with over 90% tetravalent seroconversion in naïve-
recipients358. The vaccine has been licensed to several manufacturers and several Phase 
2 and Phase 3 studies are currently on-going356. 
Another case of LCV is TDV (formerly known as DENVax), a tetravalent vaccine 
based on the LAV DENV2 candidate attenuated by serial passage in primary dog kidney 
cells (DEN-2 PDK-53)359. In this case, the tetravalent formulation was achieved by 
replacing the PrM-E genes of the DEN-2 PDK-53 strain, with those of DENV1, DENV3 
and DENV4360. After confirming safety, immunogenicity and efficacy on preclinical 
studies360, several Phase 1 and Phase 2 studies have evaluated the efficiency of the 
vaccine in a variety of setting using different tetravalent formulations and routes of 
administration. The data demonstrated that the vaccine is able to induce adequate 
seroconversion in naïve individuals and Phase 3 trials are expected to begin in the near 
future361-363. 
Sanofi-Pasteur’s Dengvaxia® (CYD-TDV), is the most advanced formulation for 
vaccination against dengue in production, and is now available for licensing in several 
countries around the world342. CYD-TDV is a LCV vaccine that uses the 17D attenuated 
strain of Yellow Fever virus as a backbone to express the prM and E genes of each 
Dengue serotype364. Although proving to be stable and highly immunogenic in preclinical 
phases, the safety of tetravalent formulation was confirmed in several Phase II studies, 
however an unbalanced and low neutralizing response (when compared to animal 
models) was noticed once the data was analysed365-367. The vaccine was then tested in 
two Phase III trials (Asia and Latin-America), although showing adequate seroconversion 
rates in vaccinated patients, the results indicated that the vaccine induced an unbalanced 
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response against the different serotypes with DENV4 and DENV2 showing the highest 
and lowest efficacy (76.9% and 43%, respectively)368,369. Moreover, the Phase 3 results 
also showed that immune efficiency was much higher in those previously exposed to 
flaviviruses compared to those naïve (pooled vaccine efficacy of 78.2% and 38.1%, 
respectively)370, and a signal of increased risk of severe and hospitalized dengue in the 2-
5 year age group during the longer-term hospital-based follow up371. Because of these 
results, the younger age group was not included in the vaccine protocol and CYD-TDV 
was licensed in subjects between 9-45 years of age living in endemic countries342.  
 
5.4. Inactivated virus vaccines 
Contrary to live attenuated vaccines, inactivated vaccines comprise the entire virion 
but without its capability to replicate; consequently, these vaccines tend to be more secure 
than the former because they don´t have the possibility to revert their virulence, however, 
they tend to be weaker immunogens which is why they usually need the aid of adjuvants 
in order to induce an acceptable immune response336.  
The first attempt to develop an inactivated vaccine against dengue dates back to 
works of Simmons, St. John and Reynolds in 1929220. After the standardization of 
adequate protocols for production and purification of the inactivated viruses, new 
candidates emerged: one of the most relevant efforts is a purified DENV 2 vaccine (DV2-
PIV) developed by the Water Reed Army Institute of Research (WRAIR) that has been 
shown to induce a protective immune response in non-human primates372. The vaccine 
has been licensed to other developers who are currently testing several adjuvants to 
increased immunogenicity and evaluate different inactivating and purifying approaches; 
thus far, results on NHPs indicate that the tetravalent vaccine is able to induce a robust 
neutralising response against all DENV serotypes373,374. 
When compared to LAV vaccines, inactivated vaccines have the additional 
advantages of being able to stimulate both cellular and humoral adaptive immune 
response while not showing interference when several antigens are vaccinated together 
which, in the case of dengue, is important given that tetravalency is a requirement for the 
final formulation. However, they also supposed a much more complex production that 
usually leads to considerably higher costs per dose220. 
 
5.5. Recombinant subunit vaccines  
The advances made in molecular biology during the past twenty years have been 
applied to vaccine development efforts, with the idea of producing a viable and effective 
candidate using the right combination of epitopes in the form of viral proteins and 
peptides220. In this way, and contrary to the strategies described before, subunit vaccines 
target specific epitopes that are thought to be relevant for protection. 
51 
 
In the case of dengue, recombinant and subunit vaccines generally use recombinant 
truncated versions of E, or fractions of it (commonly DIII), as the main immunogenic 
component of the formulation220. A fundamental step in the production of these vaccines is 
obtaining the viral protein or peptide in an adequate concentration and purity; for this, 
several expression systems have been developed including yeasts, insect cells, bacteria, 
viruses (like baculovirus and vaccinia) and mammalian cells375. Although these vaccines 
have almost no safety- or reactogenicity-related issues, one major issue attached to this 
approach, is that incomplete or altered posttranslational processing of the antigen can 
lead to important differences between the antigen and the naïve protein, thus affecting the 
immune response obtain after vaccination220. In addition, purification of the antigen can be 
very demanding342. 
Available data on the candidates that have been tested so far indicate that using the 
E ectodomain as antigen generates good immunogenic responses and protection in the 
tested subjects, however further testing needs to be done to address tetravalent 
capacity375-377. Based on the differential immunogenic properties of E structural domains, 
several DIII-based subunit vaccines have been developed with different degrees of 
success378-385. 
Besides the use of single, or partial, dengue proteins as vaccine antigens; these 
technologies have allowed also the design of fusion proteins in an attempt to increase the 
amount of neutralising epitopes available without increasing the risk of ADE. Some of 
these fusion candidates include DIII-Capsid (DIII-C)386, flagellin-E387 and tandem 
combinations of DIII from different serotypes388,389.  
 DNA shuffling has also been employed to generate a recombinant E ectodomain390 
or a consensus DIII antigen391 capable of inducing a neutralising tetravalent response 
upon vaccination.  
One of the major drawbacks of subunit vaccines has been limited immunogenicity, 
when compared to other technologies. To address low immunogenicity, subunit vaccines 
have used different adjuvant formulations without significant success342. An alternative to 
the use of adjuvants is the reformulation of vaccine to display the antigen in an repetitive 
symmetrical structures that somewhat mimic the viral surface such as VLPs342. In the case 
of dengue, several VLP-based vaccine candidates have shown enhanced immunogenicity 
in mice with on-going studies in NHPs392,393. 
 
5.6. Genetic vaccines 
5.6.1. DNA vaccines 
As a part of the new generation of vaccines, genetic vaccination offers the possibility 
to raise neutralising activity against a specific antigen without using whole viral particles or 
purifying the immunogen from exogenous expression systems220. These vaccines are 
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composed of a bacterial plasmid that serves as vector for the expression of a previously 
selected viral gene (or part of a gene) under the control of an efficient promoter and 
regulatory sequences according to the target cells; the plasmid is delivered into the host 
and internalised by cells that stimulate the immune response by producing and secreting 
the encoded protein394.  
In this way, treated cells become antigen factories that are able to stimulate the full 
spectrum of the adaptive immune response: intracellular processed peptides are 
presented by the MCH molecules on the cell surface stimulating the cellular branch of the 
adaptive immunity while the secretion of the antigen by transfected cells is fundamental 
for the induction of specific antibodies. The stimulation of these two immunologic 
branches, which is highly desirable in the case of viral infections, is one of the most 
notable advantages of genetic vaccines395-397.  
Since the protein is translated into the host’s cells by its cellular machinery, the 
antigen goes through the same maturation process that the native viral protein encounters 
during the infection; in this aspect, genetic vaccination serves as a proper viral infection 
surrogate because the protein is expressed in vivo, which favours proper folding and post-
translational modifications without the safety issues inherent to the administration of live 
viruses398-400. Additionally, genetic vaccines offer the advantage of very low cost 
production and excellent stability over a wide range of temperatures and periods of time, 
which can be critical when dealing with the conditions in some underdeveloped 
countries395,398.  
After the first clinical trial for a DNA vaccine401, other candidates against various 
pathogens have been evaluated at Phase 1 levels402-406. In the case of dengue, most of 
the DNA vaccine candidates tested so far implicate the use of PrM-E, E ectodomain alone 
or a subunit form of E (mostly DIII) as antigens398,400,407,408; likewise, attempts using non-
structural proteins as antigens have also been reported305,409.  
The efforts of the US Naval Medical Research Centre (NMRC) have produced the 
most advanced DNA vaccine candidates and the only published a Phase 1 study using a 
plasmid expressing the PrM and E proteins of DENV1 (D1ME100)410. Due to low 
immunogenicity, the vaccine was reformulated using a new adjuvant named Vaxfectin® 
that increased the immune response induced by tetravalent DNA vaccine in NHPs411. A 
Phase 1 study if this new formulation has been finished but the results are currently 
pending publication412. 
In general, the studies involving DNA vaccines have showed that these type of 
formulations are well-tolerated and safe in humans413 although low immunogenicity 
remains a main concern 413,414. A number of strategies have been implemented to 
enhance the immune response to DNA vaccines by improving DNA uptake, antigen 
expression and immune stimulation412, however, there´s still no safe and effective DNA 
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vaccine available against dengue virus infection. Moreover, the unique concerns attached 
to this type of vaccination, which include the possibility of integration into the host genome 
and the eventual induction of anti-DNA antibodies that could lead to the development of 
autoimmune diseases220, have also made their implementation difficult. 
 
5.6.2. Virus-vectored vaccines 
One alternative to improve DNA or RNA delivery into the target cells is the use of viral 
vectors as vehicles, since infection-driven delivery of the genetic material is more efficient 
than transfecting cells in vivo412. Moreover, viral vectors are also able to induce direct 
stimulation of cytotoxic T cell responses342. 
In general, viral vectors are obtained from wild type viruses by deleting a part or all 
genes encoded in the genome415. Immunogenicity of viral vectored-genetic vaccines is 
improved by the biological properties of the viral particle and can be design to target 
specific tissues of cell types415. Due to genetic deficiencies, most viral vectors are not able 
to replicate and have proven to be safe, however, pre-existing antibodies against the 
vector may hamper the immunogenicity of the vaccine342. In addition, the expression of 
remaining viral genes is still a concern as they could potentially influence the immune 
system415. 
In the case of dengue, adenovirus, poxvirus, measles and Venezuelan equine 
encephalitis virus (VEE), have been evaluated as potential platforms. 
Adenoviruses have been extensively used as vectors for genetic vaccines. The 
development of a new generation of adenoviral vectors, capable of expressing multiple 
antigens, was used to develop a tetravalent dengue vaccine that was able to induce high 
neutralisation titres in NHPs416,417. Nevertheless, due to increased risk observed in other 
candidates, the vaccine was later discontinued412. 
Themis Bioscience together with Institut Pasteur, developed a tetravalent vaccine 
based on the expression of the DIII from all four serotypes in a live attenuated measles 
virus vaccine vector418. The vaccine was able to induce neutralizing antibodies in mice 
and is being tested in NHPs342. 
VEE single-round infectious particles have been shown to express high level of 
recombinant antigens and efficiently infect dendritic cells342. These properties, together 
with the low pre-existing immunity to VEE in humans, have added weight to their attraction 
as platforms for genetic vaccines412. However, the data regarding VEE-vectored dengue 
vaccines has been mixed: recently, a tetravalent candidate was shown to induce high 
level of neutralizing antibodies in mice and macaques419,420, while other studies reported 
no significant difference in antibody titres or protection when comparing VEE-vectored 
vaccines against naked DNA immunisation421. 
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Recently, Adeno-associated viruses (AAVs) have emerged as strong and convenient 
platforms for genetic vaccines. AAVs belong to the Parvoviridae family and are small, non-
pathogenic, non-enveloped, single-stranded DNA viruses with a ≈4,7 kb genome 
composed of only two genes (rep and cap) and two flanking inverted terminal repeats 
(ITR)422. As viral vector, replication deficient AAV are produced by replacing all viral 
coding sequences with the recombinant antigen while retaining the ITR regions423. This 
recombinant genome is then packaged into AAV particles by viral proteins given in trans, 
and purified from transfected cells. Contrary to other viral vectors, the more than 120 AAV 
serotypes and variants described are able to transduce a wide variety of tissues and 
provide alternatives to circumvent pre-existing immunity422. However, low immunogenicity 
of AAVs when compared to other viral vectors, together with limited transgene capacity, 
high manufacturing cost and the need for high doses, are significant hurdles attached to 
AAV vaccine technology415.  
A vaccine candidate designed to express the E protein from all four dengue serotypes 
in a AVV-vectored system, demonstrated efficient antigen production and long-lasting 
neutralising responses in mice, although no further development has been reported 
since422. 
As emphasised throughout this introduction, the structure, functions and 
immunological properties of the different domains comprising the E protein of dengue 
virus, have been the subject of a significant amount of research during the last decades. 
Data regarding the neutralizing and cross-reactive capacity of antibodies directed against 
the E protein are mixed; nonetheless, there is a generalised tendency to emphasise both 
the complexity of the humoral immune response against dengue and the need to further 
examine the antigenic properties of E protein to develop an efficient and affordable 
vaccine.  
In this context, this PhD research project had the objective of developing of a DNA 
vaccine against dengue virus using an integral approach that would incorporate a detailed 
biochemical analysis regarding the structural and functional properties of dengue virus E 
protein as the framework to study the immunogenic properties of designed vaccination 
constructs, formulations and strategies. 
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1. Cell lines  
Mammalian cell lines HEK-293 (ATCC, Rockville, MD, USA, CRL-1573), HEK-
293T/17 (HEK-293T, ATCC CRL-11268), Vero cells (ATCC CCL-81), U-2OS cells (ATCC 
HTB-96), HeLa cells (ATCC CCL-2) and HuH-7 (provided by Dr. Alessandro Marcello, 
ICGEB, Trieste, Italy) were cultured in Dulbecco's modified Eagle's medium (DMEM, Life 
Technologies, Paisley, UK) supplemented with 10% heat-inactivated foetal calf serum 
(FCS) (Life Technologies), 50 g/ml gentamycin and 2 mM L-glutamine. In addition, Vero 
FM cells (Vero E6 derivate used for viral amplification, provided by Dr. Toni Rieger, BNI, 
Hamburg, Germany) were maintained in the same conditions with 1% non-essential 
amino acids. K562 cells (ATCC CCL-243) and THP-1 human monocytic cells (ATCC TIB-
202), were maintained in Roswell Park Memorial Institute (RPMI) 1640 Medium (Life 
Technologies) supplemented with 10% FCS and 50 g/ml gentamycin. To select HEK-293 
stable clones, 0.4 mg/ml geneticin (G418, Life Technologies) was added to the culture 
medium. Unless indicated differently, all cell cultures were grown and maintained at 37°C 
with 5% of CO2. 
 
2. Viruses 
DENV1 Hawaii A strain, DENV2 NGC strain, DENV3 3140/09 isolate, DENV4 TC25 
strain, ZIKV 976 Uganda strain, WNV New York 1999 strain and YFV French neurotropic 
virus strain (provided by Dr. Alessandro Marcello, ICGEB, Trieste, Italy) were used. All 
viruses were propagated in Vero cells using DMEM medium containing 2% heat 
inactivated FCS (DENV3 that was propagated in Vero FM cells). After amplification, viral 
stocks were prepared to a final FCS concentration of 20-30% and kept at -80ºC until used. 
Viral titres were determined by plaque assay (PFU/ml) or foci forming assay (FFU/ml) on 
Vero cells. 
 
3. Plasmid DNA constructs 
Sequences coding for PrM and E ectodomain (sE) were obtained for DENV1 Nauru 
Island strain (GenBank accession number U88535.1), DENV2 New Guinea C strain 
(GenBank accession number AF038403), DENV3 3H87 strain (GenBank accession 
number M93130), DENV4 Dominica strain (GenBank accession numbers AF326573.1) 
and ZIKV Mr766 strain (GenBank accession number AEN75266.1). 
Codon-optimised sequences for mammalian expression of PrMsE from DENV2, 
DENV3 and ZIKV, and sE from DENV1 and DENV4, were obtained as synthetic 
fragments in pUC57 vectors (GenScript, Piscataway, NJ, USA). Synthetic fragments 
carrying the viral-encoded and codon-optimised DIII sequences of all DENV serotypes 
were also obtained (E protein codons 297-416 for DENV1, DENV2 and DENV4; and 295-
414 for DENV3). Each PrMsE, sE and DIII (optimised and non-optimised) sequence were 
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cloned in pcDNA3.1 vectors (Life Technologies) and fused to an immunoglobulin leader 
sequence (sec) at the N-terminus424 and to the SV5 tag (GKPIPNPLLGLD)425 at the C-
terminus, to obtain PrMsE-SV5, sE-SV5 and DIII-SV5 constructs, respectively. DIII- 
constructs (carrying either the optimised or non-optimised DIII sequences) contained, in 
addition, the human IgG heavy chain constant domain 3 (CH3) downstream of the SV5 
tag. MsE-SV5 and sE-SV5 constructs of DENV2, DENV3 and ZIKV were obtained after 
deleting the Pr or PrM coding regions, respectively; while DI/DII-SV5 constructs (E protein 
codons 1-296 for DENV1, DENV2 and DENV4; and 1-294 for DENV3) resulted from 
removing the DIII coding regions from DENV-derived sE-SV5 plasmids. Regarding 
chimeric constructs, sE(DIII) chimeras were obtained by substituting the DI/DII sequence 
with that of another serotype, while DI-DII chimeras were obtained as synthetic fragments 
and then cloned either into the same pcDNA3.1 vectors to obtain DI-DII-SV5 chimeras, or 
into sE constructs (to obtain sE(DI) and sE(DII) chimeras). sE-SV5, DI/DII-SV5 and 
optimised DIII- constructs were cloned into pVAX1 vectors (Life Technologies) as well. 
For constructs requiring particular aminoacid mutations, site-directed mutagenesis 
(QuikChange XL Site-Directed Mutagenesis Kit, Agilent Technologies, La Jolla, CA, USA) 
was performed following the instructions of the manufacturer. This was used for: 
1. Non-glycosylated mutants (Asn67Gln-Asn153Gln) of DENV3-derived DI/DII-SV5 
and sE-SV5 plasmids. 
2. cvD variants (Covalent E dimers) of PrMsE, MsE and sE constructs from all four 
DENV serotypes and ZIKV (Ala259Cys for DENV1, 2 and 4, Ala257Cys for 
DENV3 and Ala264Cys for ZIKV). 
3. To obtained the DIII- construct from DENV4 TC25 strain that differs from the 
Dominica strain in three aminoacids (Leu357Phe, Asn360Tyr and Asn384Asp). 
For experiments involving biotinylated proteins, coding sequences were cloned into a 
bigenic pcDNA3.1 vector containing the BAP tag (biotin acceptor peptide, 
GLNDIFEAQKIEWHE)426,427 followed by roTag428 at the C-terminal end of the encoded 
protein (BAP-roTag), and the gene for a secretory Escherichia coli biotin ligase (sec-
BirA)426. Likewise, the DIII-εCH4 constructs were obtained by fusing DIII sequences to the 
human CH4 followed by the BAP tag in a modified version of the bigenic vector429. 
Constructs targeted for membrane display were engineered from SV5-tagged 
plasmids by replacing the SV5 tag, with the transmembrane and cytoplasmic domains of 
the human MHC-I chain. 
For production of pseudoviruses, codon optimised sequences coding for C-PrM-E 
genes of ZIKV Mr766 strain and a chimera containing the C gene from ZIKV Mr766 and 
the PrM-E form DENV2 New Guinea C strain (CZ-PrMED2), were obtained as synthetic 
fragments and cloned into pVAX1 vectors. Plasmids expressing only the capsid protein 
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(C) from ZIKV or PrME from DENV2 were obtained by deleting the PrME and C coding 
regions from the chimeric constructs, respectively.  
 
4. Production of recombinant Adeno-Associated Virus vectors 
Codon optimised DIII sequences from DENV3 fused to the sec signal at the N-
terminus and the CH3 domain downstream of the SV5 tagged at the C-terminus, were 
cloned into pAAV-MCS vector (AAV Helper-Free System, 240071, Agilent Technologies).  
Recombinant AAV vectors used in this study were prepared by the AAV Vector Unit 
at the International Centre for Genetic Engineering and Biotechnology Trieste, as 
previously described430. Briefly, infectious recombinant AAV vector particles were 
generated in HEK-293T cells culture in roller bottles by a cross-packaging approach 
whereby the vector genome was packaged into AAV capsid serotype-9431. 
Viral stocks were purified by PEG precipitation from clarified cell lysates and cell 
culture supernatant followed by two consecutive CsCl2 gradient centrifugations
432. 
Full viral particles obtained from the gradient were extensively dialyzed in Phosphate 
buffer solution (PBS) and stored in aliquots at -80°C until use. 
The physical titre of recombinant AAVs was determined by quantifying vector 
genomes (vg) packaged into viral particles, by real-time PCR against a standard curve of 
a plasmid containing the vector genome; values obtained were in the range of 1x1012 to 
1x1013 vg/ml.  
 
5. Animal Immunisations 
Different groups of 5-6 weeks old, female Balb/c mice (purchased from Harlan, Milan, 
Italy) were used for vaccination throughout the project. Since the groups differed 
significantly depending on the experiment, the number of animals included in each group 
is mentioned in the main text. 
For DNA immunisations, mice were immunised intradermally using Gene Gun 
technology (Bio-Rad, Hercules, CA, USA). Before vaccination, the abdominal area of each 
mouse was shaved and 1 m gold particles coated with ≈1 g of plasmid DNA were shot 
at 400 psi. Unless indicated otherwise, mice were immunised three times at two weeks 
intervals (Days -30, -15 and 0). In the case of the DIII-tetravalent formulation, animals 
followed the same immunisation protocol, but were vaccinated with two-1 g shots of DNA 
each time. 
For AAV-vectored immunisations, 100 l doses of 3x1010 viruses were administered 
either by intramuscular injection in the posterior aspect of the hindlimb, or subcutaneously 
depending on the vaccination protocol followed.  
Blood samples were collected by sub-mandibular puncture at least 15 days after 
vaccination. However, bleeding times varied significantly depending on the experiment 
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and are thus detailed when needed. Serum was separated from the blood samples, 
cleared by centrifugation and stored at -20°C until use. 
All animal procedures were approved by the Italian Ministry of Health (Ministero della 
Salute) and the ICGEB Animal Welfare Board (protocol DGSAF0024706) in compliance to 
laws and policies established in the legislation D. L.vo 26/2014 of the Italian Government. 
 
6. Monoclonal antibodies (mAb) 
Purified human mAbs 2D22, 1F4 and 5J7 as well as mouse mAb 4G2, were kindly 
provided by Prof. Aravinda de Silva (University of North Carolina, Chapel Hill, NC, USA). 
Mouse mAb 4G2 was also provided by Dr. Vivian Huerta (Centre for Genetic Engineering 
and Biotechnology (CIGB), Havana, Cuba) and purchased from Milipore (clone lone D1-
4G2-4-15, MAB10216, Millipore, Temecula, CA, USA) as well. Mouse mAb dengue 1-11 
was purchased from AbD Serotec (Now Bio-Rad) (clone dengue 1-11(3), MCA227, Bio-
Rad). Mouse mAb 4E5A was kindly provided by Prof. Jonathan R. Lai (Albert Einstein 
College of Medicine, NY, USA). mAbs EDE1-C8 (clone 752-2 C8), EDE1-C10 (clone 
753(3) C10) and EDE2-B7 (clone 747 B7) were constructed as human IgG antibodies 
from previously deposited sequences284 and used as culture supernatants from 
transfected cells.  
 
7. Expression of recombinant proteins 
Transient transfections of HEK-293T cells, and stable transfections of HEK-293 cells 
were performed as described by Sambrook et al.433, using circular or linearized plasmids, 
respectively. Transfections of HeLa, U-2OS and Vero cells were performed using 
Lipofectamine 3000 (Life Technologies) according to manufacturer's instructions. 
Cells were seeded in 6-well plates at 5x105 cells/well density 24h before transfection. 
Depending on the experiment, transient transfections were done using standard calcium 
phosphate method with 0,5-3 g of plasmid DNA. After overnight incubation at 37ºC, 
culture medium was replaced with serum-free medium and cells incubated for another 24h 
at 37ºC (or 28ºC, as indicated). Serum-free media was supplemented with 100 M biotin 
when required (Sigma-Aldrich, St. Louis, MO, USA, B4501). Culture supernatants were 
collected and cleared by centrifugation (10,000rpm for 10min), while total cellular extracts 
were prepared in 100 l of TNN lysis buffer (100 mM Tris-HCl, pH 8, 250 mM NaCl, 0.5% 
NP-40) supplemented with Protease Inhibitor Cocktail (PIC, Sigma, P8340) at 4°C. If 
needed, free biotin was removed from cultures supernatants by dialysis against PBS 
using Spectra/Por® 4 dialysis membranes (MWCO:12-14 kDa, Spectrum Labs, CA, USA). 
For hetero-dimerisation assays, SV5-tagged and BAP-tagged (or membrane-displayed) 
constructs, were co-transfected in a 2:1 ratio. All samples were kept at -20°C until use. 
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Where indicated, cell extracts and culture supernatants samples were treated with 
Peptide-N-Glycosidase-F (PGNase F, New England Biolabs, P0704, Ipswich, MA, USA). 
To produce large amounts of biotinylated antigens for ELISA, the transfection 
procedure was scale up to 10cm or 15cm culture plates. Alternatively, recombinant 
biotinylated DIII-CH4-BAP of all four DENV serotypes, sE-BAP-roTag proteins of DENV3 
and DENV4, were expressed in stably-transfected HEK-293 cells. Stable transfection was 
done with 15 g of BglII (New England Biolabs, R0144) -linearized DNA using calcium 
phosphate technique. Secretion of biotinylated proteins from stably-transfected HEK-293 
clones was screened by ELISA and further confirmed by western blot. Supernatants from 
selected clones were collected after 72 h of culture in serum-free medium supplemented 
with biotin and dialyzed as before. In experiments involving the use of denatured 
biotinylated DIII-CH4-BAP antigens, the dialyzed supernatants were denatured in 
presence of 0.5% SDS (Sigma-Aldrich) and 2.5% -mercaptoethanol (Sigma-Aldrich) and 
boiled for 10min. N-Ethylmaleimide (NEM, Sigma-Aldrich) was then added and samples 
were extensively dialyzed against PBS before using. 
 
8. Western blot (WB) and Slot blot (SB) analyses. 
Samples were separated by reducing or non-reducing 10%, 12% or 4-12% gradient 
SDS-PAGE. When needed, samples were denatured by supplementing the loading buffer 
(25 mM Tris-HCl pH 6.8, 1% SDS, 10% glycerol) with 175 mM -mercaptoethanol, and 
boiling for 10min. 
After electrophoresis, samples were transferred to polyvinylidene difluoride (PVDF) 
membranes (Millipore) and blocked with a 5% milk solution in PBS (PBS-milk). PBS and 
PBST buffer (0.05% Tween 20 in PBS, pH 7.4) were used for washing. When detecting 
SV5-tagged proteins, membranes were incubated for 1h with anti-SV5 mAb (1 g/ml in 
PBS-milk), washed, and probed with HRP-conjugated anti-mouse IgG goat antibodies 
(KPL, Gaithersburg, MA, USA, 074-1809, 1:10,000 in PBS-milk) for 1h. In the case of 
biotinylated proteins, membranes were probed with HRP-linked streptavidin (Jackson 
ImmunoResearch, Newmarket, UK, 016-030-084, 1:20,000 in PBST) for 1h after blocking. 
Mouse anti-tubulin mAb (clone DM1A, Millipore, MABT205, 1:5,000 in PBS-milk) or 
mouse HRP-conjugated anti-actin mAb (clone AC-15, Sigma-Aldrich, A5441, 1:30,000 in 
PBS-milk) were used as loading controls. Signals were developed by ECL (ThermoFisher-
Pierce, Rockford, IL, USA). Unless otherwise indicated, equivalent amounts of cellular 
extracts and culture supernatant samples were used in each experiment (0,5% of total 
sample). 
For Slot Blots, normalised samples were prepared in native (125 mM Tris-HCl pH 6.4) 
or denatured (125 mM Tris-HCl pH 6.4, 175 mM -mercaptoethanol) loading buffers, and 
blotted onto PVDF membranes using the Bio-Dot SF Apparatus (Bio-Rad, Hercules, CA, 
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USA). In addition, denatured samples were boiled for 10min before blotting. Incubation 
with anti-SV5 (1 µg/ml in PBS-milk) or 4G2 (50 ng/l in PBS-milk) was followed by and 
HRP-conjugated goat anti-mouse IgG (1:50,000 in PBS-milk). As before, signals were 
developed by ECL.  
When needed, bands were quantified using ImageJ 1.47v software (National Institute 
of Health, USA) or the Alliance detection system (UVItec, Cambridge, UK). 
 
9. Immunoprecipitations 
HEK-293T cells were transfected with different combination of DNA plasmids 
encoding sE or sE-derived constructs. Culture supernatants and cell lysates were 
prepared as before. Samples (diluted in PBS if needed) were incubated with anti-SV5 (1 
g/ml in TNN) and protein A agarose (Repligen, Waltham, MA, USA) for 2h at 4°C. 
Samples were then loaded onto Micro Bio-spin columns (Bio-Rad) and washed with TNN 
buffer, followed by RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% sodium 
deoxycholate, 0.1% SDS, 1% NP40, 1 mM EDTA). Immunoprecipitated proteins were 
eluted with from the agarose beads with 50 l of reducing loading buffer, and detected on 
SDS-PAGE following the WB procedure. In the specific case of co-immunoprecipitated 
biotinylated proteins, samples were detected with HRP-conjugated streptavidin. The 
relative amount of immunoprecipitated sample loaded is indicated when needed. 
 
10. Radioactive Labelling 
Transfected HEK-293T cells were incubated for 30min in L-methionine and L-cysteine 
free DMEM (Life Technologies) supplemented with dialyzed FCS. Cells were then labelled 
with 200 Ci/ml of a [35S]-methionine and [35S]-cysteine mix (Expre35S, Perkin Elmer, 
Waltham, MA, USA) in the same methionine and cysteine-free medium, and incubated for 
15min Cells were then collected and lysed in TNN buffer with PIC. Samples were 
immunoprecipitated with anti-SV5 antibody and protein A-agarose as previously 
described. Immunoprecipitated proteins were eluted from agarose beads and separated 
on 10% SDS-PAGE. After electrophoresis, gels were fixed (using a 10% acetic acid, 10% 
methanol solution), incubated for 20min in Amplify fluorographic enhancer (GE 
Healthcare, Little Chalfont, UK), dried and exposed to autoradiography on Kodak BioMax 
XAR films (Carestream Health, Rochester, NY, USA).  
 
11. ELISA 
Mouse sera, culture supernatants and different purified mAbs were tested on mono-
biotinylated DIII-CH4-BAP, sE-BAP-roTag, DI/DII-BAP-roTag and sE-cvD-BAP-roTag 
proteins. The relative concentrations of biotinylated proteins collected from transiently 
transfected HEK-293T and the stably transfected HEK-293 clones were normalized by 
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WB with HRP-conjugated streptavidin on the Alliance detection system, and comparable 
amounts of biotinylated protein were used for coating the ELISA plates.  
Nunc Maxi Sorp Immuno-Plates (ThermoFisher-Nunc, Roskilde, Denmark) were pre-
coated with 100 l/well of 5 g/ml avidin (Sigma) in 50 mM Na2CO3/NaHCO3 buffer (pH 
9.5) and incubated overnight at 4°C. Plates were washed in PBST buffer (0.05% Tween 
20 in PBS pH 7.4), blocked with 1% Bovine serum albumin in PBST (PBST-BSA) for 1.5h 
at room temperature (RT), and second-coated with the dialyzed biotinylated-antigen 
diluted in PBS (100 l/well) at 4°C overnight. Normalisation of captured DIII-CH4 
biotinylated proteins was further confirmed by ELISA using HRP-conjugated anti-human 
IgE goat antibodies (KPL, Gaithersburg, MA, USA, 074-1004, and 1:5,000 in PBST-BSA). 
For sE-derived proteins from the same DENV serotype, normalisation was confirmed also 
by ELISA, using mAb 4G2 (0.15 ng/l in PBST-BSA) and HRP-conjugated anti-mouse IgG 
-chain goat antibodies (Jackson ImmunoResearch, code 115-035-071, 1:50,000 in 
PBST-BSA) insteada. 
For assays designed to evaluate the structural features of captured biotinylated 
proteins, plates were incubated for 1h with 100 l/well of different mAbs diluted in PBST-
BSA (mAb 4G2, 0.15 ng/l; mAb 4E5A, 0.5 ng/l; mAb 2D22, 0.5 ng/l; mAb 1F4, 0.5 
ng/l; mAb 5J7, 0.5 ng/l; mAbs EDE1-C8, EDE1-C10 and EDE2-B7 were used as 
undiluted supernatants) after washing. The plates were then washed and, depending of 
the mAb used, 100 l/well of HRP-linked anti-mouse IgG -chain goat antibodies 
(1:50,000 in PBST-BSA) or HRP-conjugated anti-human IgG goat antibodies (KPL, 074-
1002, 1:20,000 in PBST-BSA) were added and incubated for 1h at RT. The bound 
conjugate was detected using TMB substrate (Sigma), stopped with H2SO4 1M and 
measured at 450 nm (OD450) on a Bio-Rad iMark microplate reader. 
For analyses involving sera of vaccinated animals, 100 l of different sample dilutions 
(in PBST-BSA) were added to antigen coated plates and incubated for 2h at RT. After 
washing, 100 l/well of HRP-linked goat antibodies anti-mouse IgG -chain (1:50,000 in 
PBST-BSA) were added and incubated for 1h at RT. The bound conjugate was detected 
as before. The anti-dengue IgG titres were determined as the reciprocal of the dilution at 
which the OD450 was 3 times higher than that of the negative control serum. Negative 
control sera obtained from non-vaccinated animals (pre-immune sera) showed the same 
performance as sera from animals immunised with a construct containing an irrelevant 
protein fused to CH3 or sera from animals immunised with empty vectors. 
 
 
 
                                                          
a
 Given the different reactivity of mAb 4G2 towards the FL of the four DENV serotypes and ZIKV, normalisation of the 
amount of protein captured in ELISA was restricted to constructs of the same origin.  
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11.1. Evaluation of anti-DIII specific antibody concentration 
Approximate concentrations of anti-DIII specific antibodies in immunised mice were 
determined by interpolating the OD450 form different sera dilutions on its homologous DIII 
antigen, in a calibration curve obtained by plotting the OD450 values from an ELISA on 
biotinylated 3sE with different amounts of a purified and previously quantified sample of 
mAb 4G2b. The concentrations are reported as arithmetic means ± standard deviations of 
the values obtained for all the dilutions tested. 
 
11.2. Dengue virus-capture ELISA 
Plates were coated with 100 l of a purified anti-DENV immunoglobulin fraction from 
a human serum cross-reactive with all 4 serotypes (provided by Dr. Vivian Huerta, Centre 
for Genetic Engineering and Biotechnology (CIGB), Habana, Cuba) (15 mg/ml in 50mM 
Na2CO3/NaHCO3 buffer, pH 9.5) and incubated overnight at 4
oC. Plates were then 
washed with PBS, blocked with 1% BSA in PBS (PBS-BSA), and second-coated with 
4x104 PFUs/well of each viral serotype for 2h at RT. After washing, plates were incubated 
for 1h at 36oC with 100 l/well of the different anti-DIII sera (diluted to an approximate 
concentration of 100 ng/ml in PBS-BSA) or negative control sera at an equivalent dilution. 
mAb dengue 1-11, specific for DENV1 envelope protein (1 g/ml in PBS-BSA) and a 
dilution of a DENV panreactive mouse serum (also provided by Dr. Vivian Huerta, Centre 
for Genetic Engineering and Biotechnology (CIGB), Habana, Cuba) were used as positive 
controls. For detection, HRP-conjugated goat anti-mouse IgG -chain (1:50,000 in PBS-
BSA) was used. 
 
11.3. Avidity assay 
Serum avidity indexes were measured by a modified ELISA protocol with urea 
washes 434,435. Briefly, sera samples were tested at different dilutions corresponding to an 
OD450 value of 0.5-0.9. After incubation with serum, plates were washed two times (3min 
each) with 200 l of PBST, with or without 6M urea, and incubated with secondary 
antibody as described above. The avidity index was calculated using the following 
formula: 
 
                  
             
                
     
 
 
 
                                                          
b
 In our case, the antibody reacted strongly against the 3sE protein with almost 100% avidity, and was therefore used to 
generate the calibration curve. 
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12. Cytofluorimetry 
HEK-293T cells were transfected with DNA plasmids encoding different sE or sE-
derived constructs as described before. Cells were then washed with PBS and 
resuspended in PBS-BSA (2%) supplemented with 5 MEDTA. Samples were then 
incubated with different mAbs (anti-SV5, 1 ng/l; mAb 4G2, 1 ng/l; mAb 4E5A, 1 ng/l; 
mAb 2D22, 1 ng/l; mAb 1F4, 1 ng/l; mAb 5J7, 1 ng/l; mAbs EDE1-C8, EDE1-C10 and 
EDE2-B7 were used as undiluted supernatants) or anti-3sE pooled sera from immunised 
animals (1:500 dilution), in PBS-BSA, for 1h at RT followed by Alexa488-conjugated goat 
anti-mouse IgG (Jackson ImmunoResearch, 115-545-062, 1:1,000 in PBS-BSA) or 
Alexa488-conjugated goat anti-human IgG (Jackson ImmunoResearch, 109-545-003, 
1:1,000 in PBS-BSA), and analysed for relative alexa-488 fluorescence in a FACSCalibur 
(BD Biosciences, San Jose, CA, USA). Cytofluorimetry data were analysed using FlowJo 
7.6.5 software (LLC, Ashland. OR, USA). 
 
13. Immunofluorescence 
Vero cells were seeded in sterile cover glasses 24h before the assay and infected 
with virus preparations at a multiplicity of infection (MOI) of 0.1 for 36h (24 h when using 
WNV). Cells were then fixed with 3.7% paraformaldehyde (PFA, Sigma-Aldrich) in PBS for 
20min and quenched with 150 mM glycine in PBS (two washes of 10min at RT). After 
washing with PBS, cells were permeabilised with 1% Triton (Sigma-Aldrich) in PBS for 
15min, and blocked with PBST-BSA (0.1%) for 1h. Viruses in infected cells were detected 
using different anti-DIII, anti-DI/DII, anti-sE sera or pre-immune control sera (at 1:100 
dilution in PBS-BSA), or mAb 4G2 (50 ng/l in PBS-BSA) followed by Alexa488-
conjugated goat anti-mouse IgG (1:1,000 in PBS-BSA). Labelled cells were mounted with 
ProLong supplemented with DAPI (Thermo Fisher Scientific). Images were acquired using 
a Zeiss LSM510 META microscope or, alternatively, a Nikon Eclipse Ti-E microscope. 
Transfected HEK-293T cells were treated as described for the cytofluorimetry assays 
and then plated in glass slides previously treated with poly-lysine (Sigma-Aldrich) to 
promote attachment. After 1h incubation at RT, cells were fixed with 3.7% PFA in PBS for 
10min and quenched with 150 mM glycine in PBS as before. For permeabilisation, cells 
were treated with 1% Triton (Sigma-Aldrich) in PBS for 10min Samples were then 
incubated with anti-SV5 (1 g/ml in PBS-BSA) for 1h at RT, followed by Alexa488-
conjugated goat antibodies anti-mouse IgG (1:1000 in PBS-BSA). As before, cover 
glasses were mounted with DAPI-supplemented ProLong and images were acquired 
using a Zeiss LSM510 confocal microscope. 
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14. Production and analysis of Pseudoviruses 
Pseudoviral particles were produced by co-transfection of a DNA-launched WNV 
replicon expressing EGFP436 (WNV-rep, provided by Theodore Pierson, National Institute 
of Allergies and Infectious Diseases, MD, USA) with plasmids expressing the structural 
genes of ZIKV or DENV2 in trans, as previously described437. Briefly, HEK-293T cells 
were transfected with 2 g of DNA (1:3 ratio between WNV replicon and packaging 
plasmids, respectively) using linear polyethylenimine (1 g/l in H2O, pH 7.4; used at a 6:1 
ratio with the amount DNA transfected) (PEI, MW 25,000, Polysciences, 23966, 
Warrington, PA, USA). 16h post-transfection, culture medium was replaced with a DMEM 
supplemented with 7% FCS and incubated for another 48h at 37ºC or 28ºC. 
Pseudoviruses were harvested in cell culture supernatants, clarified from cell debris by 
centrifugation (10min at 10,000 rpm) and stored at -20ºC.  
 
14.1. Detection of pseudoviral particles in WB 
Pseudoviral preparations were concentrated by ultracentrifugation at 40,000g for 24h 
Afterwards supernatants were discarded and pellets were resuspended in WB loading 
buffer. Samples were then separated by non-reducing 4-12% gradient SDS-PAGE, 
transferred to PVDF membranes and blocked as before. For detection of pseudoviruses, 
membranes were incubated with mAb 4G2 (50 ng/l in PBS-milk) for 1h, washed, and 
treated with HRP-conjugated anti-mouse IgG goat antibodies. Signals were developed by 
ECL. 
 
14.2. Quantification of pseudoviruses by Real-Time PCR.  
WNV Replicon-derived RNA was isolated from 100 l of pseudoviral preparations 
using the RNAzol-BEE solution (Tel-Test, Friendswood, TX, USA) following 
manufacturer’s instructions. For cDNA synthesis, samples were first treated with DNaseI 
(Promega, Madison, WI, USA), and reverse transcription was performed using random 
hexamers (Sigma) and M-MLV Reverse transcriptase (Life Technologies) according to the 
manufacturer’s protocols. cDNAs were used as templates for quantitative real-time PCR 
using WNV-3’UTR specific primers (Forward, 5’-CAGTGTCAGACCACACTTTAATGT-3’; 
Reverse, 5’-GCTTACAGCTTCAGCCAAG-3’) and EvaGreen Technology (Bio-Rad, 
Hercules, CA, USA) on a C1000 thermal cycler using CFX96™ Real-Time Detection 
System (Bio-Rad) following manufacturer’s instructions (Melting temperature: 67ºC). 
Quantification of the relative number of viral RNA genomic copies was calculated by 
interpolating Cq values for each sample (done in duplicate) in a standard curve made with 
a quantified WNV-rep plasmid (r2=0.9972). Values outside the range covered by the 
standard curve were considered negative. 
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14.3. Immunofluorescence.  
Vero cells (seeded as mentioned before) were infected with different pseudoviral 
preparation using a 0.1 MOI. 48 h post-infection cells were fixed with 3.7% PFA in PBS for 
20min and quenched with 150 mM glycine in PBS. After washing, cells were mounted with 
ProLong supplemented with DAPI. Images were acquired using a Nikon Eclipse Ti-E 
microscope. 
 
14.4. Infection of mammalian cells.  
24h before infection, cells were seeded at a density of 4x104 cells/well in 24-well 
plates. Cells were infected with 2x104 pseudoviral particles diluted to 200 l in serum-free 
DMEM for 3h at 37ºC. 0.5 ml of DMEM with 2% FBS were then added and cells were 
further incubated for 48h. After incubation, cells were resusupended, counted and 
analysed for EGFP expression by cytofluorimetry as above. 
 
14.5. Antibody-dependent pseudoviral infection of K562 cells.  
Equal volumes of 1:100 dilutions of either anti-4DI/DII or pre-immune sera, and 
different preparations of pseudoviral particles containing with 2x104 pseudoviral particles, 
were mixed and incubated for 1.5h at 37oC in round-bottom 96 multi-well plates (Corning-
Costar, Corning, NY, USA). 5x104 K562 cells were added to the serum-virus mixture to a 
final volume of 200 l, and incubated for 48h at 37oC. Cells were then washed, 
resuspended in PBS, counted and analysed for EGFP expression by cytofluorimetry as 
above. 
 
15. Neutralisation assays 
15.1. Plaque reduction neutralisation assay (PRNT50).  
PRNT were performed on Vero cells seeded at a density of 1.6x104 cells/ well in 24 
multi-well plates 24h before infection. Sera samples from vaccinated mice were de-
complemented (30min at 56oC) and serially two-fold diluted in serum-free DMEM medium. 
Serum dilutions were mixed with equal volumes dengue virus preparations containing 50 
PFUs in serum-free DMEM medium, and incubated for 1.5h at 36oC. Vero cells were first 
washed, infected with the virus-serum mixture and further incubated for 1h at 36oC. 
Afterwards, the viral inoculum was removed and cells were overlaid with 1ml of DMEM 
with 2% FCS and 3% carboxymethylcellulose (CMC, Sigma). Plates were incubated at 
36oC for 7-8 days depending on serotype (7 days for DENV2 and DENV3, 8 days for 
DENV1 and DENV4). After this period, cells were washed twice with PBS, fixed for 20min 
with PFA 3.7% and stained with 1% crystal violet for 30min Plaques were counted and 
percentage of plaque reduction against control serum was calculated as follows: 
67 
 
                          (
           ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅      
       ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅               
) 
 
Neutralising antibody titres were expressed as the serum dilution yielding a plaque 
reduction of 50% (PRNT50). 
 
15.2. Foci reduction neutralisation test (FRNT50). 
FRNT were carried out in Vero cells, seeded at a density of 6.5x104 cells/well in 48 
multi-well plates, 24h before infection. Preparation of sera samples, viral inoculum and cell 
infection were performed as described for PRNT50. After 3 days incubation at 36°C (48h 
for WNV), cells were washed and fixed for 20min with PFA 3.7%, permeabilised with 1% 
Triton in PBS for 10min and treated with 0.3% H2O2 solution in methanol for 30min 
Infection foci were developed by after incubation with mAb 4G2 (1 ng/l in PBS-BSA) for 
1h at room temperature (RT), followed by incubation with HRP-conjugated goat anti-
mouse IgG (Jackson ImmunoResearch, 1:1,000 in PBS-BSA). Foci were then stained with 
100 l True-Blue reagent (KPL, Gaithersburg, MA, USA) and counted. Following the 
calculation done for PRNT50, neutralising antibody titres were expressed as the serum 
dilution yielding a 50% foci reduction when compared against pre-immune sera (FRNT50). 
 
16. Antibody-dependent enhancement of infection assays 
16.1. ADE in THP-1 cells. 
This assay was performed by researchers at the Ooi Lab. (Emerging Infectious 
Diseases Programme at the Duke-NUS Medical School in Singapore) using a previously 
described ADE method 438. Briefly, serial two-fold dilutions of each serotype-specific anti-
DIII pooled sera were incubated with the virus for 1h at 37°C before being added to THP-1 
cells at a MOI of 10. 72h post-infection, the culture was clarified by centrifugation, and the 
infectious titre of dengue virus in the culture supernatant was quantified by plaque assay. 
 
16.2. ADE in K562 cells.  
10-fold serum dilutions were mixed with an equal volume of RPMI 1640 serum-free 
medium containing 4x103 FFUs of each virus and incubated for 1.5h at 36oC in round-
bottom 96 multi-well plates. K562 cells were added to the serum-virus mixture to achieve 
a final MOI of 0.1, and incubated for 72h (48h for WNV) at 36oC. Cells were then fixed for 
30min with PFA 2% on ice, and blocked in permeabilisation buffer (0.1% saponin (Sigma-
Aldrich), 2% FCS and 0.1% NaN3 in PBS) for 30min at 4°C. After blocking, cells were 
incubated with mAb 4G2 (1 ng/l in permeabilisation buffer) followed by Alexa 488-
conjugated goat anti-mouse IgG (Jackson ImmunoResearch, 1:1000 in permeabilisation 
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buffer), both for 1h at RT.  After washing, cells were resuspended in PBS containing 2% 
FCS and 0.1% NaN3, and analysed by cytofluorimetry as before. 
 
17. Statistical analysis.  
Experimental data presented in this project were obtained from at least three 
independent experiments done in duplicate or triplicate. Unless indicated otherwise, 
arithmetic means ± standard deviations were calculated. Unpaired two-tailed t test, and 
One-way ANOVA were used for analyses when needed (GraphPad Prism 6.0, GraphPad 
Software Inc., La Jolla, CA, USA); in all cases p values <0.05 were considered significant 
and variances between compared groups were not significantly different, when required. 
Sample size was not statistically assessed and data distribution was assumed to be 
normal. No randomization was done. Data collection or analysis was not blinded. 
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PART I 
 
ANALYSIS OF E PROTEIN PRODUCTION, 
FOLDING, DIMERISATION AND SECRETION 
FROM MAMMALIAN CELLS  
______________________________________________________________________________________________ 
 
1.1. SYNOPSIS 
To obtain a secretory version of E, the stem and anchor regions at the C-terminal end 
of the protein are usually removed. The resulting protein, known as E ectodomain, or 
soluble E (sE), is composed of the three main structural domains: DI, DII and DIII and, as 
mentioned before, is the main antigen for most of the described DENV vaccines based on 
subunit and genetic approaches. With the objective of characterising the secretory 
properties of the E ectodomain, we performed an exhaustive biochemical study of the 
production, folding and secretion of sE constructs from all 4 DENV serotypes and ZIKV in 
mammalian cells. Our data indicate that DII is fundamental for the secretion of sE, while 
DIII serves a pivotal function in stabilisation of the dimeric conformation of E. 
In addition, and given the importance of complex quaternary epitopes for inducing a 
strong neutralising response against flaviviruses, we also studied the dynamics involved in 
E dimerisation and demonstrate that this arrangement, and the overall folding of sE, is 
independent of PrM but highly dependent on temperature. 
Finally, we also show that the efficient antigen secretion from transfected cells 
determines the strength of the antibody response elicited following DNA vaccination, an 
aspect that should be seriously considered when developing DNA vaccines. 
  
 
 
 
 
 
 
72 
 
1.2. RESULTS 
As a disclaimer, the reader is informed that some of the results included in this 
section were previously published in The Journal of General Virology439, while an 
additional research article including most of the remaining data was recently submitted.  
 
1.2.1. DII determines sE secretion from mammalian cells. 
The secretory profiles of recombinant sE from all DENV serotypes were investigated 
by transfecting mammalian cells with constructs encoding truncated versions of E where 
the stem-anchor regions were substituted with an SV5 tag at the C-terminus. To ensure 
proper translocation to the ER upon translation, the wild type leader peptide signal from 
the different proteins was substituted with a genomic fragment of a mouse signal secretion 
peptide from an immunoglobulin VH gene (sec) at the N-terminus
424, this signal has been 
shown to be efficiently cleaved by the ER signal peptidase within the mammalian ER in a 
co-translational manner424, which allowed us to circumvent the variability derived from 
differences between the secretory signals of different proteins and viruses used 
throughout the project. Schematic representations of these and other constructs used in 
the experiments described in this section are shown in Fig. 21a. sE secretion was 
assessed by western blot (WB) of cellular extracts and culture supernatants of transfected 
HEK-293T cells. The presence of the protein in culture supernatants indicated an efficient 
secretory phenotype; conversely, a poor-secretory phenotype was assigned to the 
proteins that where mainly retained within transfected cells with only traces found in the 
supernatants. As shown in Fig. 21b, significant secretory phenotype differences were 
observed among the four DENV serotypes: while sE constructs from DENV 3 and DENV4 
(3sE and 4sE, respectively) were efficiently secreted from transfected cells, proteins 
derived from DENV1 and DENV2 (1sE and 2sE, respectively) showed a poor-secretory 
phenotype since they were mainly retained intracellularly (Fig. 21b, long exposure). In 
addition, the secretory behaviour of the sE constructs was independent of the mammalian 
cell line used for transfection (Fig. 21c). 
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Figure 21. Secretory phenotype of transfected DENV sE proteins from mammalian cells. a) Scheme of 
constructs and their products; sec corresponds to a signal leader peptide and SV5 (orange) to the C-terminal 
tag. DI/DII and DIII are indicated in light and dark grey respectively. b) WB of cellular extracts (E) and 
supernatants (S) of HEK-293T cells transfected with sE constructs of the indicated serotypes. Short and long 
exposures are indicated. c) WB of cellular extracts (E) and supernatants (S) of HeLa, Vero and U2OS cell 
lines transfected with sE constructs as in b. Anti-tubulin and anti-actin were used as loading controls. 
(Adapted from reference 439). 
 
To determine if the secretory impairment of 1sE and 2sE was imposed by DI/DII or 
DIII, we evaluated the secretory properties of constructs that independently expressed 
these two parts of sE for all four DENV serotypes (Fig. 21a). Fig. 22a shows that plasmids 
expressing DI/DII of DENV3 and DENV4 (3DI/DII and 4DI/DII, respectively) were 
efficiently secreted from mammalian cells upon transfection, thus resembling the secretory 
phenotypes of the corresponding sE. On the other hand, but also reproducing the 
secretory characteristics of their homologous proteins, DI/DII from serotypes 1 and 2 
(1DI/DII and 2DI/DII) were poorly secreted from transfected cells. Although only low 
amounts of proteins were detected, DIII constructs derived from serotypes 1 and 3 (1DIII 
and 3DIII), were secreted, while those from serotypes 2 and 4 (2DIII and 4DIII) were not; 
taken together, these results showed no correlation between the secretory phenotypes of 
DIII and sE, suggesting that secretion of sE is determined by DI/DII. 
This observation was confirmed by designing chimeric sE constructs encoding DI/DII 
and DIII from different DENV serotypes with opposing secretory behaviours. Four sE 
chimeras were obtained: i) 1sE(3DIII) and 2sE(3DIII), which encoded the DI/DII regions of 
poor-secretory DENV serotypes 1 and 2, and the efficiently secreted DIII region of 
DENV3, respectively; ii) 3sE(2DIII), formed by DENV3 secretory DI/DII and the secretory-
impaired DIII of DENV2, and iii) 4sE(3DIII), combining the secretory DI/DII and the DIII 
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domains of DENV4 and DENV3 respectively. As demonstrated in Fig. 22b, poor-secretory 
phenotypes were observed in sE chimeras expressing the DI/DII regions of poor-secretory 
serotypes DENV1 and DENV2. On the other hand, DI/DII of serotype 3 enabled the 
secretion of the chimera containing the non-secretory 2DIII. As expected, 4sE(3DIII) was 
efficiently secreted, and served as a chimeric control for the observed phenotypes. These 
combinations of profiles allowed us to confirm that the secretory nature of DI/DII defines 
the behaviour of sE in mammalian cells. 
 
 
 
Figure 22. sE secretory phenotype depends on DI/DII. a) Cell extracts (E) and culture supernatants (S) of 
cells transfected with sE, DI/DII and DIII constructs of the indicated serotypes. b) WB of cells transfected with 
the indicated DI/DII-DIII (sE(DIII)) chimeras. For comparison, the corresponding sE and DI/DII proteins were 
analysed in parallel. Anti-tubulin was used as loading control. Filled, open and grey arrowheads indicate sE, 
DI/DII and DIII proteins, respectively. (Reprint from reference 439). 
 
To further map the role of DI and DII in determining the secretory phenotype of sE, 
we obtained chimeric DI/DII constructs by combining DI (including the hinge region) and 
DII domains from DENV2 and DENV3 which showed opposing secretory phenotypes. As 
shown in Fig. 23a, the 2DI/3DII chimera containing the DII from secretory DENV3 was 
well secreted, while the 3DI/2DII, like all constructs expressing 2DII, was not, thus 
suggesting that sE secretion is DII-dependent. This observation was confirmed by 
analysing DI and DII chimeras in the context of the whole sE (Fig. 23b). While the chimera 
expressing 3DI (2sE(3DI)) maintained the poor-secretory phenotype, grafting of 3DII 
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dramatically improved the secretion of the 2sE-based chimera (2sE(3DII)) (Fig. 23b lanes 
3-6). Likewise, transferring 2DI did not affect secretion of the 3sE(2DI) chimera, while 
expression of 2DII reduced the secretion of the 3sE(2DII) to near-undetectable levels. 
These results indicate that sE secretory phenotype is strongly determined by DII rather 
than DI. 
 
 
 
Figure 23. Secretory phenotypes of sE and DI/DII proteins are DII-dependent. WB analysis of cellular 
extracts (E) and culture supernatants (S) of HEK-293T cells transfected with (a), DI/DII chimeras (2DI/3DII and 
3DI/2DII) and (b), sE chimeras (2sE(3DI), 2sE(3DII), 3sE(2DI) and 3sE(2DII)). In both cases, wild type 
versions of DI/DII and sE proteins are shown as controls; anti-tubulin was used as loading control. (Adapted 
from reference 439). 
 
Since DII appeared to be fundamental for achieving efficient sE secretion, we used 
reactivity to monoclonal antibody (mAb) 4G2, which recognises a conformational epitope 
on the fusion loop of all arthropod-borne flaviviruses440, to test the folding state of DII 
within the different proteins evaluated so far. Positive recognition by 4G2 confirmed the 
proper folding of DII not only in efficiently secreted DI/DII and sE constructs from DENV3 
and DENV4, but also in secreted 2DI/3DII and 2sE(3DII) chimeras (Fig. 24a). 
Denaturation of the proteins prevented 4G2 recognition, thus confirming the 
conformational nature of the epitope. In contrast, 4G2 showed no reactivity towards 
cellular extracts containing DI/DII and sE proteins from poor-secretory DENV1 and 
DENV2, and not secreted 3DI/2DII and 3sE(2DII) chimeras (3DI/DII and 3sE were 
included as positive controls) (Fig. 24b). Together, these profiles indicate improper folding 
of the protein that could explain the poor secretory phenotype of DENV1 and DENV2 in 
mammalian cells. 
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Figure 24. Poor-secretory phenotype of sE and DI/DII proteins is associated with compromised DII 
folding . Slot blot of (a) culture supernatants of HEK-293T cells transfected with efficiently secreted E-derived 
constructs, and of (b) cells extracts from cells transfected using poorly-secreted proteins (3sE and 3DI/DII are 
included as control). Upper panels correspond to native samples reacted with anti-SV5, while lower panels 
contain to samples in native (upper row) and denatured (lower row) conditions reacted with mAb 4G2. (Reprint 
from reference 439). 
 
Since E glycosylation was shown to be important for proper trafficking of the viral 
particles along the secretory pathway106,107, we tested the correlation between 4G2 
reactivity and secretory phenotype, using non-glycosylated mutants (Asn67Gln-
Asn153Gln) of DENV3-derived DI/DII and sE constructs. As presented in Fig. 25a, 
contrary to the wild type (wt) proteins both non-glycosylated mutants showed impaired 
secretion. The wt proteins were treated with PGNase F to demonstrate the removal of 
glycosylation sites on the mutants. As expected, the non-glycosylated mutants were no 
longer recognised by 4G2 further confirming the correlation between proper DII folding 
and efficient secretion from mammalian cells (Fig. 25b).  
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Figure 25. Non-glycosylated DENV3 proteins show impaired secretion and improper DII folding. a) WB 
of cell extracts (E) and culture supernatants (S) of cells transfected with the non-glycosylated 3DI/DII and 3sE 
mutants (N67Q; N153Q) and the wild type (wt) controls. Samples treated with PNGase F are indicated. Filled 
and open arrowheads indicate sE and DI/DII proteins, respectively. b) Slot blot of cellular extracts containing 
wt 3DI/DII and 3sE and the non-glycosylated mutants, probed with anti-SV5 or mAb 4G2, on native or 
denatured samples, as indicated. (Adapted from reference 439). 
 
Interestingly, the secretory phenotype of 2DI/DII showed a temperature-dependent 
behaviour. Contrary to cell transfection following the “normal protocol” where cells were 
maintained at 37ºC (henceforth referred as 37ºC), we tested a “low-temperature protocol” 
in which cells were maintained at 37ºC for 16h after transfection and shifted to 28ºC for 
another 24h following change of culture media (henceforth referred as 28ºC) (Fig. 26a). 
As shown in Fig. 26b, 2DI/DII was efficiently secreted at 28ºC but not at 37ºC, while the 
secretory profile of 3DI/DII was not affected. The secretory 2DI/DII formed at 28ºC, but not 
the poor-secretory version produced at 37ºC, was recognised by 4G2, consistent with the 
association between DII folding and secretion (Fig. 26b). Nevertheless, the secretory 
phenotype of 2sE was not affected by temperature despite the fact that, like 2DI/DII, 2sE 
produced at 28ºC showed positive 4G2 reactivity (Fig. 26a and 26b).  
This indicates that, although proper folding is required for efficient secretion, it is not 
sufficient and other factors restrict secretion under these conditions. 
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Figure 26. 2DI/DII secretion and folding are temperature-dependent. a) Scheme of experimental 
conditions after transfection indicating temperature shifts for both protocols. b) WB of cellular extracts (E) and 
supernatants (S) of HEK-293T cells transfected with DENV2 sE and DI/DII constructs incubated at 37ºC 
(upper panel) or at 28ºC (bottom panel), 3DI/DII is included as control. Anti-tubulin was used as loading 
control. c) Slot blot of cell extracts samples shown in b, reacted with anti-SV5 or mAb 4G2, as indicated. 
(Adapted from reference 439). 
 
 
1.2.2. sE dimerisation. 
1.2.2.1. DIII stabilises sE dimeric interactions. 
We then evaluated the ability of secreted sE and DI/DII proteins to dimerise using a 
cell-based assay to detect dimers by flow cytometry. Display of 3sE on the cell membrane 
was achieved by designing DNA constructs where the transmembrane and the 
cytoplasmic domains of the human MHC-I chain were fused to the C-terminus of 3sE 
((m)3sE) (Fig. 27a). Dimerisation was evaluated by co-expressing the (m)3sE construct 
with SV5-tagged secretory versions of 3sE and 3DI/DII, As revealed using anti-3sE 
serum, only (m)3sE proteins were displayed on the cell surface after transfection (Fig. 
27b). Thus, cells will become positive to anti-SV5 only if the secretory proteins are able to 
form hetero-dimers with the membrane-bound (m)3sE. Indeed, anti-SV5 reactivity was 
only observed when cells were co-transfected with (m)3sE and 3sE-SV5 constructs, but 
not when each construct was used alone (Fig. 27c). In addition, hetero-dimers were also 
detected when using the 3DI/DII-SV5 construct (Fig. 27d), indicating that stable hetero-
dimers between DI/DII and sE were viable. In parallel to cytofluorimetry, transfected cells 
were also evaluated by immunofluorescence which confirmed the results and revealed the 
SV5-positve hetero-dimers restricted to the cell surface (Fig. 27e). 
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Figure 27. Dimerisation of sE and DI/DII proteins. a) Schematic representation of DNA constructs (left) and 
of the sE-sE homo-dimers and sE-DI/DII hetero-dimers detected on the cell membrane (right). (b-d) 
Cytofluorimetry plots of cells transfected with the indicated constructs and reacted with an anti-3sE serum (b), 
or with anti-SV5 to detect sE-sE homo-dimers (c) and sE-DI/DII hetero-dimers (d). e) Immunofluorescence of 
cells transfected with the indicated constructs and reacted with anti-SV5 to detect homo- and hetero-dimers. 
Permeabilised controls are shown as inserts within the respective images to highlight intracellular expression 
of the 3sE-SV5 and 3DI/DII-SV5 constructs. Bar represents 20 m. (Adapted from reference 439). 
 
Co-immunoprecipitation was used to further confirm the dimerisation of secreted sE 
constructs. For this, cells were co-transfected with two differently-tagged sE constructs: 
SV5 or BAP (Biotin Acceptor Peptide, a tag that can be biotinylated in vivo, by a biotin-
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ligase BirA enzyme active in the ER lumen426,427). After transfection, cell extracts and 
culture supernatants were immunoprecipitated with anti-SV5 and analysed with HRP-
conjugated streptavidin (StrAv) by WB. 3sE, 4sE and the 2sE(3DII) secretory chimera 
were analysed. Biotinylated sE partners were able to co-immunoprecipitate in all three 
cases both from cellular extracts (Fig. 28a) and culture supernatants (Fig. 28b). 
Surprisingly, when analysing 3DI/DII we were able to co-immunoprecipitate the BAP-
tagged construct from the cellular extracts (Fig. 28c) but not from the secreted proteins 
(Fig. 28d), suggesting that DI/DII interactions have low stability and constructs 
disassociate after secretion. 
 
 
 
Figure 28. Dimerisation of secreted sE and DI/DII proteins. Co-immunoprecipitations from cellular extracts 
(a, c) or culture supernatants (b, d) of HEK-293T cells transfected with the indicated constructs. 
Immunoprecipitations were carried out with anti-SV5 and co-immunoprecipitated biotinylated partners were 
detected with HRP-conjugated streptavidin (StrAv). In (a) and (c) anti-tubulin was used as loading control. 
(Adapted from reference 439). 
 
Since dimers were only recovered from secreted sE proteins, but not DI/DII, the 
results indicated that DIII fulfils an important role in stabilising the dimeric interactions 
among sE monomers. To confirm this, we expanded the immunoprecipitation studies and 
analysed the interactions between DI/DII and sE constructs in detail. As shown in Fig. 
29a, stable dimers (in the form of co-immunoprecipitated BAP-tagged partners) were only 
observed for 3sE homo-dimers (involving two DIII) and 3sE-3DI/DII hetero-dimers 
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(involving one DIII), but not for 3DI/DII homo-dimers; the results were independent of 
whether the pull-down was performed on the sE or DI/DII constructs (Fig. 29a, lanes 6 
and 7). The amount of co-immunoprecipitated proteins from the sE-DI/DII hetero-dimers 
was around four times lower (approximately 5% of input) than the amount of protein 
recovered from sE homo-dimers (approximately 20% of input) (Fig. 29b), suggesting that 
the single DIII present in sE-DI/DII interactions is able to stabilise dimerisation to a lower 
extent that the two DIII present on sE homo-dimers, highlighting the stabilising function of 
DIII within the sE dimers. To prove the specificity of these interactions we performed an 
SV5-immunoprecipitation on extracts from [35S]methionine-labelled cells co-transfected 
with SV5-tagged 3sE and roTag-tagged 3DI/DII. As shown in Fig. 29c, 
immunoprecipitations of 3sE (with anti-SV5) and 3DI/DII (with anti-roTag) were free of 
other radioactively-labelled cellular proteins, and anti-SV5 co-immunoprecipitation of 
3DI/DII was only observed when co-expressed with 3sE. 
 
 
 
Figure 29. Dimers are stabilised by DIII. a) Co-immunoprecipitations of proteins secreted from HEK-293T 
cells transfected with DENV3 constructs to analyse the formation of homo- and hetero-dimers. The amount of 
the anti-SV5 immunoprecipitated sample loaded into the gel (bottom panel) corresponds to 10 times the 
amount of the input (middle panel). b) Quantification of the data shown in (a) (lanes 5-8), for each combination 
of co-transfected constructs data is represented as mean±s.d. of biological replicates (n=3). P values from 
statistical comparisons between sE-sE homo-dimers and sE-DI/DII hetero-dimers (t=7,496, df=4), and 
between variation of sE-DI/DII hetero-dimers (t=0,1917, df=4), are shown.*, undetected. c) 
Immunoprecipitations with anti-SV5 or anti-roTag of cellular extracts from HEK-293T cells transfected with the 
indicated constructs and labelled with [
35
S]Methionine (15 minutes pulse). Filled and open arrowheads 
correspond to sE and DI/DII, respectively. (Adapted from reference 439). 
 
 
1.2.2.2. Secretion of covalently stabilised dimeric sE is temperature-dependent. 
Taking into consideration the relationship between proper folding, dimerisation and 
secretion described thus far, and also the temperature-dependent behaviour of 2sE 
folding, we decided to further investigate how PrM and temperature influence the 
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production and secretion of sE from the four DENV serotypes and ZIKV in mammalian 
cells. For this, we designed plasmids encoding the sequence of sE alone, or in the 
presence of viral proteins M (MsE) and PrM (PrMsE). The SV5 tag was fused to the C-
terminal end of sE and to the N-terminus of M or PrM as schematically shown in Fig. 30a. 
In addition, given the importance of dimer-dependent epitopes in inducing cross-
neutralising responses against DENV and ZIKV288, we attempted to stabilise sE dimers by 
introducing an Ala to Cys mutation in the inner surface of DII (Ala259 in sE from DENV1, 2 
and 4; Ala257 in DENV3 and Ala264 in ZIKV) (Fig. 30b). If sE truly undergoes transient 
dimerisation in the secretory pathway as our previous results indicate, the introduced 
cysteine would face itself in the opposite monomer, forming a disulphide bond stabilising 
the dimeric sE.  
 
 
 
Figure 30. a) Schematic representation of DNA constructs and expected products. b) E dimeric structure of 
DENV3 (PDB reference 1uzg) indicating the position where the Ala257Cys mutation was introduced. 
 
HEK-293T cells were transfected using constructs with or without M and PrM, 
expressing the wild type (sE-wt) or mutant sE from DENV2, DENV3 and ZIKV (ZsE), 
following the temperature protocols described in Fig. 26a. Expression and secretion of the 
encoded proteins was analysed by non-reducing WB of cellular extracts and culture 
supernatants from transfected cells. Results from experiments incubated at 37ºC and 
28ºC are shown in Fig. 31a and Fig. 31b respectively. 
At 37ºC, 3sE was secreted from both wild type and mutated constructs, however, 
while the secreted sE protein from 3sE-wt constructs run as a monomer, the Ala257Cys 
mutant was found as a covalent dimer (sE-cvD) (Fig. 31a, leftmost panel). Moreover, 3sE-
wt and 3sE-cvD were equally produced and secreted regardless of the presence of PrM 
(or M). In contrast, for DENV2 and ZIKV (Fig. 31a, centre and rightmost panels, 
respectively), sE-wt and sE-cvD proteins were not secreted with any of the constructs 
tested; instead a smear of disulphide bonded folding intermediates was detected 
intracellularly. At 28ºC (Fig. 31b), however, sE-wt and sE-cvD of DENV3 and ZIKV were 
efficiently produced and secreted from transfected cells, while 2sE, in agreement with our 
previous results, was only secreted from the 2sE-cvD mutant but not from the 2sE-wt 
constructs. In all cases, the results were independent of the presence of PrM and highlight 
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the fundamental role of temperature for inducing proper folding and dimerisation of sE 
proteins in mammalian cells. 
 
 
 
Figure 31. Secretory profiles of covalently stabilised sE dimers of DENV and ZIKV in mammalian cells. 
Non-reducing WB of total cell extracts (E) and culture supernatants (S) of HEK-293T cells transfected with the 
indicated constructs and incubated at 37ºC (a) or at 28ºC (b). Anti-actin was used as loading control. Open 
and filled arrowheads indicate monomeric and dimeric sE, respectively. 
 
For DENV1 and DENV4, temperature-dependent dimerisation and secretion of sE-
cvD constructs, in absence of PrM, was also confirmed (Fig. 32a). Moreover, a 
temperature-dependent secretory phenotype was also observed for sE-wt of DENV1 that, 
just as initially described for the 2DI/DII constructs, was efficiently secreted only from 
transfected cells at 28ºC. Using constructs coding for the sE variants of DENV3 and 
DENV2 we also determined that the temperature-dependent and PrM-independent 
behaviour was also independent of the mammalian cell line used for transfection (Fig. 
32b). 
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Figure 32. Secretory profiles of covalently stabilised DENV sE dimers of different mammalian cells. a) 
Non-reducing WB of cell extracts (E) and culture supernatants (S) of HEK-293T cells transfected with sE-wt 
and sE-cvD constructs of DENV1 and DENV4, incubated at 37ºC (left panel) or at 28ºC (right panel). Open 
and filled arrowheads indicate monomeric and dimeric sE, respectively. b) Dimerisation and secretion of sE-wt 
and sE-cvD of DENV2 and DENV3 in HeLa (top) or Vero cells (bottom), incubated at 37ºC or 28ºC, as 
indicated. Anti-actin was used as loading control. 
 
ELISA and cytofluorimetry were used to evaluate the proper folding and assembly of 
sE-cvD constructs. For ELISA, secreted biotinylated covalent sE dimers from DENV2, 3 
and 4, and ZIKV were obtained from the supernatant of transfected HEK-293T cells using 
the BAP-tag/BirA biotinylation system described before (DENV1 was excluded from the 
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assay as the amount of secreted 1sE-cvD was not enough to perform a comparable 
assay), captured in avidin-coated plates and probed with a series of mAbs targeting 
different conformational epitopes: 4G2 and 4E5A (which targets a DENV-specific epitope 
on DIII441,442) recognise epitopes restricted to one domain present on a single E protein; 
EDE1-C10, EDE2-B7 (against dimeric epitopes EDE1 and EDE2, respectively284), 2D22 
(recognising also a dimeric epitope specific of DENV2285) and 5J7 (a DENV3-specific 
antibody whose footprint involves binding to 3 different E proteins from two adjacent E 
dimers on the viral surface281), bind to quaternary epitopes involving more than one E 
molecule. In addition, mAb 1F4, a DENV1-specific antibody recognising residues on DI 
and hinge regions of a single E monomer as displayed on the viral surface, but not on 1sE 
recombinant proteins obtained from insect cell lines282, was also included. The results for 
the ELISA analysis are shown in Fig. 33, EDE-specific mAbs EDE1-C10 and EDE2-B7 
were able to recognise cvD versions of 2sE, 3sE and 4sE, while only EDE1-C10 reacted 
positively with ZsE-cvD as ZsE was shown to be recognised less efficiently by anti-EDE2 
antibodies288,289. As expected, 2D22 recognised only 2sE-cvD, while 4E5A reacted with all 
DENV-derived proteins containing DIII and 4G2 was only negative against the control 
4DIII. Since DENV1 proteins were not included 1F4 did not recognise any of the tested 
proteins; likewise, the lack of higher order DENV3 E dimers arrangements explains the 
non-reactivity of mAb 5J7. 
 
 
 
Figure 33. Structural analysis of covalently stabilized E dimers from DENV serotypes 2, 3 and 4 and ZIKV in 
ELISA with the indicated mAbs (left panel). Control antigens, 4DIII, 4DI/DII and 4sE wt were also included 
(right panel); data is represented as mean±s.d. (in all cases, n=5).  
 
The same selection of mAbs (with an additional EDE1-specific antibody, EDE1-C8284) 
was then used to analyse membrane displayed versions of wt ((m)sE-wt)c and cvD 
((m)sE-cvD) constructs, following transfection of HEK-293T cells at 28ºC and 37ºC. The 
reactivity profiles for (m)sE-cvD (Fig. 34) and (m)sE-wt (Fig. 35) proteins, resembled those 
described for the ELISA with three important differences: i) the (m)sE-wt proteins of the 
                                                          
c
 There are no differences between the (m)sE constructs described in the previous section and the (m)sE-wt constructs 
mentioned here. The “–wt” termination is added to highlight the differences with the proteins carrying the cvD mutation.  
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four DENV serotypes and ZIKV were displayed as dimers, as evidenced by the positive 
reactivity to dimer-specific mAbs, ii) mAb 1F4 was positive with both 1sE formats (-wt and 
–cvD) and iii) mAb 5J7 reacted with DENV3 sE-cvD, but not with sE-wt. We therefore 
concluded that the secreted and membrane bound versions of sE-cvD constructs replicate 
the structure of the antiparallel E dimers present on the viral surface. 
 
 
 
Figure 34. Cytofluorimetric analysis of HEK-293T cells transfected with (m)sE-cvD constructs of all four DENV 
serotypes and ZIKV at 37ºC or 28ºC, and reacted with the indicated mAbs. Mock-transfected HEK-293T cells 
incubated with each mAb served as controls.  
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Figure 35. Cytofluorimetric analysis of HEK-293T cells transfected with (m)sE-wt constructs of all four DENV 
serotypes and ZIKV at 37ºC or 28ºC, and reacted with the indicated mAbs. Mock-transfected HEK-293T cells 
incubated with each mAb served as controls. 
 
 
1.2.2.3. Covalent stabilisation of E dimers on the viral surface. 
We then attempted expressing the covalent dimeric E mutants on the surface of viral 
particles. We used a pseudoviral approach based on a previously described WNV replicon 
encoding a reporter EGFP (WNV-rep436). Using this system, infectivity of pseudoviral 
particles can be assessed by determining the number of EGFP-positive cells following 
infection. Since ZIKV structural proteins have been shown to efficiently package WNV-
rep437, the objective was to produce pseudoviruses using constructs containing ZIKV-
derived C-PrME structural proteins carrying the E-wt sequence (ZE-wt) or the Ala264Cys 
E-cvD mutation (ZE-cvD). If covalent dimers were successfully assembled and 
incorporated into pseudoviruses, infectivity of the produced particles should be 
compromised since E trimerisation, and thus the fusion of the viral and endosomal 
membranes, would be blocked by the disulphide bond. On the other hand, pseudoviruses 
with the wt sequence of ZIKV E should be infective, allowing detection of EGFP from 
infected cells, as shown in Fig. 36.  
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Figure 36. Production of pseudoviral particles using E-wt and E-cvD proteins. Diagrams of the ZIKV-wt 
(a) and -cvD (b) constructs and the WNV replicon used to produce pseudoviral particles, tested for infectivity 
(EGFP expression) on Vero cells. Images correspond to representative experiments (Bar, 30m). 
 
Production of pseudoviral particles was determined by RT/PCR of the WNV-rep RNA 
from culture supernatants of transfected cells. As shown in Fig. 37a, WNV-rep RNA was 
successfully amplified from culture supernatants of cells co-transfected with either ZE-wt 
or ZE-cvD and the WNV-rep, but not from cells transfected with the WNV-rep alone. Cells 
transfected only with packaging plasmids were used as controls. Consistent with the 
temperature-dependent behaviour of ZsE-cvD proteins, production of pseudoviruses with 
ZE-cvD was more efficient at 28ºC, while the yield of particles with ZE-wt showed no 
significant differences between 28ºC and 37ºC. Moreover, non-reducing WB analysis of 
pseudoviral preparations confirmed detection of the dimeric form of the full E-cvD protein 
at 28ºC, while the E-wt protein, as expected, run as a monomer (Fig. 37b). As expected, 
all the protein recovered from the cvD pseudoviruses was dimeric.  
As expected, pseudoviral particles prepared with ZE-cvD were not able to infect Vero, 
HuH-7 or HEK-293T cells, while wt particles did (Fig. 37c). To exclude that the lack of 
infectivity of ZE-cvD pseudoviruses was due to compromised interaction with cellular 
receptors, we performed an ADE assay on K562 cells as antibody-mediated infection 
should bypass entry involving viral receptors on the cell surface. As shown in Fig. 37d, 
infectivity of wt pseudoviruses was enhanced by anti-DI/DII antibodies, while cvD 
pseudoviruses remained non-infective, consistent with impaired membrane fusion within 
the endosome due to lack of E trimerisation of cvD mutants. Collectively, these results 
indicate that viral particles with covalently-bound E protein dimers are permissive for 
assembly in the ER and compatible with trafficking through the secretory pathway.  
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Figure 37. Assemble of ZE-cvD proteins into pseudoviral particles. a) Relative quantification of 
pseudoviruses determined by RT/PCR of the replicon-derived RNA, on samples obtained with ZE-wt 
packaging construct with (n=6; t=0,5790 df=10) and without (n=6) replicon, or ZE-cvD packaging construct 
with (n=6; t=4,896 df=10) and without replicon (n=6), supernatant of cells transfected only with the WNV 
replicon were used as control, data is represented as mean±s.d. b) Left panel, non-reducing WB of 
pseudoviral preparations obtained with the ZE-wt or ZE-cvD packaging constructs developed with mAb 4G2, 
culture supernatant of cells transfected only with the WNV replicon is shown as control. Right panel, WB of the 
corresponding SV5-tagged proteins developed with anti-SV5; migration differences correspond to the effect of 
the stem-anchor region in pseudoviruses. c) Infectivity of pseudoviral particles produced at 28ºC with ZE-wt or 
ZE-cvD packaging constructs on Vero (n=5), HuH-7 (n=5) and HEK-293T cells (n=5), determined as EGFP 
positive cells at 48 h post-infection using 2x10
4 
viral particles (as quantified by RT/PCR). d) Infectivity of same 
pseudoviral particles as in (c) on K562 cells in the absence of serum (n=5) or in the presence of an anti-DI/DII 
serum (n=5) or a negative control pre-immune serum (n=5). In all cases, data is represented as mean±s.d. *, 
undetected. 
 
 
1.2.2.4. Dimerisation of heterotypic sE proteins.  
Since assembly and secretion of sE-cvD proteins were viable for all DENV serotypes 
and ZIKV, we tested whether sE proteins from different viruses were able to interact with 
each other and form covalent hetero-dimers. For this, we designed sE-cvD constructs 
carrying two different tags to distinguish between the interacting monomers following a 
similar approach used for the experiments involving immunoprecipitations (Fig. 28). 3sE 
was tagged with BAP, while 1sE, 2sE, 3sE (as control), 4sE and ZsE were tagged with 
SV5. HEK-293T cells were then co-transfected with BAP-tagged 3sE-cvD and each one of 
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the SV5-tagged cvD proteins. As outlined in Fig. 38a, the strategy for discrimination 
between homo- and hetero-dimers was based on the detection of the different tags and 
migration patterns of the constructs on non-reducing WB. The results indicate that 3sE 
efficiently formed secreted E covalent dimers with 2sE, 4sE and ZsE (Fig. 38b), while 
3sE-1sE hetero-dimers were also formed and secreted although in lower amounts (Fig. 
38b, left panel). 
 
 
 
Figure 38. Hetero-dimerisation of E proteins from different flaviviruses. a) Approach used to detect E 
hetero-dimers by WB. For all DENV serotypes and ZIKV, SV5-tagged sE constructs were used, while 3sE was 
also tagged with BAP and co-expressed with the SV5-tagged proteins. Relative migration in non-reducing 
PAGE of expected homo- and hetero-dimers and their schematic representation are indicated. b) Non-
reducing WB of cell extracts (E) and culture supernatants (S) of HEK-293T cells co-transfected with the 
indicated constructs and developed with anti-SV5 (upper panel) or StrAv-HRP (lower panel). * indicates 
biotinylated host intracellular proteins. Arrowheads indicate migration of dimers as shown in (a). Anti-actin was 
used as loading control. Open arrowheads indicate hetero-dimers. Right panel, long exposure of poorly 
secreted 1sE-3sE hetero-dimers. 
 
The WB results were confirmed by cytofluorimetry using the same cell-based assay 
used to evaluate the role of DIII in 3sE dimerisation (Fig. 27a). (m)sE-cvD constructs for 
the four DENV serotypes and ZIKV were co-expressed with secretory, SV5-tagged 3sE-
cvD in mammalian cells. As before, transfected cells stained positively for the SV5 tag 
only when the secretory protein was retained in the cell membrane following hetero-
dimerisation with the membrane displayed constructs. As observed in the WB analysis, 
3sE-cvD hetero-dimerisation was observed with all the (m)sE-cvD constructs (Fig. 39a). 
Interestingly, hetero-dimers were also produced when the experiment was performed 
using the sE-wt proteins, even though the interaction was significantly less efficient with 
(m)1sE-wt and (m)4sE-wt, and almost unnoticeable with (m)ZsE-wt (Fig. 39b). Together, 
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these results indicate that interaction between heterotypic E proteins is not imposed by 
the disulphide bridge in cvD mutants but rather a consequence of spontaneous 
interactions between monomers. 
 
 
 
Figure 39. sE Hetero-dimerisation is not imposed by the cvD mutation. Cytofluorimetry profiling of HEK-
293T cells co-transfected at 28ºC with the membrane displayed (m)sE-cvD proteins and the secretory SV5-
tagged 3sE-cvD (a) or with the (m)sE-wt proteins and the secretory SV5-tagged 3sE-wt (b) of all four DENV 
serotypes or ZIKV. Profiles correspond to anti-SV5 reactivity and are compared to HEK-293T cells transfected 
only with the secretory SV5-tagged 3sE.  
 
 
1.2.2.5. E mosaic viruses. 
After demonstrating that hetero-dimerisation was permissive in the context of 
secreted sE proteins, we decided to assess the possibility of producing viral particles with 
“mosaic” surfaces formed by distinct E proteins. Using the aforementioned pseudoviral 
approach, we attempted to package the WNV-rep using constructs expressing ZIKV and 
DENV E proteins. Following the transfection protocol at 37ºC, production of infective 
pseudoviruses was possible using the ZE-wt construct, but not with a chimera coding for 
ZIKV C protein and DENV2 PrME (CZ-PrMEDENV2) (Fig. 40a, panels 1 and 2). In the same 
way, infective particles were not obtained when transfecting ZIKV-C and DENV2-PrME in 
trans (Fig. 40a, panel 3). In contrast, infective pseudoviruses were recovered after co-
transfection of ZE-wt and DENV2-PrME (Fig. 39a, panel 4) although, as evidenced by 
Vero-cell infectivity, the production efficiency was lower when compared to transfection of 
ZE-wt alone (Fig. 40b).   
To determine if pseudoviruses produced using E proteins from ZIKV and DENV2 
presented a mosaic E display on their surface, we designed an ADE assay in which 
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infection was enhanced using a specific combination of antibodies (Fig. 40c). DENV2-
specific antibodies, such as those directed against DENV2 DIII (as thoroughly 
demonstrated in the following sections) should only promote the infectivity of particles 
displaying DENV2 E protein on their surface, while cross-reacting antibodies, such as 
those directed against DI/DII, should induce ADE on both ZIKV-only and DENV2-ZIKV 
mosaic pseudoviruses. Indeed, anti-2DIII antibodies specifically enhanced the infectivity of 
particles produced by co-expressing both E proteins, while pseudoviruses produced with 
ZE-wt only were not significantly affected. As expected, significant enhancement on both 
types of pseudoviruses was observed when using anti-DI/DII antibodies, while pre-
immune control sera had no significant effect on infectivity (Fig. 40d). Therefore, DENV2 E 
protein was (partially) incorporated on the viral surface when co-expressed with the ZIKV 
structural proteins, producing particles with a mosaic E composition.  
 
93 
 
 
 
Figure 40. Assembly of mosaic pseudoviruses with E proteins of ZIKV and DENV2. a) Production of 
pseudoviruses by co-transfection of the WNV replicon and different packaging constructs, and revealed by 
EGFP expression in Vero cells 48h post-infection. Percentages of EGFP positive cells are indicated. Z, ZIKV; 
Ch, chimeric; D, DENV2. b) Total number of infected Vero cells obtained using equal volumes of pseudoviral 
preparations (n=5), data is represented as mean±s.d. c) Expected ADE activity for particles packaged with 
only ZIKV protein or ZIKV/DENV2 mosaic particles incubated with antibodies recognising both, ZIKV and 
DENV2 E proteins (anti-DI/DII) or only DENV2 E protein (anti-2DIII). d) EGFP positive K562 cells following 
48h infection with supernatants of transfections as in (a), and treated with anti-DI/DII (n=5 for each 
preparation; t=8,868 df=8), anti-2DIII (n=5 for each preparation; t=10,70 df=8) or control antibodies (n=5), 
Equal volumes of inocula were used to infect cells, data is represented as mean±s.d. *, undetected. 
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1.2.3. Antigen secretion and immune response upon DNA vaccination. 
It has been proposed that, for genetic vaccines, induction of an efficient antibody 
response depends heavily on proper antigen secretion from transfected cells395,443. 
Therefore, in the case of DENV DNA vaccines, formulations encoding thoroughly studied 
antigens with a well-established secretory phenotype from transfected cells, would 
improve antigen availability and induce stronger antibody responses. We were able to 
confirm this hypothesis by gene-gun DNA immunisation of mice using two groups of 
plasmids encoding sE proteins that share the same DIII but have different secretory 
phenotypes in mammalian cells: i) 3DIII was expressed in the context of the efficiently 
secreted 3sE and the poor-secretory 3sE(2DII) chimera; while ii) 2DIII was included within 
the poorly-secreted 2sE and the secretory 2sE(3DII) chimera (secretory phenotypes of 
these constructs are shown in Fig. 23b). Following vaccination, anti-DIII titres were 
measured by ELISA using recombinant monobiotinylated DIII of DENV2 and DENV3 for 
coating. Since antibodies directed against DI/DII were not detected due to the DIII-specific 
coating of the ELISA plates, and the 3DIII and 2DIII regions expressed in each vaccination 
group were identical, the assay allowed us to determine how antigen secretion from 
transfected cells influenced the anti-DIII response. Animals immunised with the secretory 
3sE protein developed an anti-3DIII titre above 2000, while those that received the poor-
secretory 3sE(2DII) chimera were negative at 1/100 dilution (Fig. 41a). As with the 3DIII-
expressing constructs, the anti-2DIII titres were ten times higher in the group immunised 
with the secretory 2sE(3DII) chimera than in the group vaccinated with 2sE (Fig. 41b). 
Cross-reactivity of 3DIII-based sera against 2DIII, and the 2DIII-based sera against 3DIII 
was very low (Fig. 41c and 41d, respectively). Antibody titres against the homologous DIII 
are summarized in Fig. 41e, and further highlight how antigen availability (in the form of 
secreted antigen) determines the strength of the antibody responses. As shown by the 
immunofluorescence in Fig. 41f, anti-2sE, anti-2sE(3DII) and anti-3sE sera were able to 
recognise the mature viral protein in virus-infected cells. In all cases, pre-immune sera 
were used as negative controld. 
 
                                                          
d
 Sera from non-immunised mice (Pre-immune sera) were as negative as sera from mock-immunised animals, i.e. mice 
immunised with the empty pcDNA3.1 or pVAX1 vector. 
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Figure 41. Effect of antigen secretion on antibody responses upon DNA-vaccination in mice. ELISA 
measurement of anti-DIII antibodies in sera from mice gene gun-immunised with secretory and poor-secretory 
constructs expressing 3DIII (a) or 2DIII (b) on plates coated with the corresponding DIII antigen. Cross-
reactivity of 3DIII-based sera on 2DIII (c) and 2DIII-based sera on 3DIII (d) is shown. e) Homologous anti-DIII 
antibody titres obtained from all the constructs used for vaccination (for all antigens, n=6), data is represented 
as mean±s.d. Statistical comparison between the antibody titres of animals vaccinated with the constructs 
encoding 2DIII is shown (t=7,061 df=10), ND indicates antibody titres below the cut-off value at 1/100 dilution. 
(f) Immunofluorescence of DENV2 and DENV3-infected Vero cells reacted with sera from immunised animals 
as indicated. Pre-immune (Ctrl.) sera and non-infected cells (N.I) were used as controls. Bar represents 50 
m. (Adapted from reference 439). 
 
We then used the plaque reduction neutralisation test (PRNT50) on infected Vero cells 
to measure the capacity of the different sera to neutralise DENV2 and DENV3. Sera from 
mice vaccinated with the secretory 2sE(3DII) chimera were able to efficiently neutralise 
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DENV2 and, to a much lower extent, DENV3 (Fig. 42a). As expected from the antibody 
titres, 2sE-induced antibodies showed limited neutralising capacity towards DENV2, and 
no activity against DENV3 (Fig. 42b). On the other hand, antibodies from animals 
immunised with 3sE neutralised DENV3 but not DENV2 (Fig. 42c). In agreement with the 
ELISA analysis, responses with the poor-secretory 3sE(2DII) chimera did not show any 
neutralisation activity (Fig. 42d). PRNT50 titres towards the homologous DIII DENV 
serotype are shown in Fig. 42e.  
We then compared the properties of the anti-2DII antibodies obtained with 2sE and 
2sE(3DII). Surprisingly, although both immune responses mainly recognised 
conformational epitopes on 2DIII (Fig. 42f), the avidity of 2sE(3DII)-derived antibodies was 
significantly higher than those obtained from 2sE (Fig. 42g). 
 
 
 
Figure 42. Virus-neutralising activity of secretory and poor-secretory antigens. Plaque reduction 
neutralisation test (PRNT) on DENV2 (filled symbols) and DENV3 (open symbols) using pooled sera from 
animals immunised with 2sE(3DII) (a), 2sE (b), 3sE (c) and 3sE(2DII) (d) constructs (in all cases, n=4 for each 
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virus). (e) PRNT50 titres of sera from the indicated secretory and non-secretory constructs on the homologous 
DENV serotype. ND indicates a PRNT50 titre below 25. (f) ELISA performed on equal amounts of native or 
denatured biotinylated 2DIII, captured on avidin-coated plates and reacted with sera from the indicated 
constructs (in all cases, n=3). Statistical comparison of the anti-2sE(3DIII) reactivity on native and denatured 
antigens is shown (t=13,90 df=4). ND indicates an antibody titre below the cut-off value. (g) Avidity index of 
sera derived from animals immunised with 2sE (n=14) or 2sE(3DII) (n=14) determined on native 2DIII (t=8,436 
df=26). In all cases, data is represented as mean±s.d. (Adapted from reference 439). 
 
1.3. DISCUSSION 
As described before, studies regarding the immune response against flaviviruses 
suggest that antibodies directed against the E glycoprotein have stronger type-specific 
neutralisation capacity and represent a lower risk to induce heterotypic ADE when 
compared to antibodies towards other viral proteins342. In addition, studies on the nature of 
the epitopes recognised by anti-E antibodies have significantly increased the 
understanding of interactions between flaviviruses and the immune system, giving 
valuable tools to develop more efficient vaccine candidates, especially in the case of 
DENV and ZIKV310. 
Most of the mAbs with potent neutralising capacity against DENV have been mapped 
to DIII91,92. Paradoxically, anti-DIII antibodies have almost no effect in the overall immune 
response against dengue, since the immune response in mainly directed against epitopes 
on the surface of DI/DII, especially towards epitopes surrounding the FL and the hinge 
region271,273. However, anti-DI/DII antibodies, which are neutralising only at high 
concentrations296, have been shown to be highly cross-reactive among the different DENV 
serotypes279 and ZIKV324,444, which increases the risk of ADE. Recent evidence derived 
from the study of mAbs isolated from infected patients indicates that conformational 
epitopes, generated as a result of quaternary interactions between E monomers on the 
viral surface, are important drivers of the neutralising response after infection279.  
 
We performed a detailed biochemical and structural analysis of the expression, 
folding, dimerisation and secretion of E ectodomains from DENV serotypes and ZIKV in 
mammalian cells, with the objective of understanding their secretory properties and 
implement them in the design of DNA-based vaccines with improved immunogenicity. This 
is particularly relevant given the importance of conformational epitopes to induce effective 
immunity against flaviviruses, and the fact that E protein is the main antigenic component 
of most DENV vaccine candidates310,445. 
As shown in our results, sE proteins obtained from the four DENV serotypes have 
different secretory properties in mammalian cells. While sE proteins from DENV1 and 
DENV2 showed impaired secretion, DENV3 and DENV4 sE constructs were efficiently 
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secreted following transfection as evidenced by the presence of the proteins in the culture 
supernatants. Since expression, demonstrated by the detection of the protein in the cell 
extracts, was not compromised for any of the constructs, we suspected that 1sE and 2sE 
were retained in the intracellular compartment due to improper folding.  
Based on the primary structure of DENV E proteins and the presence of the poorly 
structured linker between DI and DIII96, we reasoned that sE folding should occur in two 
co-translational steps: the 3 segments encoding DI and the 2 segments DII need to fold 
together and establish close molecular interactions to obtain the properly folded DI/DII45, 
while DIII should be able to fold on its own as it derives from a single aminoacid sequence 
and has no significant interaction with DI and DII in the context of the monomeric E85. By 
splitting the sE constructs into these two theoretical folding units, we were able to match 
the secretory phenotype of the whole sE to the corresponding DI/DII. The studies using 
the chimeric constructs further confirmed the assumptions regarding the involvement of 
DI/DII in determining the secretory phenotype of sE constructs and allowed us to map the 
poor-secretory phenotype of DENV1 and DENV2 specifically to DII.  
To test if protein misfolding was the underlying reason behind the poor-secretory 
phenotype of constructs carrying DII from DENV1 and DENV2, we probed DII folding in 
both cell extracts (for non-secreted proteins) and culture supernatants (for efficiently 
secreted proteins), with mAb 4G2 which recognises the conformational epitope of the 
highly-conserved FL440. Although the reasoning of assuming proper DII folding only on 
4G2 reactivity could be argued, we decided to rely on this specific mAb because a) the FL 
structure depends on a series of complex interactions between several loops and -
strands throughout DI/DII, which requires the correct folding of both domains, b) it 
recognises all DENV serotypes440, which homogenises the readout of the assay and 
enables comparisons among the different constructs, and c) proper FL structure is 
instrumental for E dimerisation88. 
Even though we traced the secretory phenotype of E ectodomains to DII, there is a 
significantly high identity when comparing DI/DII aminoacid sequences from all four DENV 
serotypes, regardless of the secretory phenotype. Indeed, the high homogeneity on this 
portion of E is heavily reflected on the cross-reactivity of the antibodies elicited against 
DI/DII epitopes279. For example, the sE sequences from DENV2 (poor-secretory) and 
DENV3 (secretory) share a 71% and 75% identity on DI and DII, respectively.  
Thus, a clear indication to explain the differences in folding and secretion, and their 
direct association with DII, was not apparent from our analyses of the protein sequences. 
This suggests that the observed phenotypes could be the result of the collective 
contribution of the small differences distributed throughout the domain. It is also possible 
that the secretory phenotypes here described are not representative of each DENV 
serotype but are, instead, dependent on the viral strain; however, as shown in Fig. 43, this 
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is unlikely since the E aminoacid sequences are rather conserved within each serotype 
with no considerable differences when comparing the diversity found among the different 
domains. 
 
 
 
Figure 43. Relative sE amino acid diversity within DENV serotypes. Each of the strains used were 
compared to 20 randomly selected sE sequences of the corresponding serotype (UniProtKB database, 
GeneBank accession numbers are shown) and the relative aminoacid differences plotted to show variations 
for the whole E ectodomain (sE, grey) and DI (red), DII (yellow) and DIII (blue). a) DENV1 Nauru strain 
(U88535.1) compared to sequences AF311956.1, D00502.1, D00501.1, M87512.1, AY620953.1, 
AY620952.1, AAT39550.1, AAT39549.1, AAT39548.1, AAT39547.1, AAT39546.1, AAT40237.1, AAT40236.1, 
AAT39427.1, AAT37503.1, AAT12783.1, AAT01283.1, AAT00448.1, AAT00447.1, BAC77219.1. b) DENV2 
New Guinea C strain (AF038403) compared to sequences AEX97780.1 , AEX97778.1 , AEX97787.1 , 
AAA42942.1, AAA42962.1 , ABA61184.1, CAA33474.1, CAA33284.1, BAA00254.1, CAA38217.1, 
BAA01389.1, AAA73185.1, AAA73186.1, AAA73471.1, AAA42952.1, AAA42954.1, AAA42957.1, 
AAA42960.1, AAA42951.1, AAD32963.1. c) DENV3 H87 strain (M93130) compared to sequences 
ADF55927.1, ADF55928.1, ADF55929.1, ADF55930.1, ADF55933.1, ADF55936.1, ADF55937.1, 
ADF55938.1, ADF55941.1, AEW25108.1, AFI71754.1, AFI71773.1, AAV34603.1, AAT75224.1, AAM51538.1, 
AAM51537.1, BAC77233.1, AAN61123.1, AAN16079.1, AAK01920.1. d) DENV4 Dominica strain (AF326573) 
compared to sequences ABO27186.1, ACC68752.1, ACY01670.1, ADJ18331.1, AEJ89905.1, AER00188.1, 
AEW24968.1, AEV66313.1, AFI71472.1, AFW15987.1, AFZ40097.1, AAU89377.1, AAU89375.1, 
AAX48017.1, AAV49746.1, AAV31422.1, AAU89343.1, BAC77238.1, AGH68519.1, AGH68518.1. (Adapted 
from reference 439). 
 
The recent description of E dimer-dependent quaternary epitopes located on a 
serotype-invariant site at the E-dimer interface, has significantly impacted the study of 
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antibody responses against flaviviruses284. Even though the high neutralising capacity of 
antibodies against complex quaternary epitopes has been previously studied278,281,285, the 
description of EDE epitopes demonstrate the existence of conserved antigenic 
determinants that are capable of inducing strong cross-neutralising antibodies against all 
four DENV serotypes and ZIKV286,287,289, thus opening the possibility for the development 
of a single universal vaccine. However, the isolation of the precise epitopes outside of the 
viral surface is a complex, and yet unresolved task that has prevented their 
implementation into new vaccine formulations. These findings also highlight the 
importance of ensuring proper E folding and dimerisation in E-based immunogens, in 
particular for genetic vaccines. In addition, it has been shown that antigens presented in a 
dimeric structure are able to stimulate immune cell receptors more efficiently, which could 
lead to stronger antibody responses446. 
We exploited the parallelism between the E protein cell-surface display and E 
proteins on flaviviruses to develop an assay that allowed us to study not only the 
conformation of secreted proteins using highly efficient tools like flow cytofluorimetry, but 
also the interaction between distinct E monomers by cell-surface retention and differential 
tagging as discrimination parameters. As demonstrated by our data, by replacing the 
stem-anchor regions of E with the cytosolic and transmembrane domains of the human 
MHC-I, we successfully retained the protein on the cell membrane without any apparent 
alteration to its maturation process within the secretory pathway. Stable interactions 
between E monomers were then proved by anti-SV5 detection of the efficiently secreted 
3sE-SV5 when co-transfected with the membrane-bound homolog, and was also 
confirmed when analysing sE-DI/DII interactions. However, this strategy was restricted to 
DENV3 since cells transfected with the secretory sE constructs of the other serotypes and 
ZIKV were partially retained on the cell membrane and (m)DI/DII constructs were not 
expressed. 
To circumvent this, we developed an alternative approach based on the enzymatic 
biotinylation of proteins. By co-expression with the Escherichia coli derived biotin ligase 
BirA engineered to target the ER lumen, the system offers the possibility of specifically 
labelling proteins tagged with the BAP sequence426, a 15aa long peptide with a single 
lysine residue that serves as biotin acceptor. As previously demonstrated by others, this 
labelling process is highly efficient, specific and stable, and results in a mono-biotinylated 
product427, which means that signal detected following treatment with HRP-linked 
streptavidin are independent from the size or composition of the protein (as opposed to 
chemical biotinylation) and are directly proportional to the amount of biotinylated-protein 
detected. Similar to the membrane retention of 3sE-SV5, by combining co-transfection of 
SV5- and BAP-tagged constructs with anti-SV5 immunoprecipitation, this approach 
allowed us to detect protein interactions by co-immunoprecipitation of the biotinylated 
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partner. Relative quantification of the amount of co-immunoprecipitated protein showed 
that approximately 20% of the secretory sE-BAP protein from DENV3 and DENV4 were 
able to form stable dimers with their SV5-tagged counterparts, in agreement with reports 
indicating that sE in solution is mainly present as a monomer284. Interestingly, although it 
has been described that the majority of the intermolecular interactions involved in sE 
dimerisation take place on the inner face of DII, our results show that dimer stability is 
heavily dependent on DIII, as secreted sE-DI/DII hetero-dimers were less abundant than 
sE-sE homo-dimers, and those between DI/DII completely absent. This role of DIII in 
dimer stabilisation has been previously suggested77,447. 
Since the stability of sE dimers was limited, we introduced an Ala to Cys mutation in 
the inner surface of the E monomer to covalently stabilise the dimeric structure of sE 
proteins and study their biochemical properties. The side chain of the inserted cysteine 
points outwards from the alpha helix B (B) located on the inner surface of DII, directly 
facing itself on the opposing monomer once the antiparallel configuration of the dimer is in 
place, which resulted in dimers covalently stabilised by a disulphide bond. 
The data obtained with covalently stabilised dimers further confirm our initial 
observations regarding the temperature-dependent secretion and folding of 2DI/DII, and 
indicate that incubation at lower temperatures is important not only for the secretion of 
stable E dimers, but also for proper folding of E. This is not the first observation regarding 
the effect of temperature on the overall structure of dengue; recent data showed that 
dengue virions suffer structural reconfiguration at temperatures above 33ºC50,51. At this 
temperature, the viral envelope expands, increasing the exposure of E which would 
theoretically improve viral binding to host cells48,51. The data presented here represents, to 
our knowledge, the first report extending this temperature-dependent behaviour to the sE 
forms of DENV and ZIKV, especially to sE-cvD proteins, since their secretion was 
significantly improved with the 28ºC transfection protocol. This is in agreement with 
reports describing enhanced production and stability of DENV and ZIKV virions at 
relatively low temperatures448. 
Our data indicates that besides proper folding, secretion of recombinant E proteins 
from transfected cells depends also on their capacity to dimerise, and that relatively stable 
dimers are required for successful transit through the ER and the secretory pathway. For 
DENV3 and DENV4, secretion of sE proteins was observed for both wt and cvD forms 
regardless of the temperature conditions, suggesting higher stability of dimers and 
therefore compatibility with secretion; while for DENV1 and ZIKV, induction of proper 
folding at 28ºC was enough to achieve efficient secretion of the recombinant wt protein. In 
contrast, although our 4G2 analysis showed that proper folding of DENV2 sE is present at 
28ºC, efficient secretion was only possible in presence of the Ala-Cys mutation, strongly 
suggesting that wt dimers are relatively unstable within the intracellular secretory 
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compartment and are only allowed to traffic when covalently stabilised. In fact, recent 
structural data obtained during cryo-EM analysis of mAb 2D22 on the viral surface of 
DENV2, showed that this virus is significantly more dynamic when compared to the other 
DENV serotypes285, which might explain the low stability of the sE-wt dimer and why the 
disulphide bond was required to achieve secretion. 
Following the same approach as before, mAb-based structural analysis of membrane-
bound sE-cvD by cytofluorimetry, or biotinylated-dimers captured on avidin-coated plates 
by ELISA, confirmed that sE-cvD complexes presented proper folding of their monomeric-
structural domains, while displaying quaternary epitopes associated with E dimeric 
configuration on the viral surface. Moreover, the membrane display experiments allowed 
us to further describe the role of temperature in proper folding of E. Contrary to the 
analysis by western blot and ELISA, and as revealed by the positive reactivity of dimer-
specific mAbs, sE-wt anchoring to the cell membrane stabilised E dimeric conformations 
probably by keeping the monomers in close proximity after secretion, a close 
representation of the dynamics that could take place on the viral surface. Under these 
conditions (m)sE-wt constructs showed the same temperature-dependent secretory 
behaviour and structure as (m)sE-cvD constructs. These results demonstrate the 
structural equivalency between the dimers formed by sE-wt and sE-cvD proteins, and 
prove that the Ala-Cys mutation stabilises the naturally occurring interactions between E 
monomers. 
The level of scrutiny with which we were able to analyse the structural properties of 
sE-wt and sE-cvD constructs was achieved by incorporating the use of mAbs that target 
not only specific DENV serotypes, but more importantly, epitopes present at different 
levels of structural complexity: as previously mentioned, mAbs 4G2 (FL on DII440), 4E5A 
(DIII442) and 1F4 (DI and hinge region of DENV1, but only on the viral surface282) 
recognise epitopes restricted to a single structural domain of E; EDE1-C8, EDE1-C10, 
EDE2-B7284 and 2D22285, recognise epitopes restricted to E dimers while 5J7 docks to an 
epitope that requires higher order arrangements of DENV3 E dimers281. Our data on 
ELISA and cytofluorimetry assays proves that these epitopes are present in the analysed 
proteins. Noteworthy, 5J7 reactivity on (m)3sE-cvD constructs indicates that membrane-
bound proteins are able to replicate structural arrangements beyond the complexity of E 
dimers. When compared against (m)3sE-wt constructs (that were efficiently recognised by 
dimer-specific mAbs, but not by 5J7), data suggest that proper epitope conformation 
between un-bound proteins, is imposed upon binding of the antibody that holds the 
interacting proteins into position, stabilising the dimeric conformation in sE-wt protein in a 
similar way as the disulphide bond holds sE-cvD monomers together. This kind of 
antibody-mediated stabilisation was also described during structural mapping of EDE 
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antibodies where interaction with the Fab or single-chain Fv of the corresponding 
antibodies shifted the equilibrium of sE proteins towards the dimer conformation284.  
Since 5J7 epitope requires the simultaneous interaction of 3 independent E 
monomers in two adjacent E dimers of the raft conformation on the viral surface281, it is 
possible that the antibody is not able to achieve that level of stability with the (m)sE-wt 
proteins while the covalent stabilisation of cvD mutants facilitates the interaction as the 
antibody only requires to hold two independent units in position instead of three. A similar 
mechanism may be involved with the ability of dimer specific antibodies to recognise their 
respective epitopes in (m)wt proteins and explain the discrepancies observed between 
ELISA and cytofluorimetry profiles, since the fluidity of the cell membrane permits 
transient protein interactions due to horizontal mobility on the cell surface, while this would 
not be possible for the molecules immobilised on the ELISA plates. 
 In addition, regarding the activity of mAb 1F4, which recognises DENV1 E protein on 
the surface of the viral particle but not as a recombinant protein secreted from insect 
cells282, there are two possible scenarios: either a) mAb 1F4 indeed recognises an E 
conformation that is restricted to the viral surface, or b) the recognised epitope is 
dependent on the dimeric conformation of E, rather than one exclusively present on the 
virus, but was unresolvable due to the lack of E dimers outside of the viral particle context. 
Taking into consideration the reactivity profile of mAb 5J7, and the positive reactivity of 
1F4 to (m)1sE-wt and (m)1sE-cvD proteins, our data supports the latter; even though we 
were unable to do a definitive confirmation due to the inability to test DENV1 sE-cvD 
proteins in ELISA. Still, the possibility of achieving higher levels of resolution when 
analysing the structural complexity of epitopes, highlights the potential of our analytic 
platform.  
 
In infected cells, proper E folding and assembly could rely on the interactions with 
other viral proteins and host factors. For instance, the stem-anchor domains have been 
shown to negatively affect the production and secretion of sE proteins from transfected 
cells449 while they are obviously incorporated in virions. As shown in Fig 44 we confirmed 
the detrimental effect of the stem region on production and secretion of 3sE by using 
constructs encoding the sE alone, or fused to the first alpha helix (sE-H1), or the full stem 
region (sE-stem), at C-terminus.  
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Figure 44. Effect of the stem region on production and secretion of sE proteins from mammalian cells. 
WB analysis of cellular extracts (E) and culture supernatants (S) of HEK-293T cells transfected with constructs 
encoding DENV3 sE protein without the stem-anchor region (3sE), with the first 16 aminoacids of the stem 
(3sE-H1) and the full stem (3sE-stem). Anti-actin was used as loading control. 
 
In addition, the role of viral PrM in ensuring efficient viral release by preventing 
premature fusion of the nascent particles during their transit in the secretory pathway, has 
been addressed by previous studies77. Although it has been suggested that PrM could 
also have a chaperone-like function in assisting E proper folding, the experimental 
evidence regarding this property is less convincing, with some studies showing that 
properly folded sE secretion from transfected cells is dependent on PrM co-
expression79,450,451, while others have shown secretion of properly folded sE on its 
own102,452. More recently, reports evaluating ZIKV E protein candidates for genetic 
vaccination observed poor immunological response, in both cases this was explained by 
claiming poor protein stability because of the lack of PrM co-expression, even though 
experimental data supporting these assumptions was not shown453,454. In contrast, a 
recent DNA vaccine candidate against ZIKV, showed immune stimulation using a plasmid 
encoding only the MsE region of the viral polyprotein, suggesting that the inclusion of Pr 
was not necessary455. Our results clearly show that, surprisingly, temperature, but not PrM 
co-expression, is essential for E dimerisation, folding and efficient secretion from 
mammalian cells. This is particularly relevant when considering E-based subunit and 
genetic vaccines against DENV or ZIKV including PrM on the basis of ensuring proper 
antigen production, since it has been demonstrated that anti-Pr antibodies have almost 
non-existent neutralising capacity and mostly favour viral infection through ADE291. Given 
that we showed successful expression of complex quaternary epitopes regardless of PrM 
co-expression, these results provide further evidence supporting PrM exclusion from 
vaccine formulations. 
As shown by the experiments with pseudoviruses, the Zika virus E-cvD construct (ZE-
cvD) was able to package the WNV-rep into secreted particles, which showed all the E 
protein present as covalently-bonded dimers. Supporting the effect of temperature on E 
folding and dimerisation, and in line with the behaviour of sE-cvD protein, packaging of 
particles with ZE-cvD was significantly higher at 28ºC. Overall, the results confirm that the 
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covalent dimers not only have the proper antiparallel conformation, but are also 
compatible with the complex arrangements required to assemble the viral particle. The 
assembly and secretion of these pseudoviral particles indicate that E dimerisation occurs 
shortly after translation, and that transport and secretion of full particles as the covalently 
stabilised dimers is permissive. In addition, it also indicates that the “spiky” immature 
intermediates observed in the ER lumen are not strictly required for particles to traffic 
through the secretory pathway. Yet, they may reflect the highly dynamic structures of E 
needed to fulfil the viral life cycle456.  
As expected, these particles were not infectious as E trimerisation, and thus the 
fusion-mediated scape of the viral RNA from the early endosome, was inhibited by the 
disulphide bond. This supports the idea that viral neutralisation can be obtained by 
interfering with the dynamics of viral E, a mechanism that has been proposed to explain 
the strong neutralising capacity of antibodies targeting complex quaternary 
epitopes285,288,457. In this mechanism, docking of the antibody to its epitope locks E 
structure into a fixed configuration thus preventing the trimerisation process457. A similar 
mechanism has also been proposed for antibodies targeting the hinge region310, 
highlighting the importance of E conformational changes.  
 
The description of hetero-dimers between sE proteins from different viruses was 
surprising. The alternative use of SV5- and BAP-tagged proteins in the context of WB 
experiments, allowed us to clearly detect the presence of hetero-typical complexes, a 
finding that was confirmed using an adapted version of the membrane display assay 
described previously. Interestingly, the results were successfully replicated with the 
(m)sE-wt constructs, which indicate that these interactions occur naturally. The same 
conclusions were drawn from the production of mosaic pseudoviruses co-expressing E 
proteins from ZIKV and DENV2.  
The mosaic nature was demonstrated by ADE experiments on K562 cells with anti-
DENV2 specific antibodies. Although at present we lack the means to describe the 
structural characteristics of these mosaic particles, our data indicates that they can exist 
as infective particles. It is difficult, however, to speculate on the true impact (if any) of 
these hypothetical particles during the infection process, since single-cell flaviviral co-
infection has not been reported. 
Collectively, these data are in line with observations that the residues involved in E 
dimerisation are conserved across the flaviviruses, explaining not only the cross-
neutralising nature of antibodies against quaternary epitopes284,288,457, but also allowing for 
heterotypic interactions without disrupting viral infectivity, as shown here. In fact, a recent 
study compared the sE sequences from different flaviviruses and showed that the level of 
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aminoacid identity of the B helix is only matched by that of the FL (Fig. 45), highlighting 
the importance of this region for the dimer structure of E and the viral fitness458.  
           
Figure 45. Conservation of B helix among DENV serotypes and ZIKV. a) Conservation profile of the 
nucleotide (red line) and aminoacid (black line) sequences of 480 coding sequences; a conservation value of 
1 represents the highest conservation possible. A schematic representation of the primary structure of E 
shows the relative position of the corresponding residues (and bases) on the protein, the FL and B helix 
location are indicated. b) WebLogo schematic showing the aminoacid composition of the E250-270 region 
(which includes the B helix) for each DENV serotypes and ZIKV, the highly conserved alanine involved in the 
cvD mutations is indicated (red arrow). Polar (green), neutral (purple), basic (blue), hydrophobic (black) and 
acidic (red) aminoacids are shown. (Adapted from reference 458) 
 
Limited understanding of viral pathogenesis has been an important hurdle in 
developing treatments against viruses like DENV and ZIKV. Although it has been shown 
that the antibody response is one of the most important mechanisms to neutralise the 
virus, the specificity required for efficient protection is still unknown310. Due to their strong 
neutralising potential and low ADE risk, antibodies against DIII and complex quaternary 
epitopes have been singled out by studies of monoclonal antibodies isolated from animal 
model or immune patients for future vaccine formulations444. Together, the ELISA and 
cytofluorimetry based-assays described in this section, constitute a new virus-free 
platform to study anti-E antibodies and differentiate their binding properties. Indeed, the 
use of different E-derived constructs allowed us to discern between mAbs able to bind 
single E domains, the monomeric sE, sE dimers or even higher order arrangement of 
dimers without the concerns related to the use of whole viral preparations, and can be 
implemented to screen for antibodies that target neutralising epitopes. 
Given that most of the strongly neutralising antibodies target conformational E 
epitopes64, reproducing the native conformation of this viral protein is pivotal for the 
development of an efficient vaccine against DENV and ZIKV102. Several DNA and protein 
subunit vaccines have been developed based on truncated versions of E obtained after 
removing the anchor regions of the viral protein375,376,407,459. Strikingly however, only a few 
of the studies involving DNA vaccination reported the efficiency of production and 
FL αB helix 
DENV sE 
DENV1 
DENV2 
DENV3 
DENV4 
ZIKV 
a b 
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secretion of the antigen from transfected cells, and experimental data supporting proper 
folding of the antigen was also rarely published. In the context of DNA vaccines, a 
previous study compared the secretion of different full-length and truncated version of 
DENV1 E constructs460. The results revealed that all sE constructs were poorly secreted 
from transfected cells even when co-expressed with PrM and induced only modest 
neutralising responses in vaccinated animals. A DNA vaccine candidate encoding 2sE 
was shown to be poorly secreted from BHK-21 cells and induced low neutralising titres in 
vaccinated mice408, closely resembling the anti-2sE response reported here. While these 
results are in agreement with our observations on the secretory phenotypes of DENV sE 
proteins, an AAV-based genetic vaccine candidate recently reported a secretion analysis 
for sE proteins from all four DENV serotypes indicating that only 1sE was efficiently 
secreted422. Collectively, these data suggests that sE secretion from transfected cells 
might also be influenced by other yet undefined factors, but highlight the importance of 
performing this sort of profiling to evaluate secretory properties of antigen design for 
genetic vaccines. 
After the first clinical trial involving a DNA vaccine against HIV401, several other DNA 
vaccine candidates have been developed against a range of infectious agents402-406. Even 
though a series of studies have attempted to apply the DNA vaccination approach to 
dengue390,407,408,422,461-467, only one of these candidates was able to progress to a Phase 1 
clinical study using a plasmid coding for PrME of DENV1410. As mentioned previously, this 
candidate was reformulated and a new tetravalent vaccine based on this format is now 
being evaluated in Phase 1 studies342. Although, low immunogenicity has prevented 
further advances in the field, the different human tests that have been conducted, 
confirmed the safety of DNA vaccines413,414. In our case, the careful combination of 
constructs designed to express the same antigenic but with different secretory 
phenotypes, demonstrate that antigen secretion is indeed a critical aspect to consider 
when designing an efficient candidate for genetic vaccination. Even though 
immunogenicity is also a critical aspect to consider, failure to examine and improve the 
secretory efficiency of encoded antigens may explain the poor performance of the DNA 
vaccines tested so far against DENV460,466,468,469. Our chimera approach also shows that 
chimeric constructs could be used to improve the immune response towards specific 
epitopes that are poorly secreted on their source protein, as the response against 2DIII 
was significantly improved by modifying the sE in which it was expressed. These 
modifications not only improved the antibody titres and the neutralising response after 
vaccination, but also the avidity of the elicited antibodies.  
As a corollary, the results presented in this section provide a careful and detailed 
dissection of the factors regulating sE proteins expression and secretion from mammalian 
cells, and demonstrate that proper design and evaluation of encoded antigens for DNA 
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vaccines is crucial to develop strong neutralising responses against DENV, the main focus 
of the next section of this thesis. 
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PART II 
 
DEVELOPMENT AND PRELIMINARY 
EVALUATION OF A DIII-BASED DNA VACCINE 
AGAINST DENGUE VIRUS 
______________________________________________________________________________________________ 
 
2.1. SYNOPSIS 
Developing an effective vaccine against dengue has been one of the highest priorities 
for researchers in the field. Recent data questioning the effectiveness of the only licensed 
vaccine available, Sanofi-Pasteur’s Dengvaxia®, has revamped the interest for new 
alternative candidates using next generation approaches like genetic vaccination and 
properly designed subunit vaccines. However, recent description of immunological cross-
reactivity between flaviviruses, especially DENV and ZIKV, has added new hurdles to the 
already complex task of developing a balanced and effective tetravalent formulation to 
avoid ADE. With the objective of developing an efficient DNA vaccine against DENV, we 
designed four DIII-based constructs and evaluated their immunogenicity by gene gun 
vaccination in mice. Likewise, the results of different tetravalent formulation are also 
described.  
In addition we also evaluated the immunological properties of other E-based genetic 
constructs, mainly DI/DII and sE, to assess their potential as immunogens in DNA 
vaccines. 
Our results indicate that properly engineered DIII-based constructs are able to drive 
strong neutralising antibody responses that remain stable for at least a year after 
vaccination. Moreover, contrary to DI/DII or sE constructs, the antibodies elicited against 
DIII were highly specific towards DENV and did not promote ADE of other related 
flaviviruses like ZIKV, WNV and YF, supporting further development of this candidate.  
It should be noted that the experiments and results presented in this section were 
done in close collaboration with Dr. Monica Poggianella (Molecular Immunology Group, 
ICGEB). Other relevant collaborations are duly acknowledged.  
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2.2. RESULTS 
As in the previous section, some of the data presented in this section were published 
as a research article in PLOS Neglected Tropical Diseases470. Most of the remaining data 
has been submitted for publication in two additional research articles.  
 
2.2.1. Design and evaluation of a tetravalent DIII-based DNA vaccine. 
2.2.1.1. Production and secretion of engineered DIII antigens. 
As demonstrated before, DNA vaccines rely heavily on efficient antigen production 
and secretion from transfected cells for inducing proper B cell activation and strong 
antibody responses. Similar studies have also concluded that broad antigen expression is 
required for optimal induction of acquired immunity in the framework of DNA vaccines443. 
Fragments encoding the DIII domain of all four DENV serotypes (carrying the 
nucleotide sequence obtained from viral cDNAs and shown as translated products in Fig. 
46a) were cloned into pcDNA3.1(+) vectors with or without the dimerising CH3 domain 
from the human IgG H-chain (CH3) fused at the C-terminus (DIII and DIII-CH3 
(henceforth referred as DIII-), respectively). In addition, a secretion leader peptide (sec) 
at the N-terminus to ensure translocation into the ER, and the SV5 tag to facilitate 
detection of the protein were also included (Fig. 46b). The secretory profiles of the 
encoded proteins in transfected HEK-293T cells are shown in Fig. 46c. In agreement with 
our previous results, DIII constructs were poorly secreted from transfected cells. However, 
the addition of the CH3 domain significantly enhanced active production and secretion of 
all DIII- constructs. Knowing that efficient antibody response to a DNA vaccine is a 
corollary of properly secreted antigens, we decided to incorporate the DIII- format as the 
core antigen for our DNA vaccine. 
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Figure 46. Enhancement of DIII expression and secretion by CH3 domain. a) Amino acid sequences of 
the DIII domains from each DENV serotype. Amino acids conserved across the four serotypes are highlighted. 
b) Schematic representation of the plasmids encoding the DIII alone or C-terminally fused to CH3 domain. c) 
WB of cell extracts (E) and culture supernatants (S) of HEK-293T cells transfected with the DIII and DIII-
constructs from all DENV serotypes; anti-tubulin was used as loading control. (Adapted from reference 470). 
 
Another important observation made from the aforementioned experiment was that 
DIII- proteins were not equally obtained in supernatants; notably, the efficiency of 
secretion for 1DIII- was clearly higher, while the amount of 4DIII- recovered after 
transfection was very low (Fig. 47a). With the idea of increasing production in transfected 
cells, the nucleotide sequences of DENV2, DENV3 and DENV4 DIII- plasmids were 
codon-optimised for mammalian cells. As shown in Fig. 47b, optimised DIII- showed 
enhanced secretion compared to constructs carrying the viral sequence and the amount 
of protein recovered from transfected cells was comparable for all serotypes. 
 
 
Figure 47. Codon-optimisation increases DIII-secretion from transfected cells. a) WB of supernatants 
(S) of HEK-293T cells transfected with equal amounts of the four non-optimised DIII- plasmids. d) WB of 
supernatants from cells transfected with DIII- constructs with the viral-encoded (V) or the codon-optimised 
(CO) nucleotide sequences. (Adapted from reference 470). 
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2.2.1.2. DIII- constructs induce strong and highly specific antibody responses in 
mice. 
Experimental groups comprising 10 female Balb/c mice, were DNA-immunised by 
intradermal biolistic delivery of three 1g doses of plasmids encoding a specific DIII- 
given at 15 days intervals (Days -30, -15 and 0). Mouse sera were collected at days 15 
and 30 and analysed for anti-DIII antibodies in conformational ELISA using normalised 
amounts of in vivo mono-biotinylated DIII (for all DENV serotypes) and sE (for efficiently 
secreted 3sE and 4sE) proteins (produced with the BAP-/BirA system) captured on avidin-
coated plates. To avoid interference of antibodies elicited against the CH3 domain, the 
DIII antigens used for ELISA were fused to the human IgE H-chain (εCH4), thus enabling 
efficient DIII secretion without CH3 cross-reactivity. In both DIII and sE antigens for 
ELISA, the SV5 tag was removed as well.  
High titres of homologous anti-DIII antibodies were obtained for all four DENV 
serotypes (Fig. 48a-d, left panels), and the immune responses elicited with all DIII- 
constructs were comparable among the mice treated within each group (Fig. 48a-d, right 
panels). In addition, there was no significant difference from sera obtained 15 or 30 days 
post-vaccination. As shown in Fig. 48e, antibody titres ranged from 19,500, for 1DIII, to 
41,300, for 2DIII; which correspond to approximated DIII-specific IgG concentrations of 16 
g/ml and 35 g/ml, respectively (Table 1). Moreover, the anti-DIII antibodies were able to 
recognise the DIII antigen expressed in the context of the full sE protein, as indicated by 
the anti-3DIII and anti-4DIII reactivity to both DIII and sE antigens.  
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Figure 48. Anti-DIII responses measured in conformational ELISA. a-d) ELISA reactivity performed on the 
homologous DIII antigens for (a) anti-1DIII (n=14), (b) anti-2DIII (n=14), (c) anti-3DIII (n=16) and (d) anti-4DIII 
(n=15) pooled sera from vaccinated animals (left panels) and reactivity of each individual sera compared to 
the corresponding pool (OD450 at a 1:2700 dilution, n=4 for each mice, pooled sera and ctrl.) (Right panels). 
Ctrl: pre-immune sera. For anti-3DIII and anti-4DIII pooled sera, reactivity against 3sE (n=10) and 4sE (n=6) 
proteins, respectively, was also included. e) Antibody titres of each pooled sera against its homologous DIII 
antigen; titres determined on the corresponding sE proteins were also included for anti-3DIII and anti-4DIII 
sera. In all cases, data is represented as mean±s.d. (Adapted from reference 470). 
 
Table 1. Estimated homologous anti-DIII concentration in sera from vaccinated mice. Anti-DIII ELISA 
titres expressed as antibody concentrations, obtained from dilution curves compared to mAb 4G2. 
 
Immunogen Coating [Antibody] (g/ml) 
1DIII- 1DIII 16±3
 
2DIII- 2DIII 35±9 
3DIII- 3DIII 21±3 
4DIII- 4DIII 20±1 
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To evaluate if the anti-DIII antibodies were able to recognise not only the recombinant 
protein used in ELISA, but also the E protein expressed in virus-infected cells, we 
performed immunofluorescence assays on Vero cells infected with the different DENV 
serotypes. As seen in Fig 49a, all anti-DIII sera were able to recognise the homologous E 
protein in infected cells. This reactivity was further confirmed by ELISA on infective viral 
particles (Fig. 49b-c). Together, these results suggest that the structure of the DIII, as 
displayed in the DIII- antigen, successfully replicates the structure of the domain in the 
virus. 
 
 
 
Figure 49. Anti-DIII sera recognise viral E protein. a) Immunofluorescence of Vero cells infected with each 
DENV serotype, reacted with the serotype-specific anti-DIII pools of sera (top row), pre-immune sera (P.I., 
middle row) and mAb 4G2 (bottom row), were used as negative and positive controls, respectively. Non-
infected cells (n.i., rightmost column) were also used as controls. Bars represent 50 m. b) Schematic 
representation of the ELISA on infective viral particles. c) Homologous anti-DIII pooled sera (diluted to ≈100 
ng/ml) and pre-immune sera were used for ELISA on whole infective viral particles captured with a human 
serum reactive against all four serotypes. mAb Dengue 1-11 (reactive against DENV1 E, at 1 g/ml) and a 
Dengue pan-reactive serum against all four serotypes were used as positive controls. In all cases, data is 
represented as mean±s.d. (n=4). (Adapted from reference 470). 
 
We then tested the anti-DIII sera against equal amounts of native and denatured DIII 
antigens in ELISA. As seen in Fig. 50a-b, the four anti-DIII sera lost most of their reactivity 
when reacted against the denatured protein, indicating that antibodies induced with the 
DIII- antigens recognised conformational epitopes. In addition, avidity studies performed 
115 
 
with the immune sera, which measure the relative strength of antibody binding under 
stringent dissociating conditions, confirmed that high affinity antibodies were present in a 
significant concentration (Fig, 50c). The avidity index of mAb 4G2 against 3sE and 4sE 
was included as a control. 
 
 
 
Figure 50. DIII- induced antibodies recognise conformational epitopes with high avidity. a) Reactivity 
of the four anti-DIII sera on equal amounts of native or denatured biotinylated homologous DIII-εCH4 proteins 
(in all cases, n=3). Data is represented as mean±s.d. b) Antibody titres from the curves shown in (a). Data is 
represented as mean±s.d. c) Box and whiskers plot of the avidity index for each anti-DIII sera on the native 
homologous DIII-εCH4 antigen (n=14 for each sera; for the comparison between anti-3DIII and anti-4DIII, 
t=12,08 df=26). Avidity index of mAb 4G2 on 3sE (n=6) and 4sE (n=8) is shown as a control. + indicates the 
mean value for each group. (Adapted from reference 470). 
 
We then sought to determine the extent of cross-reactivity induced by the DIII- 
vaccines. For this we measured the reactivity of the different anti-DIII sera against 3sE, 
4sE and the four DIII antigens (Fig 51a). Although, as expected, each pooled sera showed 
highest reactivity against the homologous serotype in a conformational ELISA, the level of 
heterotypic recognition differed among them. As shown by the antibody titres presented in 
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Fig. 51b, anti-DIII antibodies against DENV1, DENV2 and DENV4 were highly specific, 
with only limited cross-reactivity to other serotypes. Anti-3DIII antibodies, in contrast, were 
cross-reactive to 4DIII, 2DIII and 1DIII. The data in Table 2 summarises the cross-
reactivity results by showing the titres obtained against heterotypic serotypes as relative 
values of the homologous response, i.e. expressing the cross-reactive response as a 
percentage of the antibody titre obtained against the homologous serotype. 
 
 
 
Figure 51. Cross-reactivity profiles of anti-DIII antibodies. a) ELISA reactivity of the four different anti-DIII 
pooled sera on the four DIII-εCH4 (left panels) and on the two secreted sE (3sE and 4sE), (right panels) (In all 
cases, n=4). b) Cross-reactive titres from the curves shown in (a). * indicates titre below control (absence of 
cross-reacting antibodies). Data is represented as mean±s.d. (Adapted from reference 470). 
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Table 2. Relative cross-reactivity of serotype-specific anti-DIII sera. Reactivity of each anti-DIII pooled 
sera against each all four DIII-εCH4 antigen, expressed as a percentage of the reactivity against the 
homologous antigen (100%). 
 
Coating 
Serum 
anti-1DIII anti-2DIII anti-3DIII anti-4DIII 
1DIII 100 14 43 17 
2DIII 8 100 40 6 
3DIII 3 ND 100 ND 
4DIII 27 33 94 100 
ND: cross-reactivity was not detected 
 
2.2.1.3. Antibodies induced by DIII- vaccines show neutralising activity. 
After determining the level of DIII-specific antibodies induced by DIII- vaccines, we 
tested the neutralising capacity of each serum against the corresponding DENV serotype 
by means of a plaque reduction neutralisation test (PRNT50) in Vero cells. Fig. 52a shows 
the PRNT50 curve of each pooled sera against its homologous serotype (Fig. 52a, left 
panels). The neutralisation titres obtained were representative of the variation found when 
evaluating individual mice within each group. Although with some differences (particularly 
in the group immunised with 3DIII-), the DIII- vaccines induced similar neutralising 
responses in most vaccinated animals (Fig. 52a, right panels). When comparing the 
results from each group, we found high neutralising titres against DENV1 (≈300), DENV2 
(≈1600) and DENV3 (≈300), while the neutralising response against DENV4 was 
somewhat weaker (≈65) (Fig. 52b). 
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Figure 52. Neutralising capacity of anti-DIII sera. a) Plaque reduction curves (left panels) using anti-1DIII 
(n=5), anti-2DIII (n=18), anti-3DIII (n=9) and anti-4DIII (n=4) pooled sera, relative to the activity of pre-immune 
control sera. PRNT50 titres obtained for each vaccinated animal (in all cases, n=3) are also shown (right 
panels) (* indicates PRNT50 titre is higher than 800). b) PRNT50 titres from curves shown in (a), comparisons 
between anti-1DIII and anti-2DIII (t=12,25 df=21), anti-2DIII and anti-3DIII (t=16,71 df=25), anti-1DIII and anti-
3DIII (t=0,4383 df=12) and between anti-3DIII and anti-4DIII (t=4,950 df=11), are shown. In all cases, data is 
represented as mean±s.d. (Adapted from reference 470). 
 
Since the neutralisation titres against DENV4 were the weakest, we assessed the 
possibility that factors associated with the DIII sequence used for the 4DIII- immunogen 
could have led to significant differences in the antibody response. For this, we designed a 
4DIII- variant encoding a different DENV4 DIII sequence (DENV4 strain TC25 from 
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genotype I, as opposed to the Dominica strain from genotype II) with three aminoacid 
changes: F357L, Y360N and D384N. As shown in Fig. 53, the neutralising antibody 
responses induced by both constructs did not show significant differences, which 
suggests that strain and genotype factors are not linked, at least in this case, to the 
relatively reduced neutralisation induced by the 4DIII- vaccine. 
 
 
Figure 53. Effect of DENV4 strain and genotype on viral neutralisation. a) Plaque reduction curves on 
DENV4 TC25 strain using pools of sera from animals vaccinated with 4DIII- constructs derived from DENV4 
Dominica strain (open symbols) or TC25 strain (filled symbols). b) PRNT50 titres from curves shown in (a) 
(n=4; t=0,09914 df=6). In all cases, data is represented as mean±s.d. (Adapted from reference 470). 
 
 
2.2.1.4. Cross-neutralisation and ADE activities of DIII- antigens. 
Given that anti-DIII sera, besides anti-3DIII, showed limited cross-reactivity to DIII and 
sE proteins from other serotypes, we decided to also evaluate their ability to neutralise 
heterotypic DENV viruses. For this, all pooled sera were tested against each DENV 
serotype using the PRNT50 in infected Vero cells. Besides confirming the previous 
neutralisation titres, the data shown in Table 3 revealed that, similarly to the cross-
reactivity behaviour determined by ELISA, antibodies induced with the 1DIII-, 2DIII- and 
4DIII- were not able to significantly neutralise any DENV serotype besides the 
homologous serotype that the antibody was raised against. In contrast, anti-3DIII 
antibodies showed limited cross-neutralising activity against DENV2 and DENV4 but not 
against DENV1. 
In collaboration with Prof. Eng Eong Ooi, from the Emerging Infectious Diseases 
Programme at the Duke-NUS Medical School in Singapore, we performed an ADE assay 
with the anti-DIII sera to analyse their ability to enhance heterologous DENV infections 
and further describe the activities of the DIII- vaccines. The experiment was performed in 
the THP-1 human monocytic cell line expressing both FcRI and FcRII296. The results 
presented in Fig. 54 indicate that, for each anti-DIII serum, significant enhancement of 
DENV infectivity was observed only against the homologous serotype, as expected, with 
only limited effect on the heterologous serotypes; which suggest a high functional 
specificity of the antibodies induced with the DIII- vaccines. 
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Table 3. Anti-DIII cross-neutralising activity. PRNT50 titres of each serotype-specific anti-DIII pooled sera 
on all four DENV serotypes. 
 
Serum 
Viral serotype 
DENV1 DENV2 DENV3 DENV4 
anti-1DIII ≈300 <25 <25 <25 
anti-2DIII <10 ≈1600 <10 <10 
anti-3DIII <25 ≈135 ≈300 ≈30 
anti-4DIII <10 <10 <10 ≈65 
 
 
 
Figure 54. Comparison of ADE responses of anti-DIII sera in THP-1 monocytes. (a-d) Each anti-DIII 
pooled sera and a pre-immune control serum were two-fold diluted and incubated with (a) DENV1, (b) 
DENV2, (c) DENV3 and (d) DENV4 before infecting THP-1 cells for 72h. The culture supernatant was 
quantified for DENV using plaque assay afterwards. Dashed line indicates DENV baseline infection of THP-1 
cells in absence of serum. Data is represented as mean±s.d (In all cases, n=3). (Adapted from reference 470). 
 
 
2.2.1.5. Immune responses against DIII depend on DIII- secretion. 
To support our findings regarding the effect of efficient antigen secretion on the 
immune response induced by DNA vaccines, we vaccinated mice with the non-optimised 
(and, as a consequence, poorly secreted (Fig. 47b)) DIII- constructs of DENV2, DENV3 
and DENV4 (DIIINOp-). As shown in Fig. 55, even though the encoded antigens were the 
same at the aminoacid level, the antibody titres obtained with the codon-optimised 
plasmids were considerably higher in all cases. This indicates that the efficiency showed 
by the DIII- DNA vaccines was mostly due to enhanced level of DIII secretion, and further 
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highlights the importance of proper antigen design before undergoing immunisation 
experiments, in the context of DNA vaccines. 
 
 
 
Figure 55. Increased DIII- secretion after codon-optimisation improves the immune responses elicited 
by DNA vaccination. (a-c) ELISA reactivity on the homologous DIII antigens of sera from animals gene-gun 
immunised with DIII- constructs from DENV2 (a), DENV3 (b) and DENV4 (c), with viral (DIII
NOp
-) or codon-
optimised (DIII-) nucleotidic sequences. In all cases, n=6. d) Plot of the titres from the curves shown in (a) 
(t=26,68 df=10), (b) (t=12,06 df=10) and (c) (t=5,585 df=10). Data is represented as mean±s.d. (Adapted from 
reference 470). 
 
We then set out to determine how the design of the DIII- vaccine influenced the 
immune response elicited after DNA immunisation. For this, we compared the anti-3DIII 
responses induced by different constructs. As a reference, we used the preferred 3DIII- 
construct and included the non-optimised 3DIII- and 3DIII (3DIIINOp- and 3DIIINOp, 
respectively), and the 3sE construct, which encodes 3DIII along with 3DI/DII.  
As seen in Fig. 56a, although all the constructs were secreted from transfected HEK-
293T cells, the 3DIII- protein showed the most efficient secretory phenotype, while the 
3DIIINOp antigen was scarcely detected. Groups of 5 Balb/c mice were vaccinated following 
the same protocol as before, and pooled sera from each group were then evaluated in 
ELISA to determine anti-DIII, anti-sE and anti-DI/DII antibodies titres (to discriminate 
between the different specificities and allow representative comparisons, these analyses 
were done in plates coated with normalized amounts of biotinylated 3DIII, 3sE and 
3DI/DII, respectively). As showed in Fig. 56b-c, the anti-DIII (Fig. 56b, top panel) and anti-
3sE (Fig. 56b, middle panel) responses were significantly higher for the group vaccinated 
with 3DIII-, while the immune responses after vaccination with 3DIIINOp, which is also the 
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least secreted protein, were the lowest. Anti-DI/DII antibodies were detected only in the 
3sE-vaccinated animals, emphasising the specificity of anti-3DIII antibodies (Fig. 56b, 
bottom panel). Fig. 56d provides further details on the immune response using 3sE, which 
was mainly directed against DI/DII rather than DIII, confirming the immunodominance of 
DI/DII epitopes271. Notably, antibodies elicited with the 3DIII- vaccine showed more 
neutralising capacity than those induced with the other constructs (Fig. 56e). This is 
particularly important for sE-based vaccines, since this test also measured the 
contribution of the anti-3DI/DII response, confirming the potential of DIII as a target for 
strong neutralising responses. Surprisingly, the anti-3DIII antibodies induced with different 
constructs differed also in their relative avidities. Sera obtained using constructs with the 
CH3 domain showed significantly higher avidity indexes than those without, suggesting 
that CH3 plays a role also in enhancing the quality of the induced antibodies (Fig. 56f). 
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Figure 56. Effect of DIII- antigen design on anti-DIII antibody responses compared to 3sE. a) WB of 
total cellular extracts (E) and supernatants (S) of HEK-293Tcells transfected with plasmid constructs encoding 
3DIII
NOp
 (16 kDa), 3DIII
NOp
- (28 kDa), 3DIII- (28 kDa) and 3sE (54 kDa), anti-tubulin was used as 
loading control. b) ELISA reactivity of anti-3DIII (from mice immunised with 3DIII
NOp
, 3DIII
NOp
- and 3DIII-) or 
anti-3sE  on plates coated 3DIII-εCH4 (3DIII), 3sE and 3DI/DII (immunising antigens indicated in parenthesis, 
n=4 in all cases). c) Antibody titres determined on each of the different coating proteins, from the curves 
shown in (b) (* indicates no reactivity at 1:300 dilution). Comparisons between anti-3DIII (3DIII-) and anti-3sE 
titres on 3DIII (t=15,51 df=6) and 3sE (t=103,0 df=6) antigens are shown. c) Anti-3sE sera reactivity on 3DIII, 
3sE and 3DI/DII proteins as showed in (b). Insert: anti-3sE titres for each coating protein. Differences of 
reactivity towards 3DIII and 3DI/DII (t=28,75 df=6), and against 3DI/DII and 3sE (t=1,817 df=6), are 
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highlighted. e) PRNT50 titres of anti-3sE (n=4) and the different anti-DIII sera (from mice immunised with 
3DIII
NOp
 (n=4), 3DIII
NOp
-n=4) and 3DIII-(n=9)) on DENV3. Responses from mice immunised with 3DIII-
were compared against anti-3DIII(3DIII
NOp
-) (t=3,677 df=11) and anti-3sE (t=3,704 df=11) sera. f) 
Avidity index of antibodies derived from animals gene-gun immunised with 3DIII
NOp
, 3DIII
NOp
-, 3DIII- or 3sE 
(immunising antigens indicated in parenthesis) tested on 3sE-coated plates. In all cases n=4; comparisons 
between 3DIII
NOp
- and 3DIII-constructs (t=2.057 df=6), 3DIII
NOp
 and 3sE (t=2.231 df=6), and between 3DIII-
and 3sE (t=19.76 df=6) are shown. Data is represented as mean±s.d. (Adapted from reference 470). 
 
 
2.2.1.6. A tetravalent formulation of the DIII- DNA vaccine. 
Since viable vaccine candidates against DENV are required to demonstrate efficient 
and balanced response against all four serotypes due to the risk of ADE, we next 
combined the four DIII- constructs into a tetravalent formulation that was then tested in 
mice using the same vaccination protocol. In this case, even though each dose of DNA 
was doubled (two 1g shots containing an equivalent mix of 1DIII- and 2DIII-, and mix of 
3DIII- and 4DIII-, respectively), the relative amount of serotype-specific DNA was halved 
(0,5g) when compared to the monovalent responses (1g). The pooled sera from 
vaccinated animals was then tested by ELISA and PRNT50, and compared against their 
monovalent counterparts. As seen in Fig. 55, the tetravalent vaccine induced DIII-specific 
antibodies against all serotypes (Fig. 57a, left panels), albeit in significantly lower titres 
than those measured for the monovalent formulations. This was true for all serotypes 
except DENV1 where anti-DIII titres were not significantly different between both 
formulations (Fig. 57b). Although the PRNT50 titres of the tetravalent vaccine were also 
reduced, the differences between the monovalent and tetravalent PRNT50 titres, with the 
exception of DENV2, were much smaller than the ones found for the antibody titres (Fig. 
57a, right panels). In addition, the avidity indexes of the antibodies induced with both 
formulations were comparable (Fig. 57c). 
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Figure 57. Tetravalent DIII- formulation. a) ELISA (left panels, n=4 in all cases) and plaque reduction 
curves (right panels, n=4 in all cases) of tetravalent (open symbols) and monovalent (filled symbols) pooled 
sera from gene-gun immunised mice. In right panels, curves correspond to the tetravalent vaccine and the 
PRNT50 titres from the monovalent immunisations (determined in Fig. 52) are shown for comparison. Data is 
represented as mean±s.d. b) ELISA titres (expressed as anti-DIII antibody concentrations) from tetravalent 
immunisations, determined on all four DIII proteins and compared against the respective monovalent sera. 
Data is represented as mean±s.d. c) Avidity index of sera from monovalent (n=13, for all four specific sera) 
and tetravalent immunisations (n=10 in all cases), determined on the different DIII serotype antigens. Data is 
represented in a box and whiskers plot. (Adapted from reference 470). 
 
2.2.2. Optimisation of the DIII- DNA vaccine. 
2.2.2.1. Expression of DIII- in pVAX1 vectors enhances antigen availability. 
With the aim of further developing our DIII- DNA vaccine we decided to switch DNA 
platforms by cloning the DIII- constructs into pVAX1 vectors instead of the pcDNA3.1 
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backbone. Although pcDNA3.1 vector is commonly used it was not designed for clinical 
research purposes, which would prevent future evaluation of the DIII- candidate in an 
eventual Phase I study. In contrast, pVAX1 vector has a modified backbone to comply 
with the Food and Drug Administration (FDA) requirements for plasmid DNA vaccines 
against infectious diseases471. Upon analysis of the secretory profile from transfected 
mammalian cells, production and secretion of the pVAX1-encoded constructs from 
transfected mammalian cells increased, when compared to profiles obtained with the 
pcDNA3.1 vector (Fig 58). This effect was stronger for 4DIII-. 
 
 
 
Figure 58. Cloning into pVAX1 expression vector enhances DIII- production and secretion form 
transfected cells. WB of comparable cell extracts (E) and culture supernatants (S) samples from HEK-293T 
cells transfected with equal amounts of the four DIII- constructs cloned into pcDNA3.1 or pVAX1 expression 
vectors. Anti-actin is included as loading control. 
 
Given the importance of antigen secretion in DNA vaccination, and the design 
benefits of the pVAX1 vector, we decided to implement this format as the antigenic 
platform to be used for the DIII- DNA vaccinee. 
 
2.2.2.2. Evaluation of alternative vaccination protocols and DNA delivery systems. 
Next we evaluated alternative DNA delivery strategies and vaccination protocols in an 
attempt to optimise the protection induced by the DIII- vaccine. For this, we measured 
antibody titres, avidity and neutralising capacity of sera obtained from nine groups of 6 
Balb/c mice immunised with the 3DIII- construct in different ways and for different periods 
of time. The strategies, protocols and timetables used for the immunisation of each group 
are shown in Fig. 59.  
 
                                                          
e
 From this point forward, all the experiments involving DNA gene-gun mediated immunisations were done with constructs 
encoded in pVAX vectors. 
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Figure 59. Schematic representation of the different vaccination strategies and protocols. 
 
Two different serotypes of Adeno-Associated virus (AAV6 and AAV9) were introduced 
as an alternative DNA delivery system using single doses of 3x1010 viruses in both cases. 
In addition, AAV6 and AAV9 vectors were also implemented in combination with gene-gun 
(GG) delivery using prime/boost strategies where the DNA GG priming was done either 
previously or contemporarily to the AAV boosting (GG+AAV). Due to AAV9 preferential 
tropism for muscle cells415, delivery was done intra-muscularly, while AAV6, that 
preferentially infects muscle cells but has also been described to infect keratinocytes472, 
was injected both intra-muscularly and sub-cutaneously. When using the GG+AAV 
approach with AAV6, the sub-cutaneous route of administration was preferred to avoid 
similarities with the GG+AAV protocol using AAV9. We also evaluated the immunogenicity 
induced by a single dose of DNA as administered by GG (1g). The vaccination protocol 
used in our previous experiments (3 doses (1g) of biolistic-delivered DNA (3xGG)), was 
also included for comparison. In all cases, sera were obtained 1, 3 and 5 months after 
vaccination.  
Antibody titres were measured on ELISA using 3DIII and 3sE as antigens (Fig.60a 
and 60b, respectively, upper panels). All the evaluated vaccination protocols induced anti-
DIII specific antibodies, even though the immunisation efficiency was different. While the 
immune response in the 1xGG and AAV6SC groups were the lowest, the 3xGG group 
showed the highest antibody titres with no significant difference between months 1 and 5. 
Notably, antibody titres from protocols involving AAV administration were low at month 1 
with consistent increases at months 3 and 5. Among these groups, the AAV6IM protocol 
showed the highest efficiency, even though it was still 3 times lower than titres from the 
3xGG group. To determine the relative strength of the antibodies induced with each 
protocol, we measured sera avidity indexes on 3DIII and 3sE, 1 and 5 months after 
vaccination (Fig.60a and 60b, respectively, lower panels). Despite the differences in 
antibody titres, all protocols were able to induce high avidity responses (>30%) with higher 
values consistently present at month 5. For all groups, antibody titres and avidity indexes 
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were independent of the protein used for coating (3DIII or 3sE), further confirming that the 
antibodies induced by the DIII- antigens are able to recognise DIII in the context of the 
whole E protein. 
 
 
 
Figure 60. Characteristics of the antibody responses elicited by the different vaccination protocols. 
(a,b) Antibody titres measured in ELISA (top panels) and avidity indexes (bottom panels) of pooled anti-3DIII 
sera obtained 1, 3 and 5 months after vaccinations for the protocols evaluated, on plates coated with (a) 3DIII 
and (b) 3sE. In all cases, n=4. Antibody titres of the 3xGG protocol at months 1 and 5 were compared on 3DIII 
(t=0.3017 df=6) and 3sE (t=1.680 df=6). * indicates values below the 1/900 dilution threshold, (x) indicates that 
the avidity was not performed due to reduce reactivity in ELISA. c) Neutralisation titres of the different 
protocols at months 1 and 5 on DENV3 (in all cases, n=6, (+) indicates FRNT50 below 25). Data is represented 
as mean±s.d. 
 
We then determined neutralising activity of the antibodies produced with the different 
protocols using sera obtained 1 and 5 months post-vaccination (Fig. 60c). Instead of the 
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PRNT50 assay reported previously, at this point we implemented the immunocolourimetric-
based foci reduction neutralisation test (FRNT50). Similar to ELISA titres, FRNT50 titres of 
the 3xGG group were higher than all others groups. Neutralising titres above 100 were 
obtained for several of the groups involving AAV vectors. The neutralisation curves for 
each vaccination protocol are shown in Fig. 61. 
 
 
 
Figure 61. Foci reduction neutralisation curves for the different vaccination protocols using sera take 1 and 5 
months after vaccination against DENV3 on Vero cells. In all cases, n=6 and data is represented as 
mean±s.d. 
 
Even though some of the data from AAV-based protocols confirmed that AAV-
mediated delivery as a valid option for genetic vaccination; these results indicate that our 
original 3xGG protocol was the most efficient strategy for inducing a strong neutralising 
antibody response with the DIII- DNA vaccine.  
 
2.2.3. Longitudinal analysis of anti-DIII DNA-induced antibody responses. 
2.2.3.1. Monovalent DIII- formulations. 
After analysing the short-termed immune response induced by the DIII- plasmids and 
confirming the efficiency of the 3xGG DNA vaccination protocol, we next evaluated the 
behaviour of the elicited antibodies over long periods of time. For this, we vaccinated 
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groups of 8 Balb/c mice with the DIII- constructs of each DENV serotype, and studied 
their sera for a period up to 1 year after vaccination. 
Sera were obtained from each group after 1, 2, 3, 5, 8 and 12 months of completing 
the vaccination protocol; as seen in Fig. 62a, anti-DIII titres were determined for each 
group of sera, on all four DIII antigens at each time point. In agreement with our data 
regarding anti-DIII cross-reactivity, each group of sera showed high specificity towards the 
homologous DIII antigen, and only reduced cross-reactivity against the heterologous DIII. 
As before, the anti-3DIII response was the most cross-reactive. Notably, in all cases 
antibody titres against the homologous antigens showed no significant differences over 
the one-year period. Furthermore, the homologous anti-DIII antibody titres showed no 
significant differences between them when comparing the four groups at each time point 
(Fig. 62b). Likewise, avidity indexes determined on the homologous DIII showed little 
variation for all serotypes, and values remained above 30% throughout the one-year 
follow-up (Fig. 62c). In summary, the results indicate that gene-gun delivered DIII- 
plasmids are able to induce strong, stable and long-lasting antibody responses against 
each DENV serotype.   
 
 
 
Figure 62. Longitudinal analyses of antibody responses induced with monovalent DIII- formulations in 
mice. a) Reactivity profile of serotype-specific anti-DIII sera on DIII antigens from all four serotypes during a 
one-year follow up( n=4 for the heterologous antigens, and n=8 for the homologous DIII in all cases). One-way 
131 
 
ANOVA was used to compare the antibody titres measured at each time point (anti-1DIII, F=2.318; anti-2DIII, 
F=1.524; anti-3DIII, F=0.4154 and anti-4DIII, F=2.502). b) Comparison of the antibody titres induced by the 
four monovalent vaccines on their homologous DIII antigens at each time point (month 1, F=2.390; month 2, 
F=1.242; month 3, F=2.700; month 5, F=2.812; month 8, F=2.753 and month 12, F=2.846). c) Time course of 
avidity indexes determined by ELISA, for each pool of sera, on plates coated with the homologous DIII (in all 
cases, n=6). Data is represented as mean±s.d. 
 
Considering the results obtained in ELISA, we next measured the neutralising 
capacity of each pooled sera against their homologous DENV serotype, and evaluated 
their behaviour in time by comparing samples collected after 1 and 12 months of 
vaccination (Fig. 63a). As seen in Fig. 63b, DIII- constructs from all four serotypes were 
able to induce strong neutralising responses although, in contrast to ELISA titres, the 
FRNT50 titres of each group were different. Importantly, the neutralising titres from all 
groups showed a significant increase in time, as revealed by comparing FRNT50 titres 
obtained at both time points. In agreement with previous results, these data indicate that 
antibodies induced by the DIII- vaccines not only maintain their neutralising capacity in 
time, but also show maturation-related improvement of the neutralising activity. 
 
 
 
Figure 63. Longitudinal analyses of neutralising activities induced with DIII- monovalent vaccination 
in mice a) Foci reduction neutralisation curves for each anti-DIII against the homologous DENV serotype with 
sera form months 1 and 12 post-vaccination (for anti-4DIII at month 1 and 12 , n=12 and 9, respectively; for 
the rest, n=6). b) Neutralisation titres of the anti-1DIII (t=4.734 df=10), anti-2DIII (t=7.769, df=10), anti-3DIII 
(t=6.448 df=10) and anti-4DIII (t=6.719, df=19) sera as shown in (a). Data is represented as mean±s.d. 
 
 
2.2.3.2. Tetravalent formulations 
As for the monovalent formulations and since a viable vaccine against DENV should 
ideally show stable efficiency against all four serotypes, we also analysed long-term 
antibody responses induced by tetravalent formulations of the DIII- constructs. Parting 
from our initial approach to a gene-gun delivered tetravalent DNA vaccine, we tried 
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different, but equivalent, formulations aimed at optimising the response obtained in our 
first attempt. In this case, our main objective was to develop a formulation that would 
efficiently deliver all four DIII-constructs and induced an immune response equivalently 
distributed between the four DENV serotypes. As previously mentioned, this is a critical 
point to consider when developing a vaccine against DENV since the elicited response 
should be not only protective against all four serotypes, but also balanced to avoid the risk 
of ADE as a result of the natural waning in antibody titres after vaccination. Since the 
vaccination protocol consisted of biolistic immunisation using gold particles carriers coated 
with DNA, we designed tetravalent formulations by either mixing plasmid DNAs, coding for 
different DIII- constructs, before coating the gold beads (DNA mix), or by mixing gold 
beads that had been previously coated with a single DIII antigen (Beads mix). 
5 groups of 5 Balb/c mice were vaccinated following the 3xGG protocol. As before, 
each immunisation consisted of twice the amount of total DNA used for monovalent 
immunisations (two 1g DNA shots), but only half the amount of each DIII construct 
(0,5g). Group A received a DNA-mix formulation consisting of one shot with plasmids of 
serotypes 1 and 2, and one shot with a mix of serotypes 3 and 4 (DNA mix(1+2)(3+4)). 
Tetravalent formulations for groups B and C were designed using the remaining paired 
arrangements of the four DIII constructs; i.e. group B consisted on a DNA mix of 
serotypes 1+3 and serotypes 2+4 (DNA mix(1+3)(2+4)), while group C involved a DNA 
mix of serotypes 1+4 and 2+3 (DNA mix(1+4)(2+3)). Group D received a formulation 
consisting of two equal shots of gold beads coated with a mix of all four DNAs (DNA 
mix(1+2+3+4)). Instead, mice from group E received a beads-mix formulation consisting of 
one shot with a mix of gold particles coated with plasmids for 1DIII- and 2DIII-, and one 
shot of a mix of particles coated with plasmids for 3DIII- and 4DIII-(Beads 
mix(1+2)(3+4)). 
Animals were bled at different time points and antibody titres against each DIII 
antigen were determined (Fig. 64a-e). For all groups, immune responses to all constructs 
were essentially maintained throughout the one-year follow up. However, specific DIII 
titres were lower in all formulations when compared to monovalent responses. This is 
consistent with our previous results and with the reduced amount of serotype-specific 
DNA used during immunisations. We noticed some similarities among the antibody 
responses obtained in all groups: while anti-3DIII titres were consistently the lowest, 
responses towards 1DIII and 2DIII were the highest. Responses at month 1 for all 
formulations were unbalanced and normalised in time. Notably, mice from group E (beads 
mix) developed an antibody response that was equally distributed among the four DIII 
serotypes, while anti-3DIII responses were consistently lower in all groups involving DNA-
mix formulations. Together, the results indicate that vaccine formulation has an important 
effect on the immune responses.  
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Using sera from groups A and E, which involved the same pairing of serotype-specific 
plasmids but differed in the way of preparation (DNA-mix for group A, Beads-mix for group 
E), we measured the neutralisation titres against all DENV serotypes and evaluated their 
variation in time by comparing samples obtained at month 1 and 12 after vaccination. As 
seen in Fig. 64f, relevant neutralising activity was detected against all serotypes in both 
groups. Compared to monovalent responses, neutralising activity of both groups towards 
DENV2, DENV3 and DENV4 were lower, while neutralisation of serotype 1 was enhanced 
but only in mice vaccinated with the Beads-mix formulation. Of note, while the 
neutralisation of serotypes 2, 3 and 4 were similar in both groups, the response against 
DENV1 was a significantly higher for the beads-mix formulation. Tetravalent neutralising 
responses were not significantly different at the beginning and end of the one-year study, 
highlighting the stability of the immune responses induced with the tetravalent 
formulations. 
 
 
Figure 64. Longitudinal analysis of antibody responses induced with different tetravalent formulations 
in mice. (a-d) Antibody titres of the different tetravalent formulations as determined in ELISA against the four 
DIII antigens with pooled sera samples at each time point (n=8 in all cases). f) Neutralisation titres of sera 
from animals vaccinated with DNA mix (1-2)(3-4) (corresponding to (a)) and Beads mix (1-2)(3-4) 
(corresponding to (e)) tetravalent formulations against the four DENV serotypes using samples taken 1 and 12 
months after vaccination (in all cases, n=6). Comparison of both formulations against DENV1 is shown 
(t=13.07 df=10); for the beads mix group the neutralising responses showed no significant differences in time 
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(t=1.267 df=10 for DENV1, t=0.7358 df=10 for DENV2, t=2.050 df=10 for DENV3 and t=2.181 df=10 for 
DENV4). Data is represented as mean±s.d. 
 
 
2.2.4. Functional dissection of the antibody response against DENV sE. 
2.2.4.1. DI/DII epitopes dominate the immune response against sE. 
The data so far presented confirmed that DNA immunisation with DIII- constructs 
induce long-lasting, strongly neutralising antibodies against the homologous DENV 
serotype with only limited cross-reactivity and ADE capacity against heterotypic serotypes. 
In addition, we have also showed that, in agreement with other studies271,278, anti-sE 
responses consist mainly of antibodies with anti-DI/DII activity and very limited reactivity to 
DIII. 
To complete the study of the immune responses induced by the different E structural 
domains, and assess their potential use as immunogens in DNA vaccines, we decided to 
vaccinate animals with constructs encoding the DIII- antigen, DI/DII or the complete sE 
protein of DENV3 and DENV4 (Fig. 65a). DENV1 and DENV2 were not included as only 
DI/DII and the sE proteins from serotypes 3 and 4 were efficiently secreted from 
mammalian cells (Fig. 22a). The secretory properties of these constructs in the pVAX1 
vector were confirmed after transfection in HEK-293T (Fig. 65b).  
 
 
 
Figure 65. Secretory profiles of sE, DI/DII and DIII- proteins derived from DENV3 and DENV4. a) 
Scheme of DNA constructs and the expected products used for immunisations. b) WB profile of expression 
and secretion from transfected HEK293T cells (E, cellular extracts; S, culture supernatants) of the constructs 
shown in (a); anti-actin was used as loading control. 
 
Pooled sera of immunised animals were then tested by ELISA on plates coated with 
the homotypic sE, DI/DII or DIII antigens to determine the reactivity profile of the induced 
antibodies. As seen in Fig. 66a, for both DENV3 and DENV4, anti-DIII and anti-DI/DII sera 
were highly domain-specific, while both anti-sE sera preferentially reacted with DI/DII and 
sE, as expected due to DI/DII immunodominance. Indeed, there were no significant 
differences between titres of anti-sE sera determined on sE and DI/DII, while the 
differences between titres determined on sE and DIII were (Fig. 66b and 66c). 
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Furthermore, both anti-DI/DII antibodies showed significantly lower avidity compared to 
antibodies induced with DIII- (Fig. 66d). 
 
 
 
Figure 66. Antibody responses against DENV sE antigens are highly dominated by DI/DII epitopes. a) 
ELISA reactivity of antibody responses from mice immunised with sE (n=12), DI/DII (n=9) and DIII (n=9) 
constructs from DENV3 and DENV4, tested on plates coated with sE, DIII or DI/DII antigens from the 
homologous serotype (DENV3, top panels) and (DENV4, bottom panels) as indicated. (b, c) Antibody titres of 
sera from animals immunised with constructs of DENV3 (b) and DENV4 (c) as determined in (a), comparisons 
of anti-sE reactivity between sE and DI/DII (t=1.714 df=19 for DENV3, t=2.082 df=19 for DENV4), and 
between sE and DIII (t=6.361 df=19 for DENV3, t=28.16 df=19 for DENV4) are shown. d) Avidity index of sera 
from animals immunised with DIII and DI/DII from DENV3 (left panel, n=18, t=15.10 df=34) and DENV4 (right 
panel, n=18, t=22.07 df=34). Data is represented as mean±s.d. 
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In addition, as demonstrated by the analysis of sera from animals vaccinated with 
both DIII- and DI/DII constructs (groups of 6 Balb/c mice, following the same vaccination 
protocol, with animals receiving 1g DNA/shot) DI/DII immunodominance was only 
observed within the context of the whole sE protein (in cis) but not when DIII and DI/DII 
were expressed separately (in trans). As shown in Fig. 67a, addition of DI/DII had no 
significant effect on the antibody titres against DIII (Fig. 67a). Antibody titres against 
3DI/DII are also included to demonstrate the presence of anti-DI/DII antibodies in the 
group vaccinated with both constructs (Fig. 67b). 
 
 
 
Figure 67. DI/DII immunodominance on DIII is observed only with the context of sE. a) Antibody titres on 
3DIII-coated ELISA plates of pooled sera from animals vaccinated only with 3DIII- or with 3DIII- and 3DI/DII 
in two different shots (n=8, t=0.9558 df=14). b) ELISA reactivity of the same sera on 3DI/DII coated plates 
(n=8). Data is represented as mean±s.d. 
 
 
2.2.4.2. Antibodies induced against DI/DII, but not against DIII are highly cross-
reactive to other flaviviruses.  
We then investigated the reactivity profile of the immune sera by immunofluorescence 
of cells infected with all DENV serotypes and with other three closely related flaviviruses 
(ZIKV, WNV and YFV). In addition to the sera of animals vaccinated with all four DIII- 
constructs, and DI/DII and sE from serotypes 3 and 4, we also included sera from mice 
vaccinated with the tetravalent DIII- beads-mix formulation (henceforth, Tetra-DIII) 
described before. 
As stated in previous sections, anti-DIII antibodies were highly reactive when exposed 
to cells infected with their homologous DENV serotype; predictably, sera antibodies 
induced with the Tetra-DIII formulation were also able to recognise all four DENV 
serotypes. Likewise, anti-DI/DII and anti-sE sera, from both DENV3 and DENV4, were 
highly cross-reactive to cells infected with every serotype, an expected feature given the 
DI/DII homology of DENV viruses271,278 (Fig. 68). mAb 4G2 and pre-immune sera were 
used as positive and negative controls, respectively. 
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Figure 68. Reactivity profiles of different anti-DENV sera in DENV-infected cells. Immunofluorescence of 
Vero cells infected with all four DENV serotypes and reacted with antibodies elicited with 3sE and 4sE or the 
corresponding 3DI/IDII and 4DI/DII. mAb 4G2 as well as the homologous DIII and tetravalent anti-DIII sera 
were included as controls. N.I., non-infected cells; P.I., pre-immune serum. Bar, 30 m. 
 
Strikingly, when the same sera were analysed on cells infected with the non-dengue 
flaviviruses the reactivity profiles were different. Sera of mice immunised with DI/DII and 
sE constructs, from both serotypes, remained strongly cross-reactive to ZIKV, WNV and 
YFV. In contrast, anti-DIII antibodies obtained from groups vaccinated with each DIII- 
protein or with the Tetra-DIII formulation were completely negative to all three viruses (Fig. 
69). As before, given that the FL epitope is conserved in the three viruses440, mAb 4G2 
and pre-immune sera were used as a positive and negative controls, respectively. 
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Figure 69. DENV anti-DIII sera recognise DENV infected cells specifically and do not cross-react with 
other flaviviruses. Immunofluorescence of Vero cells infected with ZIKV, WNV and YFV and reacted with 
antibodies elicited with the four DENV DIII antigens (1DIII, 2DIII, 3DIII and 4DIII), the Tetra-DIII formulation, 
3sE, 3DI/IDII, 4sE and 4DI/DII. mAb 4G2 was included as a control. N.I., non-infected; P.I., pre-immune 
serum. Bar, 30 m. 
 
 
2.2.4.3. Neutralising and enhancing activities of polyclonal antibodies against 
DENV DIII and DI/DII. 
Given the clear contrast between the reactivity profiles of the broadly cross-reactive 
antibodies induced with proteins containing DI/DII epitopes (DI/DII and sE) and the highly 
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specific responses against immunogens restricted to DIII, we then evaluated their 
performance in ADE and FRNT50 assays (using K562 and Vero cells, respectively) against 
all the aforementioned viruses. A control of ADE assay on K562 cells was done with mAb 
4G2, which showed enhancing activity to all viruses (Fig. 70).  
 
 
 
Figure 70. mAb 4G2 induces ADE of all four DENV serotypes, ZIKV, WNV and YFV on K562 cells (n=3). 
  
In order to successfully dissect the activities of the immune responses induced with 
defined E structural domains, and since the reactivity profiles of anti-DI/DII and anti-sE 
sera (for both DENV3 and DENV4) were the same regardless of the virus, we only 
compared anti-DI/DII with anti-DIII specific sera. 
As seen in Fig. 71a, we found strong ADE activities for both anti-DI/DII sera (anti-
3DI/DII and anti-4DI/DII) not only for the different DENV serotypes, but also against ZIKV, 
WNV and YFV. Interestingly, the overall patterns of the neutralising activity were different, 
as viral neutralisation was relevant only against DENV and completely negative on the 
other flaviviruses. The summary of the neutralisation titres for both anti-DI/DII is shown in 
Fig. 71b.  
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Figure 71. Cross-reactive anti-DI/DII induces poorly-neutralising and highly-enhancing responses. a) 
Foci reduction neutralisation curves (n=6) and ADE (n=3) of all four DENV serotypes, ZIKV, WNV and YFV, 
with DENV anti-3DI/DII and anti-4DI/DII sera. b) FRNT50 titres for anti-DI/DII sera derived from the curves 
shown in (a), * indicates FRNT50 titres below detection limit of the assay (<25).  
 
In contrast to the profiles obtained with anti-DI/DII antibodies, immune responses 
induced with the different DIII- proteins showed no reactivity, in both ADE and FRNT50, 
when tested against ZIKV, WNV and YFV (Fig. 72a). As expected, strong neutralisation 
and, consequently, ADE activity, was found when testing each anti-DIII sera against their 
homologous DENV serotype. The neutralisation titres of each anti-DIII sera are 
summarised in Fig. 72b. 
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Figure 72. DIII- DNA vaccination induces DENV-specific neutralising antibodies. a) Foci reduction 
neutralisation (n=6) and ADE (n=3) of all four DENV serotypes, ZIKV, WNV and YFV, with DENV anti-DIII 
sera. DENV viruses were tested using sera against the homologous serotypes while non-DENV viruses were 
tested against all four anti-DIII sera. b) FRNT50 titres for anti-DIII sera as shown in (a), * indicates FRNT50 
titres below detection limit of the assay (<25). 
 
To further confirm the DENV specificity of the DIII- immunogens, we then determined 
the neutralising and ADE activities of antibodies induced with the Tetra-DIII formulation. 
Not surprisingly, anti-Tetra-DIII sera showed no neutralising activity against ZIKV, WNV 
and YFV, but were able to induce significant neutralisation to the four DENV serotypes. 
Notably, there was no ADE activity towards the non-dengue flaviviruses; while, as 
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expected, enhancement of DENV serotypes was positive (Fig. 73a). FRNT50 titres of anti-
Tetra-DIII sera are shown in Fig. 73b. 
 
 
 
Figure 73. DENV tetravalent DIII- vaccine formulation elicits DENV-specific neutralising antibodies. a) 
Foci reduction neutralisation curves (n=6) and ADE (n=3) of all four DENV serotypes, ZIKV, WNV and YFV, 
with sera from mice vaccinated with the Bead mix(1-2)(3-4) tetravalent DIII- formulation. b) FRNT50, as 
determined in (a), * indicates FRNT50 titres below detection limit of the assay (≥25). 
 
Together, these data support the implementation of DIII antigens to induce DENV-
specific neutralising responses without the risk of enhancing infection of other related 
flaviviruses like ZIKV, WNV and YFV. 
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2.3. DISCUSSION 
Even though the development of an effective Dengue vaccine has been a highly 
sought objective for decades, it remains an unresolved task. The lack of proper animal 
models and laboratory tests able to reliably extrapolate data to the clinical reality337,473, 
together with the poor understanding of the infection process of the virus, have been 
major caveats to circumvent220. Furthermore, the need to develop a candidate able to elicit 
a balanced and stable neutralising response to all four DENV serotypes due to the risk of 
ADE has hindered many efforts to move more viable vaccine candidates down the 
pipeline.  
Recently, the promising CYD-TVD vaccine from Sanofi-Pasteur has been seriously 
questioned due to unbalanced protection against the different DENV serotypes and 
increased risk for haemorrhagic disease among children between 2-5 years of 
age368,369,371. Thus, as a result of the limitations shown by classical vaccine approaches, 
next-generation strategies have emerged as new alternatives to overcome this complex 
task with new candidates based on recombinant VLPs392, molecularly attenuated live 
viruses356-358,361-363, viral-vectored genetic vaccines and tetravalent DNA vaccines342, all 
moving closer to Phase III studies. In fact, the current urge to quickly address the need of 
an effective vaccine against ZIKV has led to the development of several genetic vaccine 
candidates (both as DNA and viral-vectored vaccines) that are swiftly moving into clinical 
studies ahead of other, more traditional, candidates453-455,474,475. In addition, DNA vaccines 
against other flaviviruses like WNV405, and against viral diseases like human 
immunodeficiency virus (HIV) and Ebola virus, have also been clinically tested in humans 
402,404. 
As mentioned before, genetic vaccines are able to stimulate cellular and antibody-
mediated adaptive immunity, which is among their main advantages395-397. Other benefits 
of DNA vaccines, especially relevant when dealing with rapidly spreading viruses in 
underdeveloped countries like DENV and ZIKV, include: a) exceptional safety profile in 
humans, b) the possibility to screen several antigenic designs in shorts periods of time, c) 
fast manufacturing and d) regulatory simplicity for clinical evaluation395,398,454,475. In 
addition, given that the antigen is synthesised intracellularly in vivo, proper conformation 
of the epitopes is favoured since the immunogen undergoes the same maturation process 
as the native viral protein would during infection398-400.  
Although most DNA vaccine candidates in development include the whole E protein 
as the main antigen, we show that DNA vaccination with properly engineered antigens 
based on DIII induced strong antibody responses to all DENV serotypes in mice. The 
results confirm previous indications regarding the neutralising properties of anti-DIII 
antibodies and the reduced the risk of ADE due to their specificity476. It is important to 
mention that due to the lack of resources and appropriate facilities to handle infected 
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animals, the study of the vaccine was restricted to the Balb/c immunocompetent mouse 
model; a more complete evaluation of vaccine effectiveness should have included 
protection studies in passively immunised AG129 mice.  
 
In order to enhance anti-DIII responses, we took an integral approach in designing 
the DIII immunogen. Based on the biochemical analysis done on sE proteins from the 
different DENV serotypes (and their respective structural domains), our data clearly 
indicate that efficient antigen production and secretion from transfected cells is crucial to 
induce strong immune responses via DNA vaccination, and that antibody responses 
towards a particular antigen could be significantly improved by increasing the secretory 
properties of the immunogen. The importance of antigen secretion in DNA vaccination has 
been addressed by other studies as well395,396,443.  
Despite the inclusion of an N-terminal secretory leader peptide to guide the 
translocation of DIII into the ER, significant protein secretion was only observed when the 
dimerising CH3 domain was fused to the C-terminal end of DIII, and was further 
improved after optimising the DIII coding sequences for expression in mammalian cells. 
The inclusion of the CH3 domain was critical for the efficacy of the vaccine, as it led to a 
significant increase in protein secretion by allowing intracellular transport after 
translocation into the secretory pathway. Although these modifications were relevant for 
all DIII constructs, the effect on 2DIII and 4DIII antigens was particularly important since 
the secretion of the viral encoded domains was barely detected. Surprisingly, the inclusion 
of the CH3 not only increased the immune response against the DIII antigen (in terms of 
anti-DIII titres measured in ELISA), but also enhanced the quality of the induced 
antibodies, as revealed by comparison of avidity indexes of sera from animals vaccinated 
with and without CH3. 
Out of the several delivery strategies available for genetic vaccines, we decided to 
immunise mice with biolistic-delivered plasmid DNA. Our results confirm that gene-gun 
technology is an efficient way to induce strong antibody responses with very low amounts 
of total DNA: classical intramuscularly delivered genetic vaccines employ up to 100g of 
DNA per dose460,464,466,469, while our protocol required only 1g (2g for the tetravalent 
formulations) and was able to induce high antibody titres nonetheless.  
 
It is particularly relevant to address the benefits of the conformational ELISA protocol 
implemented when discussing the results of the DIII- DNA vaccines. We took special 
care into designing the assay in order to properly evaluate immune responses. As 
pictured in Fig. 74, using the BAP/BirA system, the different proteins were obtained 
exclusively as mono-biotinylated products secreted from mammalian cells, and did not 
require any further purification since dialysed cultured supernatants were directly used as 
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a source of antigen and captured on avidin-coated plates. To ensure that equal amounts 
of protein were applied each time, the different antigens were normalised by western blot 
(using HRP-conjugated streptavidin). Thus the native structure and properties of the viral 
proteins were maintained and enabled us to determine the ability of the induced 
antibodies to recognise conformational epitopes, a feature commonly related to strong 
neutralising capacity310. 
 
 
 
Figure 74. Conformational ELISA for detection of antibodies against E-derived antigens. a) Schematic 
representation of constructs used with the BAP/BirA system for obtaining mono-biotinylated sE, DI/DII and DIII 
proteins secreted from mammalian cells and used in the conformational ELISA. b) Scheme of the ELISA, with 
avidin-coated plates to equally capture biotinylated sE, DI/DII and DIII. 
 
Different variations of ELISA are commonly used when evaluating new vaccines; 
however, the lack of standardised assays represents a significant problem when 
considering data reproducibility and reliable comparisons between studies. Since the 
amount of antigen used in our conformational ELISA has been normalised, all the results 
are comparable between them regardless of the nature, size or complexity of the protein 
used as antigen. Moreover, since our protocol was optimised and kept unchanged from 
the beginning of the project, the ELISA data obtained from mono-biotinylated antigens is 
highly reproducible. Given the impossibility to properly compare our results with previously 
published dengue vaccine studies, we decided to express the reactivity of the induced 
antibodies in terms of estimated antibodies concentrations. The antibody quantification 
was done by interpolating the OD value of different sera dilutions within a calibration curve 
of mAb 4G2 measured on 3sE. As mAb 4G2 is widely available and recognises a highly 
conserved epitope, it could be easily implemented as a reference to allow comparisons. 
As shown in the results of our first round of vaccinations with DIII- candidates, all 
four antigens induced strong immune responses as revealed by the high antibody titres 
(and estimated concentrations) determined in ELISA. Of note, anti-2DIII responses were 
the strongest, while there were no significant differences between titres induced by 1DIII, 
3DIII and 4DIII constructs against their homologous serotypes. Anti-DIII responses also 
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proved to be highly specific towards the homologous DIII antigens with very reduced 
cross-reactivity to the other serotypes, thus confirming the relatively high variability of DIII 
among DENV serotypes271. Anti-3DIII antibodies, however, showed higher cross-reactive 
activities when tested on all four antigens, especially towards 2DIII and 4DIII. Moreover, 
the results demonstrate that anti-DIII antibodies were mainly directed to conformational 
epitopes readily exposed on the infective virion, as they strongly recognised the captured 
virus and the native DIII (and sE) antigen in ELISA, with only minimal reactivity towards 
equivalent amounts of denatured DIII proteins.  
 
The results also suggest a correlation between antibody titres induced by the different 
DNA constructs and their neutralising capacity measured in PRNT50 assays, since anti-
2DIII antibodies showed significantly higher neutralising titres than the other groups, while 
there were no significant differences between the neutralisation induced by 1DIII- and 
3DIII- against their homologous DENV serotypes. The anti-4DIII response was the 
exception as it showed significantly lower PRNT50 titres than anti-1DIII and anti-3DIII sera 
despite their similar titres in ELISA. This appears to be characteristic of the 4DIII domain 
as presented in our vaccine format since DNA immunisations with a DIII- construct 
derived from a different strain (and genotype) of DENV4, led to essentially equivalent 
responses. In contrast, experimental data from previous studies indicate that variation 
between genotypes within each DENV serotype could impact vaccine efficacy 
significantly28,461,477-479. For instance, failure of the CYD-TDV vaccine to protect against 
DENV2 (only 9.2% efficiency) during the Phase 2 study in Thailand, was thought to be 
due to differences in the circulating genotype365. Considering that the alternative 4DIII 
antigen belonged to same viral strain used in the neutralisation assay, our results suggest 
that DIII differences between the isolates used for vaccine design and evaluation, at least 
in our case, do not influence the neutralisation results of the study; further studies are 
needed to established if this is true also for the other serotypes and their respective DIII 
domains. In any case, if this effect is demonstrated, genetic vaccines, and particularly our 
DIII- platform, are highly adaptable and can be easily modified to take these elements 
into account. 
It has been proposed that, in flaviviruses, neutralisation is achieved after the number 
of antibodies bound to the virus surpasses a determined threshold306,307. In this way, 
binding of antibodies that target highly accessible epitopes, like the ones on DIII, is 
favoured and neutralisation can be achieved at low antibody concentrations as only a 
reduced occupancy of the available epitopes is required310. Besides epitope accessibility, 
the neutralisation threshold is also dependent on antibody avidity272. Indeed, recent 
studies have shown a positive correlation between antibody avidity and in vitro 
neutralisation for monoclonal antibodies against flaviviruses and other viral 
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infections28,307,309,477,480,481. Recently, this correlation was also demonstrated in sera of 
DENV-infected patients482. Our results confirm that DIII- immunisations induced high 
avidity antibodies in vaccinated animals, and that the avidity indexes were better 
predictors of the neutralising activities of sera when comparing samples with similar 
antibody titres: anti-3DIII and anti-4DIII sera, for example, were not significantly different in 
ELISA, but anti-3DIII antibodies showed a significantly higher avidity than the anti-4DIII 
sera, which correlated with the better performance of the 3DIII- vaccine in neutralisation 
assays. Thus, our results support the inclusion of avidity measurements, together with 
estimations of antibody titres and neutralising potential, into the preliminary evaluation of 
vaccine candidates, to better understand the behaviour of the induced antibody 
responses482.  
As mentioned before, antibodies exert their neutralising potential either by blocking 
viral interaction with cell receptors, or promoting the detachment of virus from the cell 
membrane, or by preventing the membrane fusion process following clathrin-mediated 
endocytosis. Even though we successfully proved the neutralising nature of anti-DIII 
antibodies induced by the DIII- vaccine, their mechanism of action remains an open 
question. 
 
We believe that a combination of factors explain the efficacy and performance of the 
DIII- DNA vaccine. Intradermal, gene-gun delivery of plasmid DNA is particularly well-
suited to target keratinocytes present at the immunisation site483. These cells show not 
only a high transfection efficiency, but are also able to modulate the immune response in 
the skin by staying in close interaction with immune cells of skin (such as Langerhans 
cells and intradermal lymphocytes) and producing a wide range of CKs which allows for 
proper presentation of the secreted antigen484. In the context of the DNA vaccine, this 
leads to both Th1/Th2 immune responses, contrary to the classical intramuscular injection 
of DNA, which mainly activates the Th1 pathway485. Increased antigen availability, 
achieved by optimising the secretory profile of the DIII proteins, was also critical since 
codon-optimised DIII- constructs induced immune responses that were significantly 
stronger, both in terms of antibody titres and neutralising capacity, than those elicited by 
the non-optimised (and less secreted) DIII- antigen, which were stronger than those from 
mice vaccinated with the non-optimised DIII alone. Furthermore, the CH3-mediated 
dimerisation of the DIII antigen, could have also contributed to the immunogenicity of the 
vaccine, as it would favour engagement of the B-cell receptor (BCR) and subsequent 
activation of naive B cells. In addition, the xenogeneic nature of the CH3 domain may 
have induced further activation of T helper cells486; however, since the study was focused 
on the analysis of the antibodies elicited by the vaccine, the cellular factors were not 
specifically addressed. Together, when considering the contribution of the modifications 
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introduced to the DIII antigen as part of the vaccine design process, our data confirms that 
codon optimisation significantly improved antibody titres by enhancing protein secretion 
from transfected cells, while the inclusion of the CH3 domain increased immunogenicity 
and secretion levels of the antigen, as revealed by the avidity index and neutralising 
capacity of the induced antibodies.  
 
As a proof of principle, we designed a tetravalent DIII formulation using a combination 
of the plasmids coding for the different DIII- constructs. Anti-DENV immunity was 
efficiently induced by the tetravalent formulation; however, immune responses were 
considerably lower in terms of antibody and PRNT50 titres when compared against the 
four monovalent vaccines, most likely a reflection of the reduced amount of DIII-specific 
plasmid used for vaccination. Notably, for the tetravalent formulation, neutralisation 
activity was strongest against DENV3, while PRNT50 titres towards DENV4 were further 
reduced. Avidity indexes measured against each DIII protein were lower than those 
obtained when evaluating monovalent vaccines in all cases, even though this value could 
be misleading due to the cumulative effect of the cross-reactive antibodies present in the 
tetravalent sera. Together, the data obtained from the tetravalent formulation indicated 
that further development and optimisation of the DIII- vaccine was needed to reach 
values comparable to those of the monovalent formulations. 
 
The enhancement in DIII- secretion after changing the expression vector used for 
DNA vaccination was surprising. As explained before, the FDA-approved pVAX1 vector 
replaced the pcDNA3.1 backbone as part of the optimisation of the DIII-vaccine in order 
to simplify the transition to an eventual clinical trial and augment the significance of our 
experimental data. However, upon preliminary evaluation of the new expression platform, 
it became evident that the secretion of the same DIII- encoded proteins increased. These 
results could be explained by accounting for the size differences between both vectors, 
since pVAX1 is considerably smaller (5.428 vs. 2.999 nucleotides for the empty pcDNA3.1 
and pVAX1 plasmids respectively) given that all sequences not required either for plasmid 
replication in bacteria, or protein expression in mammalian cells, were removed from it in 
order to comply with FDA requirements471; as a result, pcDNA3.1-encoded DIII- plasmids 
are almost 40% bigger than their pVAX1-equivalents, which means that the number of 
plasmid units transfected (and consequently vaccinated) when using the same mass of 
DNA is higher for the pVAX1-encoded protein. Since the differences in secretion were not 
equal among the four DIII proteins, other vector-related factors could also be involved in 
the secretory enhancement of DIII- protein; however, we did not perform any additional 
investigation on the subject. Independently of the cause, this is a highly desirable feature 
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due to the positive correlation demonstrated between antigen secretion and genetic 
vaccination. 
The decision to evaluate different vaccination protocols and delivery alternatives was 
made in an attempt to further optimise the DIII- vaccine. AAV vectors have been largely 
evaluated in gene therapy and are increasingly becoming attractive vaccine carriers to 
mediate DNA delivery in genetic immunisations. In fact, several AAV-vectored DNA 
vaccines against pathogens like Influenza virus, Human Papilloma virus (HPV) and HIV 
have been described415. In the case of dengue however, only one AAV-vectored vaccine 
has been reported, with modest results422.  
Our results indicate that both AAV serotypes employed were able to efficiently deliver 
the plasmids to intradermal cells of vaccinated animals, as evidenced by the detection of 
anti-DIII specific antibodies in all groups; however, induction of antibody responses was 
more efficient in AAV6 than AAV9, and none of the examined groups were able to 
measure up to our initial 3-dose gene-gun strategy, in terms of both antibody titres and 
neutralising capacity of the induced sera. Notably, our data confirmed AAV6 preferred 
tropism for muscle cells, as the subcutaneous inoculation (to target keratinocytes) of the 
virus was poorly immunogenic while the intramuscularly administration was the second 
best protocol analysed. In addition, protocols involving combinations of gene-gun and 
AAV strategies were successful in eliciting stronger antibody responses with a simplified 
vaccination schedule that would be more easily implemented in a clinical setting. It was 
unfortunate that a GG+AAV6IM group was not included in the assay, since the results 
suggest that it could have elicited responses closer to those of 3xGG vaccinated mice; 
future experiments should address this question. Collectively, our data indicate that 
genetic vaccination using a gene-gun mediated delivery platform is superior to vaccination 
protocols involving AAV. Indeed, together with high manufacturing costs and the need to 
employ high titre doses, low immunogenicity has been one of the major drawbacks for the 
development of AVV-vectored vaccines415. However, future projects should seek to 
improve AAV vaccination efficiency given their significant benefits in the context of 
dengue; in particular, the possibility of developing an effective single-dose vaccine would 
be highly suitable not only for implementation in the clinical setting, but also to facilitate 
mass vaccination of vulnerable populations. Proper evaluation of vaccination protocols 
involving different AAV serotypes, combination with novel adjuvants and heterologous 
prime/boost strategies, would provide valuable additional data.  
 
In addition to strong neutralising protection towards the four DENV serotypes, the 
efficacy of a vaccine also relies on its safety and capacity to induce persistent protective 
immunity over prolonged periods of time. Indeed, the WHO recommends verifying that the 
vaccine-induced antibody responses do not lead to increased risk of severe disease due 
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to waning antibody titres in time487. For this reason, we decided to evaluate the 
immunogenicity of the pVAX1-encoded antigens in mice over relatively long-periods of 
time. Our results showed that monovalent antibody titres were considerably higher in 
these groups than in the pcDNA3.1-vaccinated mice, probably reflecting the enhanced 
secretory profile of the DIII- within the pVAX1 vector. Notably, the immune responses 
remained high and stable over the follow-up period both on terms of antibody titres and 
relative avidity. In agreement with our preliminary vaccine evaluations, the four types of 
anti-DIII sera were highly specific and mainly recognised the homologous DIII antigen; as 
before, anti-3DIII sera showed the highest cross-reactivity. However, as a result of the 
enhanced homologous responses, the differences between homologous and heterologous 
activities increased. Besides long-term stability, the antibody titres were highly balanced 
when compared amongst them, in contrast to the results obtained in the first round of 
vaccinations and further confirming the improvement of the DIII- vaccine.  
As expected from the higher antibody titres, the neutralising capacity of each group of 
sera, as measured by the FRNT50 tests, was also higher; notably, the new 4DIII- 
formulation, whose secretion increased the most when switching to the pVAX1 backbone, 
showed DENV4 neutralisation titres ≈4 times higher than the ones measured initially. It 
should be noted that the introduction of the FRNT50 assay instead of the classical PRNT50 
could have influenced the results and at least part of the observed differences might 
derive from methodological factors and not to actual improvements of the DIII- vaccine; 
however, the differences seen for anti-2DIII (≈2 times higher), anti-3DIII (>2 timer higher) 
and anti-4DIII could not be explained by a modification in the read-out approach alone.  
 
After an infection, anti-DENV antibodies start to decline rapidly until reaching levels 
that remain stable for years220. It has been suggested that these rapidly declining 
antibodies are not selected for expansion due to high cross-reactive activity and weak 
binding to the viral particle, while the stable level of remaining antibodies comprise, on the 
contrary, strongly neutralising type-specific antibodies488. The increase in the FRNT50 titres 
over the one-year follow up are difficult to explain: even though the results suggest a 
maturation-related enhancement of the immune response induced by the DIII-, the 
stability of the antibody titres, the specificity of the responses and the avidity of the sera 
remained unchanged. Small increases of potent neutralising antibodies as part of the 
evolution and selection of the immune response could have a significant impact on the 
neutralisation assays but not on the other tests as they would be masked by the high 
concentration of antibodies. Adsorption studies using heterologous antigens to remove 
cross-reactive, and likely poorly-neutralising, antibodies may help to evidence subtle 
differences in the behaviour of highly specific antibodies over time; however, even at their 
lowest, the neutralising capacity of these sera was significantly better that the previous 
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pcDNA3.1 vaccines, and considering that the main focus of these experiments was the 
optimisation of a tetravalent DIII- formulation, we did not investigate this behaviour in 
detail. 
One of the main problems observed during the preclinical studies of CYD-TDV 
vaccines was the apparent immunological interference between DENV serotypes which 
resulted in an unbalanced immune response dominated by some serotypes. In an attempt 
to mitigate this effect they implemented several immunization approaches including i) 
sequential and simultaneous administration of different and complementary bivalent 
formulations, ii) pre-immunisation with different flaviviruses and iii) reformulation of the 
vaccine dosage based on the detected immunodominance489. In our case, we 
implemented a similar approach by evaluating different and complementary bivalent 
formulations of our DNA vaccine in attempt to obtain an immune response evenly 
distributed among the four DENV serotypes in mice. As with the monovalent formulations, 
tetravalent formulations of the pVAX1-encoded DNA vaccine also showed enhanced 
antibody titres against all DIII epitopes when compared to the results of the first tetravalent 
immunisation. Similar to the first round of vaccination, antibody responses were 
unbalanced among the different DIII antigens with all formulations showing higher 
reactivity towards 1DIII soon after vaccination; however, immune responses balanced in 
time even though anti-3DIII responses were consistently lower for all DNA-mix 
formulations. Indeed, compared to tetravalent formulations using the DNA-mix approach, 
the antibody responses obtained with the Beads-mix preparation were better balanced. 
This could reflect a potential benefit of inducing expression of a single DIII- antigen per 
transfected cell (assuming that each cell is transfected by only one DNA-coated carrier) as 
each gold particle was treated with a single plasmid as opposed to the DNA-mix 
formulations, where each transfected cell would express, at least, two different DIII 
proteins simultaneously. Unexpectedly, results of the FRNT50 performed on each DENV 
serotype did not reflect the balanced response seen in ELISA and were distributed 
similarly to the neutralisation responses observed during the first tetravalent test. Since 
this behaviour appeared to be independent of the formulation analysed, the results 
probably reveal the properties of the anti-DIII response when all DIII- antigens are equally 
administered in mice, thus, future evaluations where the amount of each DIII plasmid 
follows the ratio of the FRNT50 titres seen here, would provide important data towards the 
development of a formulation with balanced neutralising activity. Notably, the neutralising 
activities of the tetravalent sera differed from the monovalent vaccines in two main points:  
1. Except for strong enhancement in DENV1 neutralisation, FRNT50 titres against the 
other three DENV serotypes did not show any major differences when compared 
against the initial pcDNA3.1 results. The improvement in DENV1 neutralisation 
was seen only for the Beads-mix preparation, further supporting the benefits 
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attached to this formula.  
2. Neutralising activities against the four DENV serotypes remained stable over the 
one-year study as FRNT50 titres measured at months 1 and 12 after vaccination 
were not significantly different. 
Collectively, even if the mouse immunisation model poorly reproduces the human 
immune responses against dengue, the results obtained from these longitudinal analyses 
provide important information that could be used to further improve the vaccine. 
Specifically, the data suggest that evaluation of DIII- tetravalent vaccines with increased 
dosages of DNA could match the responses measured in mice vaccinated with single 
antigens; in addition, due to the unbalanced neutralising titres obtained repetitively when 
using equal amounts of each DIII- plasmid, future experiments should implement a 
FRNT50 titre-based normalisation approach when determining the ratio of constructs 
included in the tetravalent vaccine formulations.  
 
The use of DIII in the development of vaccines against Dengue has been previously 
reported for recombinant protein subunit vaccines378-385,388,490, DNA vaccines398,408,465 or 
viral-vectored vaccines463,491. Our DIII- vaccine is different as the antigen was carefully 
designed to increase immunogenicity. Indeed, when compared to candidates evaluated 
using similar methodologies, the DIII- DNA vaccines elicited higher neutralisation titres 
against all four serotypes, even when considering protocols implementing heterologous 
prime/boost strategies using a combination of proteins and DNA379,408. Significantly, the 
evaluation of ADE induced by DIII-specific sera on THP-1 cells demonstrated that the 
highly specific immune responses elicited by the DIII- DNA vaccine mainly promote the 
infection of the homologous serotypes, with reduced effect over the heterologous ones 
therefore; ADE would be driven mainly by the decay of homologous antibody titres to sub-
neutralising levels. However, given the poor reproducibility of the mouse model in the 
case of dengue, the conclusions that can be extracted from this study regarding the 
efficacy of the vaccine in NHPs or humans, are very limited and require further 
assessment. These results also highlight the need for further optimisation and analysis of 
the tetravalent formulation to ensure not only the strength and balance of the response, 
but also to measure antibody longevity and reduce eventual risks of ADE. 
Even if anti-DIII antibodies have been shown to have higher neutralising capacity than 
those directed against epitopes on DI and DII271, most DENV vaccine candidates continue 
to use the whole E protein as their main immunogenic component336. This is of relevance 
as data indicate that the immune response against E is heavily dominated by epitopes on 
DII, especially those located in the vicinity of the FL279,492. Taking this into account, we 
compared DIII- and sE-induced responses using the gene-gun platform. The results 
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clearly showed that immune responses to the better secreted DIII- were significantly 
stronger than those obtained from animals vaccinated with whole sE. DI/DII 
immunodominance was evidenced by the significantly different reactivity of anti-sE sera 
against DI/DII (strong) and DIII (weak) antigens. This was further confirmed after 
comparing the reactivity profile of anti-DI/DII and anti-sE sera obtained after vaccinating 
with plasmids derived from DENV3 and DENV4. As a result, the neutralisation titres 
induced by the DIII- construct were also significantly higher than those observed in sE-
vaccinated animals. Indeed, when measured against other (methodologically comparable) 
DENV E-based DNA vaccines, the DIII- constructs induced stronger neutralisation titres 
in vaccinated mice despite the low amount of DNA used for immunisation460,464,466,468,469. 
Furthermore, the neutralising response towards the DIII- candidate was higher than other 
DNA vaccines in which the sE antigen was further modified to enhance 
immunogenicity390,409,462,467,493,494. 
 
Even though the possibility of ADE among heterologous flaviviruses has been known 
for many years322,323, it was only recently that the close immunological relationship 
between DENV and ZIKV was described by demonstrating that poorly-neutralising cross-
reactive antibodies against either virus are able to enhance infection of the other324,444,495. 
In fact, studies using mAbs isolated from DENV or ZIKV infected patients, showed in vivo 
and in vitro enhancement of ZIKV and DENV, respectively287,444. DENV and ZIKV are 
closely related as evidenced by the high degree of homology shared between their 
respective E proteins (between 54-59% when comparing ZIKV against all four DENV 
serotypesf) explaining the cross-reactivity revealed by these studies27,287. In addition, the 
overlap of DENV-endemic areas and those involved in the current ZIKV outbreaks has 
raised concerns regarding the possible effect of pre-existing DENV immunity in ZIKV 
pathogenesis324. The same reasoning could also apply to other flaviviruses that show 
cross-reactivity with DENV, such as WNV and YFV323. These new data have significant 
repercussions for vaccine research, as they raise the additional need to consider infection 
enhancing properties of the induced antibodies not only against the different serotypes of 
DENV, but against other flaviviruses as well. 
Considering this, we decided to compare the ADE and neutralisation profiles of 
polyclonal sera obtained from mice vaccinated with plasmids encoding DIII or DI/DII from 
different DENV serotypes, among different flaviviruses. In contrast to the broad cross-
reactivity of anti-DI/DII sera (and anti-sE sera in consequence, due to DI/DII 
immunodominance), the lack of cross-reactivity of anti-DIII antibodies against other 
flaviviruses further confirmed the specificity of DIII epitopes. 
                                                          
f
 For context, the aminoacid sequence of E protein differs by 30-35% among the four DENV serotypes. 
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As expected, anti-DIII antibodies induced by the monovalent or tetravalent vaccine 
formulations, showed no neutralising activity nor, notably, enhanced the infection of WNV, 
ZIKV and YFV, thus confirming the DENV specificity of the DIII- vaccine. On the other 
hand, both anti-DI/DII sera induced relatively weak neutralisation of DENV serotypes, but 
did not neutralise and strongly enhanced WNV, ZIKV and YFV infection in Fc-receptor 
bearing cells. This is an important feature to consider as it has been described that ADE 
capacity is present even in strongly neutralising antibodies309; now, our data indicate that 
vaccination with DI/DII epitopes contribute almost exclusively to ADE with no 
neutralisation.  
In agreement with previous studies, our data confirm that highly cross-reactive 
antibodies, especially those against DI/DII epitopes, are the main drivers of ADE not only 
among DENV serotypes278, but also among other flaviviruses like ZIKV, WNV or 
YFV323,444. Moreover, a recent study with mAbs isolated from mice immunised with ZIKV E 
protein, showed that highly-neutralising, type-specific antibodies were mainly directed to 
DIII epitopes, suggesting that ZIKV DIII would be a safe immunogen in vaccine 
formulations437.   
Our results complement the information extracted from the study of monoclonal 
antibodies and also provide much needed data regarding the functions and characteristics 
of domain-specific polyclonal antibodies, which are critical to properly understand the 
natural immune response following immunisation. Indeed, most of what is known about 
the immune response against flaviviruses comes from the study of mAbs; however, the 
reality of polyclonal responses is significantly different as it comprises a mixture of 
antibodies that recognise several epitopes, have different neutralising potency and cross-
reactive features310. In this context, our experiments represent one of the first domain-
specific descriptions of the antibody response induced against DENV E protein. Together, 
the results suggest that DIII could be used to develop a tetravalent DENV-specific vaccine 
avoiding cross-reactivity with other flaviviruses.  
The recent description of conserved complex quaternary epitopes in DENV and ZIKV, 
able to induce strong cross-neutralising antibodies, has opened the possibility for the 
development of universal effective vaccines against both viruses287,289. However, there are 
serious concerns regarding them as viable vaccine candidates in the near future, since 
their structure is largely composed by DI/DII determinants, which would, by virtue of their 
immunodominant nature, induce poorly-neutralising cross-reactive responses. In this 
scenario, the effective use of cross-neutralising epitopes would require, in theory, either 
the isolation of the specific conformation of the epitope, or the removal of the other 
immunogenic epitopes on the surface of the E proteins, which are both highly complex 
tasks.  
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There are limitations to these conclusions that should be considered: As detailed in 
the introduction, there is abundant evidence supporting the effect of antibody-mediated 
enhancement and disease between dengue serotypes; however, there are no reports 
confirming a correlation between in vitro ADE assays and increased risk of infection by 
other flaviviruses; moreover, there is no clinical evidence of increased disease severity 
from WNV, ZIKV and YFV in dengue-immune patients. Nonetheless, even though the full 
influence of ADE during Flavivirus infection has not been determined, the risk for 
haemorrhagic complications found in (CYD-TVD)-vaccinated children suggests that these 
concerns are relevant and should be kept under consideration during the development of 
new vaccines, where proper antigen selection and design is of paramount importance. 
 
In conclusion, the results presented in this section explain the efficacy of the DIII- 
DNA vaccine in four key points: 
1. The use of the DNA vaccination allowed us to produce the antigen in a way that 
effectively surrogates the viral infection process, thus enabling the induction of 
stable and long-term immune responses. 
2. The design and engineering of the immunogen to maximise antigen availability, by 
introducing the dimerising CH3 domain and codon-optimisation, significantly 
increased protein production and secretion, favoured antigen presentation to 
immune cells and improved the quality of the induced antibodies. 
3. The selection of DIII, instead of the whole E, as the main immunogen produced 
DENV-specific strongly-neutralising responses, reducing the level of cross-
reactivity between DENV serotypes and the risk of ADE toward other flaviviruses. 
4. By targeting the intradermal compartment using gene-gun technology, plasmid 
DNA can be delivered to keratinocyte cells within the epidermis that are able to 
produce and secrete the encoded antigen in an immunologically favoured 
environment483,484.  
The results discussed in this section support the idea of further developing biolistic-
delivered DNA-vaccines focused on DIII to induce strong, stable and type-specific 
neutralising antibodies that circumvent the risk of ADE among flaviviruses.  
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